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STUDIE OPSOMMING 
 
AGTERGROND: Skisofrenie is ‘n heterogene siekte wat ontstaan vanuit 
ingewikkelde geen-omgewing interaksie. Die meerderheid van bestaande 
molekulêre genetiese studies het Kaukasiers betrek en resultate vanuit hierdie 
en Asiatiese populasies wys dat 2-32% van lyers kromosomale afwykings toon. 
Tot dusver ontwyk die ontdekking van ‘n spesifieke vatbaarheidsmeganisme of 
geen ons, maar die gebruik van endofenotipes word aanbeveel as bruikbaar vir 
hierdie soektog. Soortgelyke sitogenetiese studies is nog nie in enige inheemse 
Afrika populasie beskryf nie.  
DOELWIT: Die doel van die studie was om genotipiese en fenotipiese data, soos 
gestruktureerd versamel in ‘n homogene populasie, te kombineer, met die hoop 
om ‘n endofenotipe te beskryf wat gebruik sou kon word vir meer akkurate 
identifikasie van individue met moontlike kromosomale afwykings.  
METODOLOGIE: Xhosa skisofrenie pasiënte (n=112) is onderwerp aan ‘n 
gestruktureerde kliniese onderhoud. (Diagnostic Interview for Genetic Studies, 
insluitend Schedules for the Assessment of Negative and Positive Symptoms.) 
Bloedmonsters (kariotipering en/of FISH analise) sowel as urinemonsters 
(dwelmsifting) is versamel en nege kop en gesigsafmetings is geneem. 
Beskrywende statistieke met verwysing na demografiese, kliniese en 
morfologiese veranderlikes is bereken. Vergelykings tussen gemiddelde verskille 
vir hierdie veranderlikes is gedoen. 
RESULTATE: FISH analise is gedoen op die monsters van 110 deelnemers en 
geen kromosoom 22q11 mikrodelesies is waargeneem nie. Monsters van 50 
 
deelnemers is gekariotipeer en kromosomale afwykings is in vyf deelnemers 
(10%) gevind. Hierdie afwykings was: [46,XY,22pss]; [46,XY,1qh+]; 
[46,XY/47,XXY/47,XX+asentriese fragment] en twee gevalle van  [46,XY,inv(9)]. 
Geen beduidende verskillende kon gedemonstreer word tussen die 
kariotiperingsubgroep (KSG) en die totale studiegroep vir enige van die 
veranderlikes nie. ‘n Beduidende verskil vir een morfologiese afmeting, d.i. 
glabella na subnasale (p=0.036), kon gedemonstreer word tussen die KSG en 
die vyf deelnemers met afwykings. 
BESPREKING & AFLEIDINGS: Die kromosomale afwykings in ons studiegroep 
is almal as normale variante gerapporteer. Bloot omdat spesifieke afwykings nog 
nie met skisofrenie geassosieer is kan ons hulle egter nie sondermeer as nie-
beduidend afmaak nie. Indien ons werklik enige moontlike skakel met 
psigiatriese siekte sou wou uitsluit, is dit nodig dat groepe individue met hierdie 
spesifieke afwykings omvattende gestuktureerde psigiatriese evaluasies 
ondergaan. Opsporingstegnieke is vinnig besig om meer gesofistikeerd te raak 
en, veral belangrik, meer nie-Kaukasiese groepe word gewerf. Ons deelnemers 
met kromosomale afwykings is bevind om, in vergelyking, beduidend langer 
neuse te hê. Kraniofasiale dismorfologie is reeds voorheen bewys om in die breë 
geassosieer te wees met afwykings wat beskou word om op skisofrenie-
breinpatologie te dui. So, ‘n verlenging van die neus verteenwoordig moontlik ‘n 
onderbreking in ontwikkeling van die frontonasale prominensie, ‘n struktuur wat 
‘n intieme embriologiese verhouding met die ontwikkeling van die anterior brein 
geniet. Dus, in opsomming, ondersteun ons bevindinge, in teenstelling met die 
 
gerapporteer in byvoorbeeld Turkse en Afrikaner populasies, nie ‘n beduidende 
rol vir kromosomale afwykings in die vatbaarheid vir die ontwikkeling van 
skisofrenie in hierdie populasie nie. Ons kon egter etno-spesifiek morfologiese 
eienskappe in ons studiegroep aantoon. Te same gesien, onderstreep ons 
resultate dus die belang van meer nie-Kaukasiese studies in skisofrenie, met 
morfologiese en genetiese resultate wat duidelik nie bloot oor studiegroepe heen 
geekstrapoleer kan word nie.  
 
 
 
 
 
STUDY SYNOPSIS 
 
BACKGROUND: Schizophrenia is a heterogeneous illness resulting from 
complex gene-environment interplay. The majority of molecular genetic work 
done has involved Caucasian populations, with studies in these and Asian 
populations showing 2-32% of sufferers to have chromosomal aberrations. So far 
the discovery of a specific susceptibility mechanism or gene still eludes us, but 
the use of endophenotypes is advocated as a useful tool in this search. No 
cytogenetic studies of this nature have been reported in any African 
schizophrenia population.  
AIM: The aim of the study was to combine genotypic and phenotypic data, 
collected in a homogenous population in a structured manner, with the hope of 
characterising an endophenotype that could be used for more accurate 
identification of individuals with possible chromosomal abnormalities.  
METHODOLOGY: A structured clinical interview was conducted on 112 Xhosa 
schizophrenia patients. (Diagnostic Interview for Genetic Studies, including 
Schedules for the Assessment of Negative and Positive Symptoms.) Blood 
samples (karyotyping and/or FISH analysis) as well as urine samples (drug 
screening) were obtained and nine head and facial measurements were 
performed. Descriptive statistics were compiled with reference to demographic, 
clinical and morphological variables. Comparisons between mean differences for 
these variables were made. 
 
 
RESULTS: FISH analysis was performed on 110 participant samples, with no 
chromosome 22q11 microdeletions detected. Fifty participant samples were 
karyotyped revealing chromosomal aberrations in five (10%). These were: 
[46,XY,22pss]; [46,XY,1qh+]; [46,XY/47,XXY/47,XX+acentric fragment] and two 
cases of  [46,XY,inv(9)]. No significant differences could be demonstrated 
between the karyotyping subgroup (KSG) and the sample as a whole for any of 
the variables reported on. A significant difference for only one morphological 
measurement, ie glabella to subnasale (p=0.036), could be demonstrated 
between the KSG and the five participants with aberrations. 
DISCUSSION & CONCLUSION: The chromosomal aberrations detected in our 
group were all reported as normal variants. However, the fact that particular 
aberrations have not yet been linked to schizophrenia does not conclusively 
mean that they can be disregarded as non-significant. In order to truly exclude a 
possible link to psychiatric illness, groups of individuals with such variants need 
to undergo comprehensive psychiatric evaluation in a structured manner. 
Detection techniques are rapidly becoming more sophisticated and, very 
importantly, more non-Caucasian samples are being recruited.   Our participants 
with chromosomal aberrations were demonstrated to have, comparatively, 
significantly longer noses. Craniofacial dysmorphology has been shown to be 
associated in general terms with abnormalities found to evidence brain pathology 
in schizophrenia. The lengthening of the nose possibly represents a disruption in 
the development of the frontonasal prominence, a structure which enjoys the 
most intimate embryologic relationship with the development of the anterior brain. 
 
In summary, our findings, in contrast to those reported in e.g. Turkish and 
Afrikaner populations, do not support a significant role for chromosomal 
aberrations in the susceptibility to develop schizophrenia in this population. 
However, ethno-specific morphological characteristics could be demonstrated in 
our sample. Taken together, these results highlight the need for more non-
Caucasian studies in schizophrenia, as clearly, morphological and genetic results 
cannot just be extrapolated across samples. 
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1. WHY IS SCHIZOPHRENIA RESEARCH NEEDED? 
 
Schizophrenia is a severe chronic psychiatric disorder with the main clinical 
features of delusions, hallucinations, disorganised thinking, disorganised 
behaviour and negative symptoms such as affective flattening, alogia and 
avolition.1 It has a prevalence rate of about 1% and although outcomes are 
variable, the typical course is one of relapses followed by only partial remission. 
It leads to significant impairment in functioning and social isolation for sufferers 
and creates a substantial financial burden to society, both directly and in loss of 
productivity.2 In spite of the rapid expansion of knowledge achieved in recent 
years in the fields of neuroscience and behavioural science, many issues 
surrounding the pathophysiology of schizophrenia remain unresolved. Continued 
prioritisation of schizophrenia research therefore remains imperative if we hope 
to not only effectively manage this illness but also, ultimately, to prevent it. 
 
2. SEARCHING FOR SCHIZOPHRENIA GENES 
 
Numerous family, twin and adoption studies have shown in a conclusive manner 
that schizophrenia has a high familial heritability risk and that genes have a major 
contributory role in the aetiology of the disorder.3 In fact, schizophrenia has one 
of the highest heritabilities (approaching 80%) among the complex genetic 
disorders, similar to that of type I diabetes mellitus (72-88%) and greater than 
that of breast cancer (30%) and heart disease in males (57%).4-6 Specific genes 
that have been associated with schizophrenia risk in a number of populations 
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around the world include: catechol-O-methyltransferase (chromosome 22q), 
dysbindin-1 (chromosome 6p), neuregulin 1 (chromosome 8p), metabotropic 
glutamate receptor 3 (chromosome 7q), glutamate decarboxylase 1 
(chromosome 2q), and disrupted-in-schizophrenia 1 (chromosome 1q).7 
 
Studies in Caucasian and Asian populations have revealed that between 2% and 
32% of schizophrenia subjects have major chromosomal abnormalities such as 
translocations, deletions and inversions.8;9 Indeed, research on this type of 
developmental insult has yielded some of the strongest risk factors for the 
development of schizophrenia to date.  Specifically, the chromosome 22q11 
deletion and the balanced chromosomal translocation [t(1,11)(q42.1;q14.3)] 
disrupting two genes on chromosome 1 (DISC1 and DISC2) have both been 
demonstrated to increase the risk for schizophrenia.10;11 
 
A microdeletion at chromosome 22q11 is the most frequently known interstitial 
deletion found in humans, occurring in approximately one of every 4 000 live 
births, and its occurrence is associated with a characteristic facial 
dysmorphology, a range of congenital abnormalities and schizophrenia.12 In fact, 
the prevalence of psychosis in those with 22q11 deletion syndrome is high 
(30%), suggesting that haploinsufficiency of a gene or genes in this region may 
confer a substantially increased susceptibility risk.13 
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Unfortunately, the search for chromosomal loci and genes has been a slow and 
tedious process, most probably because there are multiple susceptibility genes, 
each with small effect, which act in conjunction with epigenetic processes and 
environmental factors.6 Currently, the number of susceptibility loci, the disease 
risk conferred by each locus, the extent of genetic heterogeneity and the degree 
of interaction among all the loci, remain unknown quantities. 
 
Furthermore, schizophrenia shows considerable clinical heterogeneity as 
reflected by an early description of this disease: "Dementia praecox, a number of 
disease entities".14 This clinical heterogeneity arguably reflects the 
heterogeneous nature of susceptibility factors for schizophrenia.  Not only do we 
find multiple combinations of symptoms existing in individuals but also both 
disease course and outcome display considerable heterogeneity. Currently, we 
cannot be certain whether this is a single disorder with different clinical 
manifestations or in fact a group of syndromes, each with unique or overlapping 
pathophysiology.  
 
3. THE USE OF ENDOPHENOTYPES IN LIMITING 
HETEROGENEITY 
 
Considerable attempts have been made to elucidate the heterogeneity of the 
schizophrenia phenotype by exploring the relationships between the various 
symptom dimensions and possible subtypes. In the search for susceptibility 
genes it has became apparent that one possible method would be to consider a 
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role for endophenotypes. Several approaches have been advocated for 
endophenotype analysis in schizophrenia. These include demographic variables, 
clinical symptoms, physical characteristics and neurodevelopmental insults.15 
 
Previous work from our research group has led to the publication of both an 
exploratory and subsequent confirmatory factor analysis and concordance 
analysis on affected sibling pairs of Xhosa patients with schizophrenia.16;17 Not 
only did this reveal a five factor symptom solution similar to that found in 
Caucasian samples, but specific symptoms (e.g. delusions of control) were 
delineated. These findings may serve as good markers for developing 
exploratory clinical subtypes for genetic studies.  
 
Furthermore, one such possible clinical subtype may be linked to the early 
developmental model for schizophrenia.18 This model implies that peri-natal 
insults (including chromosomal rearrangements) will predispose the individual to 
the later development of schizophrenia. The quantative and qualitative 
measurement of anthropometric proportions to demonstrate the presence or 
absence of dysmorphic features (so-called minor physical anomalies (MPAs)) 
represents one endophenotype that can be used. The presence of MPAs act as 
biologically-timed markers of developmental disturbance within a foetus and as 
such craniofacial anomalies are of special interest as the brain and the overlying 
face both develop from common embryonic ectoderm.19  
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Although some of the current evidence is contradictory and more research is 
needed, the presence of an excess of MPAs in schizophrenia subjects, in 
comparison to normal controls, has repeatedly been demonstrated.20 The use of 
MPAs as endophenotype fits in well with the neurodevelopmental hypothesis of 
schizophrenia and seems to be particularly appropriate in our setting as these 
measurements can not only be done inexpensively, but observers can be 
relatively easily trained to perform these measurements.    
 
Indeed, our findings of increased concordance of specific morphological 
abnormalities (linked to crucial brain developmental phases) in affected sibling 
pairs, make it imperative for us to explore chromosomal aberrations (e.g. 
breakpoints) that could account for these abnormalities and possibly predispose 
the individual to the development of schizophrenia.21  These aberrations may 
provide candidate loci and unique phenotypes linked to genetic aberrations in the 
affected region.   
 
4. WHY USE AN AFRICAN POPULATION? 
 
To date, by far the majority of molecular genetic work done in schizophrenia has 
involved Caucasian populations. In fact, no cytogenetic studies of this nature 
have been reported in any African schizophrenia population. There is a general 
paucity of data on schizophrenia, as well as other mental illness, in this group. 
Taking into account the evidence suggesting ethno-specific loci as well as 
apparent ethno-specific pharmacological responses to atypical antipsychotic 
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treatment in African-American and African samples, it seems clear that 
indigenous African populations also need to be investigated.22-25    
 
The Xhosa people are the second largest and southernmost indigenous African 
grouping within South Africa and belong to the Nguni linguistic grouping.26 Given 
the historical and geographical influences that formed this group, the Xhosa 
population can be regarded to represent a culturally homogenous grouping with 
an active traditional belief system. Therefore, taking into account the seemingly 
uniform core symptom profile reported in both Caucasian and African groups 
(including the Xhosas), as well as the marked paucity of clinical and susceptibility 
data for Xhosa-speaking schizophrenia patients, this group would seem to 
present us with an invaluable opportunity for molecular genetic research.16;25;27-31 
 
5. SUMMARY 
 
We therefore believe that by combining genotypic with phenotypic data collected 
in comprehensive clinical interviews, our study could lead to the discovery of 
unique characteristics that may be used to assist in the more accurate 
identification of individuals with possible chromosomal abnormalities. Such a 
discovery would not only help mental health care workers to better understand 
and care for patients with schizophrenia, but should also lead to the referral of 
the most appropriate candidates for genetic research in particular. This will 
increase the future chances of identifying chromosomal breakpoints and other 
aberrations that could provide candidate regions associated with genetic 
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susceptibility to schizophrenia in this population. Ultimately, breakthroughs such 
as these will contribute to more accurate diagnosis of the illness as well as the 
development of more effective treatment. 
- 19 - 
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1. INTRODUCTION 
 
Symptom descriptions suggestive of a diagnosis of schizophrenia date back to 
pre-classical cultures. However, with the exception of the ancient Greek and later 
Arabic physicians, societies believed these symptoms could mostly be attributed 
to supernatural forces. It was only in the late 17th and 18th centuries that the 
concept of organic etiologies for mental illness was more broadly adopted, 
leading to the establishment of the modern concept of schizophrenia in the early 
19th century. Ultimately, Emil Kraepelin and Eugen Bleuler (who coined the term 
schizophrenia in 1911), can be credited with finally delineating schizophrenia 
from other psychoses.1 
 
Furthermore, although the 20th century has seen the introduction of the concepts 
of schizophreniform (1933) and schizo-affective (1939) disorders, after Kraepelin 
and Bleuler there have been relatively few modifications to the central 
schizophrenia concept.1 
  
Schizophrenia is a severe chronic psychiatric disorder with the main clinical 
features of delusions, hallucinations, disorganised thinking, disorganised 
behaviour, and negative symptoms such as affective flattening, alogia and 
avolition.2 Current thinking holds schizophrenia to be a syndrome with 
characteristic symptoms and impairments resulting from multiple causal 
pathways involving disorders of normal brain function. 
- 26 - 
Research has revealed a number of well-established predictors of outcome, 
which include: family history of affective disorder, good premorbid adjustment, 
affective symptoms, acute onset, early treatment, good response to treatment 
(positive) and family history of schizophrenia, long duration of untreated 
psychosis, substance misuse, bizarre delusions, negative symptoms, schizoid 
traits (negative).3;4 
 
Although outcomes are variable, the typical course is one of relapses followed 
only by partial remission and resulting in significant impairment in social 
functioning and social isolation.5 In fact, current evidence would seem to support 
the notion that less than half of patients with a diagnosis of schizophrenia or 
schizophrenia spectrum disorders show any substantial functional improvement 
at five to six year follow-up.6;7 
 
2. EPIDEMIOLOGY 
 
Schizophrenia exerts a significant economic burden, both directly and indirectly, 
(reported to be $1.2 trillion in the USA alone) and it also places a severe 
emotional burden on both sufferers and their family members.8;9 
 
Research by the World Health Organisation (WHO) has shown that narrowly- 
defined schizophrenia exists in all cultures around the world.10 However, contrary 
to the popular belief (also supported by the initial report of the WHO 10-country 
study), that the illness has a uniformity of incidence, a recent systematic review 
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by McGrath et al. has concluded that the incidence of schizophrenia in fact 
shows clear worldwide variation.11;12 This review included data from 158 studies 
drawn from 32 countries and showed that, based on conservative estimates, 
rates for the incidence of schizophrenia fell within a range of 7.7 to 43.0 per 
100000, in other words, over a five-fold difference.11  
 
This data is further supported by recently published findings of the AESOP study 
supporting significant and independent variation of incidence of schizophrenia in 
terms of sex, age, ethnicity and place.13 Developing an understanding of the 
factors that contribute to these observed variations in incidence will no doubt be 
of great value in the ongoing process of discovery surrounding this disabling 
illness. 
 
3. AETIOLOGY 
 
One of the many challenging aspects of schizophrenia lies in the heterogeneity 
observed in this illness. The clearly observed variability in symptomatology, 
course and outcome has long led researchers to suspect an underlying 
etiological heterogeneity. Broadly, the main developmental models for 
schizophrenia have been divided into two categories – neurodegenerative and 
neurodevelopmental.14 
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3.1 NEURODEGENERATIVE 
 
With no direct evidence for neurotoxicity having yet been demonstrated post-
mortem, the concept of a neurodegenerative process contributing to 
schizophrenia remains a controversial topic.  
 
To date, numerous magnetic resonance studies have shown abnormalities in the 
brain structure of schizophrenia patients.15 These include decreased grey matter 
volume and increased ventricular size. This then gives rise to the question as to 
when these changes first occur? Grey matter changes have been demonstrated 
in vulnerable individuals prior to onset of psychosis.16;17 Also, progressive loss of 
brain volume has been shown in first-episode patients, this feature being 
particularly prominent in those with a poorer clinical outcome.18-21 
 
The cognitive decline associated with schizophrenia has also been suggested to 
represent a neurodegenerative process with some evidence supporting the 
duration of initial untreated psychoses to be associated with this decline.22 
However, due to the fact that other factors influencing prognosis can also be 
linked to speed of and access to treatment, this finding remains debatable.23 
Cognitive testing, although clearly showing abnormalities, has also not tended to 
support a decline during the first few years following onset of psychosis.24  
 
Interestingly, a correlation between the severity of tardive dyskinesia (TD) and 
that of cognitive impairment has also been reported.25  Although this could lend 
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support to the presence of a shared neurotoxic process contributing to both, it 
could also just indicate poor cognition to be a risk factor for TD. Furthermore, 
antioxidants, such as vitamin E, have been studied as a potential treatment for 
TD, but results have been inconsistent.26-28 A potential role for antioxidants in 
slowing a proposed neurotoxic component to the illness has not been shown. 
 
Thus, the definitive discovery of a mechanism for a putative neurodegenerative 
process in the developments of schizophrenia continues to elude us. 
 
3.2 NEURODEVELOPMENTAL 
 
In contrast to the neurodegenerative model, considerably more evidence has 
consistently been put forward in support of the neurodevelopmental etiology of 
schizophrenia. These include many risk factors, both environmental and genetic, 
and at least some of them could offer us pointers toward developing rational 
preventions for the illness. The remaining part of the chapter will be dedicated to 
a summary of the salient points with regard to each of the risk factors that are 
currently regarded to show most promise for inclusion in a neurodevelopmental 
model. 
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3.2.1 PRENATAL 
 
3.2.1.1 NUTRITIONAL DEFICIENCY 
 
Some evidence suggests that nutritional deficiency during pregnancy may play a 
role in the origin of some cases of schizophrenia.29 Due to the existence of 
comprehensive records, interesting data was obtained from the so-called Dutch 
Famine period (1944-1945) at the end of World War II. For this cohort, early 
prenatal famine could specifically be associated with each of three conditions: (1) 
congenital anomalies of the central nervous system, (2) schizophrenia, and (3) 
schizophrenia spectrum personality disorders.30 In fact, the risk for schizophrenia 
was demonstrated to increase two-fold in offspring exposed to famine.  
 
Similar results have been demonstrated in a Chinese cohort exposed to a 
massive famine period from 1959 to 1961.  Among births that occurred during the 
famine years, the adjusted risk of developing schizophrenia in later life increased 
significantly, from 0.84% (1959) to 2.15% (1960) and 1.81% (1961).31 
 
Possible mechanism 1: Vitamin D (Vit D) insufficiency has been proposed as one 
possible explanation for this phenomenon. Recently some data have suggested 
a neuroprotective role for Vit D.32 The most active metabolite of Vit D3, 1,25-
dihydroxy-vitamin D (1,25(OH)2D) is a hormone with multiple roles, in particular 
genomic stability, and there is growing evidence that low prenatal levels of it can 
influence critical components of brain development.33 Furthermore, it has been 
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demonstrated that supplementation with Vit D in the first year of life could be 
associated with a greatly diminished risk for schizophrenia in males.34 
 
Possible mechanism 2: Another hypothesis is that of DNA hypomethylation in 
which either stress and/or nutritional factors are postulated to modify DNA 
transcription.35;36 DNA methylation is an essential epigenetic mechanism, 
modulating gene expression during cellular differentiation as well as being 
essential for the expression of imprinted genes. In humans, DNA methylation 
involves mainly the addition of a methyl group to the 5’ position of cytosine within 
Cytosine-phosphodiester-Guanine dinucleotides.35 These methyl groups are 
supplied either from diet (e.g. folic acid or Vitamin B12) or synthesised from one-
carbon metabolism. It is therefore suggested that the folate deficiency that has 
been reported in patients with schizophrenia could possibly be responsible for an 
increased risk via this mechanism.37-39 As pregnancy burdens maternal folate 
reserves, it could also possibly account for the suggested association between 
shorter birth intervals and increased schizophrenia in offspring.40 
 
3.2.1.2 VIRAL INFECTIONS 
 
It has long been debated whether there is a possible role for certain viral 
infections contributing to the risk of developing schizophrenia. Whilst a number of 
studies have shown increased rates of schizophrenia after maternal exposure to 
influenza, other infections including rubella, the poliovirus and the herpes simplex 
virus, have shown less robust associations.41-46 
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However, the mechanisms by which these infections might lead to schizophrenia 
have yet to be well-delineated.42 Potential mechanisms include teratogenic 
effects of maternal antibodies on neurodevelopment and a surge in circulating 
cytokines. Interestingly, recent animal models have suggested that influenza and 
immune activation do have effects on the foetal brain that appear to be 
concordant with findings observed in schizophrenia.47 
 
To date, no consistent evidence of viral markers in the cells of schizophrenia 
sufferers have been identified. Therefore, the evidence remains circumstantial. 
Still, could the link be proven, data from, for example, Brown et al., would 
suggest that as many as 14% of schizophrenia cases would not have occurred if 
influenza infection during early to mid-gestation had been prevented.41 This may 
have significant implications, given the numerous preventive strategies available 
for influenza and other infections, including vaccination, antibiotics, and simple 
hygienic measures. 
 
3.2.2 OBSTETRIC-RELATED EVENTS 
 
A significant body of literature exists to support a link between obstetric 
complications/events and an increased risk for the development of 
schizophrenia. Currently, the pooled odds ratio of this effect is estimated to be 
about 2.0.48 In their comprehensive meta-analysis Cannon et al. separated 
obstetric complications into three categories that could be correlated to increased 
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risk for development of schizophrenia – complications of pregnancy, 
complications of delivery and abnormal foetal development.49 
 
3.2.2.1 COMPLICATIONS OF PREGNANCY 
 
Definite increased vulnerability for psychosis has been demonstrated for pre-
eclampsia, diabetes, rhesus incompatibility and severe bleeding. Although the 
mechanisms by which these factors influence susceptibility remain unclear, some 
theories have received strong support. These include: abnormal foetal blood-flow 
with resulting hypoxia (pre-eclampsia, bleeding), abnormal glucose metabolism 
(diabetes), autoimmune process (diabetes, rhesus) and even the so-called 
uterine rejection of the “schizophrenia-vulnerable” foetus (bleeding). 
 
3.2.2.2 COMPLICATIONS OF DELIVERY 
 
Associations have been demonstrated for asphyxia, emergency caesarean 
sections and the atonic uterus. As such, neurotoxic effects as a consequence of 
foetal hypoxia are thought to be the possible common mechanism by which 
increased vulnerability to schizophrenia is conferred by these complications. With 
regard to this category it is of course important to remember that delivery 
complications could in fact be due to pre-existing problems during pregnancy.50 
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3.2.2.3 ABNORMAL FOETAL DEVELOPMENT 
 
 A fairly consistent association with low birth weight has been demonstrated and 
as there is no clear association between this and prematurity, intrauterine growth 
retardation has been postulated as a contributing factor. However, as women 
with schizophrenia tend to exhibit an increase in other behaviours associated 
with adverse effects in the foetus (e.g. smoking), this theory remains 
controversial. An association with reduced head circumference at birth, once 
again independent of prematurity, has also been demonstrated but until now no 
clear evidence has emerged to support either a genetic component or early 
somatic trauma in the development thereof. 
 
Interestingly, there is some evidence from animal studies to show that caesarean 
section and perinatal hippocampal damage (such as associated with hypoxia and 
prematurity) can facilitate the development of dopamine sensitisation once the 
animal matures, therefore providing a possible link to the development of 
schizophrenia.51;52 
 
In summary, as it is well-known that obstetric complications occur commonly in 
the general population and the vast majority do not lead to the development of 
schizophrenia, it would be fair to say that these complications are neither 
necessary nor sufficient causal factors for schizophrenia. However, as obstetric 
complications remain one of the best-replicated ‘‘environmental’’ risk factors for 
schizophrenia it is clear that they form a part of the causal pathway for at least 
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some individuals and as such should remain strongly represented in our quest to 
elucidate the causal mechanisms and gene-environment interactions leading to 
this complex disorder. 
 
3.2.3 SUBSTANCE USE 
 
The possible link between substance use and increased schizophrenia risk has 
long been acknowledged.53 The majority of the research has focused on 
attempting to delineate the relationship between cannabis, psychosis and 
schizophrenia.  Multiple explanations have been offered for the observed 
increased rates of cannabis use in schizophrenia. These range from simple self-
medication to dull early symptoms to postulating a possible role for cannabis as 
trigger mechanism for illness onset in vulnerable individuals.54 Interestingly, there 
is also some evidence showing that in experiments where cannabis was 
administered to healthy volunteers under controlled laboratory circumstances, a 
broad range of transient symptoms, behaviours and cognitive deficits resembling 
some aspects of schizophrenia could be produced.55 
 
With a number of cohort studies, such as the Dunedin study, now having shown 
that cannabis use usually predates psychosis, there is consistent evidence to 
support a role for an association with cannabis.56 In fact, the Dunedin study, even 
after controlling for many potential confounding factors, showed a four-fold 
increase in rates of schizophreniform disorder by age 26 for individuals using 
cannabis at age 15.57 Furthermore, a meta-analysis by Henquet et al. revealed 
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that the use of cannabis could be associated with nearly a doubling in risk of 
schizophrenia.58  
 
However, as the majority of cannabis users do not later develop a psychotic 
disorder it remains patently clear that the relationship is not a straightforward 
one. In fact it seems likely that other risk factors interacting or acting with 
cannabis may be necessary for the final outcome. One possibility could be that 
there is a great variation in individual sensitivity for the psychosis-inducing effects 
of cannabis. At least two independent studies have supported this theory by 
using subtle measures to determine levels of expression of psychosis 
proneness.58;59  
 
Caspi et al., also studying the Dunedin birth cohort, presented the first evidence 
of a gene by environmental interaction predisposing schizophrenia.60 They 
demonstrated that a functional polymorphism in the catechol-O-
methyltransferase (COMT) gene (enzyme essential in breakdown of dopamine in 
prefrontal cortex) moderates the influence of adolescent cannabis use. Users 
homozygous for the high activity Val allele showed an at least five-fold increased 
risk of developing schizophreniform disorder in comparison to those with Met/Met 
(odds ratio 1.1) and Val/Met (odds ratio 2.5) status. PET and post-mortem 
studies have indicated that the Val allele is associated with markedly increased 
dopamine synthesis in midbrain neurones projecting to the ventral striatum.61 
Furthermore, it has been shown that cannabis markedly increases dopaminergic 
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neuronal firing and that cannabinoid receptor (CB1) agonists increase the 
release of dopamine at terminal fields in the striatum and prefrontal cortex.62 
Taking these two pieces of evidence into account, this could in fact explain why 
Val/Val individuals are more susceptible to the psychotogenic effects of 
exogenous cannabis. 
 
 
The psychostimulant methamphetamine has also received some attention. Not 
only is it well-known that use of this substance can induce a syndrome in many 
ways identical to schizophrenia, but an interaction between methamphetamine 
abuse and premorbid schizotypal personality traits as a measure of personal 
vulnerability for psychosis, has also been reported.63 Furthermore, with some 
preliminary data seeming to suggest that schizophrenia risk may be increased 
with use, this area clearly warrants further study.64 
 
3.2.4 DEMOGRAPHIC FACTORS 
 
3.2.4.1 FAMILY HISTORY 
 
Numerous family, twin and adoption studies conclusively support the notion that 
genetic factors play an important role in influencing susceptibility to many adult 
psychiatric disorders. General estimates of heritability can be calculated from 
twin studies and these have been shown to be high, comparable to (e.g. 
diabetes) or higher than (e.g. heart disease in males) that of other complex 
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disorders.65 See chart 1 for a comparison of some of these heritability 
percentages. 
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CHART 1: COMPARISON OF HERITABILITIES BETWEEN SOME 
PSYCHIATRIC AND COMPLEX MEDICAL DISORDERS 
 
Schizophrenia has one of the highest heritabilities with a 10-fold increase in risk 
to siblings of probands. However, as heritability is not 100% and an estimated 
85% of schizophrenia sufferers have no first-degree relative with the illness, we 
are left with the suggestion that at the heart of this illness there are probably 
several susceptibility genes working in conjunction with epigenetic and 
environmental factors.66 The reader is referred to the chapter on chromosomal 
aberrations where the topic of genetic vulnerability to schizophrenia is discussed 
in more detail.  
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3.2.4.2 SEASON OF BIRTH 
 
Nearly 300 studies have looked at season of birth as a risk factor for the 
development of schizophrenia.67 The majority of the data comes from the 
northern hemisphere (NH) and systematic meta-analysis of NH data supports an 
association between excess winter/spring births and an increased risk for 
schizophrenia in later life.67;68 Although the seasonality effect has not been so 
clearly validated by Southern Hemisphere data, season of birth has also been 
associated with different subtypes of schizophrenia, differences in prognosis, 
demographic factors and clinical presentation.69-71 In a study from our own group 
on a previous Xhosa schizophrenia sample, we demonstrated a spring excess of 
4% in birth rate compared to the general Xhosa population.72 Furthermore, 
patients born in autumn/winter were more likely to have avolition/apathy than 
those born in summer/spring.  
 
Several possible reasons for the seasonality of schizophrenia births have been 
proposed, including, but not limited to, light variations, nutrition, infective 
processes, genetic factors and environmental toxins.68;73 Although seasonality 
confers only a small increased risk and the mechanism for this is currently still 
unknown, evidence seems to suggest that this observation is unlikely to be due 
to chance.  
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3.2.4.3 URBANICITY 
 
As far back as 1939, Farris and Dunham published data showing that the rate of 
schizophrenia was higher in urbanised areas.74 Since then, a number of well-
designed studies have supported the notion that those born or brought up in 
cities have an increased risk (possibly close to twofold) of developing 
schizophrenia in comparison to those born and/or brought up in rural 
regions.11;75;76 Evidence supporting an especially greater risk for those having 
lived for a greater number of years in an area with a higher degree of 
urbanisation has also been presented.77 Studies have suggested that the 
increased risk is not confined to a diagnosis of schizophrenia alone but that it can 
also be observed for subtle psychosis-like phenomena.78;79 This effect was 
demonstrated to be independent of numerous important variables, including, but 
not limited to, the rate of psychotic disorders, ethnic groupings and drug use. 
 
Currently the mechanism for the increased risk linked to urbanicity is not known. 
Numerous hypotheses such as greater facilitation of the transmission of 
infections, diet toxin exposure, pollutants, increased health risk behaviours (e.g. 
drinking, other substance abuse) and obstetric complications have been put 
forward, but none been conclusively proven.80 However, there is some 
consensus that the kind of geographical variation in incidences associated with 
urbanization, is in support of an environmental effect that has its impact through 
continuous or repeated exposure.77;81 Furthermore, it seems most likely that this 
effect is exerted during childhood and adolescence and not in adulthood.76;82  
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With only a small minority of those living in urban areas developing 
schizophrenia, it would however seem that any environmental effect would need 
to be conditional on another factor. With some data in support of a link between 
urbanicity and pre-existing indicators of genetic risk for psychosis, it could 
ultimately be that this factor boils down to a gene-environment interaction.83;84 
 
3.2.4.4 GENDER 
 
Some controversy still exists regarding the possible influence of gender in the 
development of schizophrenia. For some time the view most commonly held, was 
that there was either no gender difference in terms of lifetime risk for developing 
the disorder or that the evidence was inconclusive.85 However, two recent 
independent large systematic reviews, each using a different summary method, 
have both reached the conclusion that the incidence of schizophrenia is 
significantly higher in men than in women.11;86 
 
Aleman et al. included studies published between 1980 and 2001 whilst McGrath 
et al. included the date range from 1965 to 2001.11;86 Both reviews found that the 
overall male:female risk ratio could be demonstrated to be 1.4 and that the 
difference could not be accounted for by methodological factors related to age 
range or diagnostic criteria. 
 
A substantial body of literature exists to support gender differences in the way 
schizophrenia presents.87 Of these, the finding of an earlier age of onset for 
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males is probably the most commonly known. Evidence shows this finding to 
exist irrespective of culture, definition of onset or definition of illness.88-91 
Furthermore, women have been shown to demonstrate a relative risk of late 
onset schizophrenia two to three times greater than that of men.92;93 Interestingly, 
the age of onset difference appears to apply only to sporadic and not to familial 
cases of schizophrenia.94 
 
Considerable support has also been shown for numerous other gender 
differences, including, but not limited to, poorer premorbid functioning, more 
negative symptoms and cognitive deficits and greater structural brain and 
neurophysiological abnormalities (males) and more affective symptoms, a more 
favourable short and middle-term course of illness and less smoking and 
substance abuse (females). As a comprehensive overview of these is beyond the 
scope of this chapter, the reader is referred to an excellent review by Leung and 
Chue for more on this topic.87 
 
Interestingly, no clear sex differences in family history, obstetric complications, 
minor physical anomalies or neurological soft signs have yet been 
demonstrated.87 Taking this into account, it can be postulated that the 
neurodevelopmental model of schizophrenia most likely accounts for the majority 
of cases in both males and females. With males seemingly more prone to this 
model, estrogen may play a prominent role in the explanation of some of the 
gender differences.95;96 Estrogen has been shown to have neuroprotective 
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effects and protects against necrotic neuronal death.97;98 Since most 
schizophrenic illnesses manifest themselves after adolescence, the neural 
processes which occur during puberty, including intensive synaptic pruning, may 
play a significant role. Estrogen affects synaptic pruning, which occurs intensively 
during adolescence, in a sex-specific manner and may contribute to less aberrant 
pruning in females versus males.99 
 
Recently, it has also been demonstrated that normal males respond to an 
amphetamine challenge by releasing more striatal dopamine than normal 
females.100 Possibly this greater sensitivity of the dopamine system in males 
renders them more likely to develop the striatal hyperdopaminergia that underlies 
psychosis. Further studies in the area of gender differences are necessary, with 
the hope of developing individualized preventative and treatment strategies for 
both males and females with schizophrenia. 
 
3.2.4.5 MIGRANT STATUS 
 
Ödegaard first reported in 1932 on the observed phenomenon of an increased 
prevalence of psychosis in Scandinavian immigrants to the USA.101 Since then 
much data has emerged, confirming the increased incidence of schizophrenia in 
immigrants. In their 2005 meta-analysis, Cantor-Graae and Selton included 18 
rigorously selected studies, including both first and second-generation migrants 
and calculated that overall, immigrants were 2.9 times more at risk for developing 
schizophrenia than the host population.102 This increase in risk was similar in 
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both genders but was significantly increased for migrants from countries were the 
majority of the population was black.  
 
Furthermore, the increased risk is not restricted only to young adults; it has also 
been observed both for very late onset schizophrenia-like psychosis and in the 6-
18 years age group.103;104 Although much less studied, literature also seems to 
support increased rates of mania and bipolar disorders, as well as discrete 
psychotic symptoms (i.e. hallucinations) in migrant populations.105-107 The 
increased risk has also been noted in second generation and very young 
immigrants.102;108 Taking all of this into account, as well as the reported normal 
incidence rates for schizophrenia at the migrants’ points of origin, it becomes 
clear that Ödegaard’s initial suggestion of selective migration as a causal link 
cannot be regarded as the sole explanation for these findings.101;109;110  
 
Other possible suggestions have been urbanisation, social defeat and adversity 
as well as stressful life-events.111-114 Although some of these in themselves are 
associated with an increased risk for developing schizophrenia (see elsewhere in 
this chapter), current available evidence cannot support any of these to fully 
explain the magnitude of the observed immigration effect. 
 
Interestingly, Vitamin D insufficiency (see elsewhere in chapter), has also been 
suggested to be the culprit in the increased psychosis risk observed in especially 
dark-skinned immigrants.37 Vitamin D is mainly synthesized in the skin by the 
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ultra-violet component of sunlight and fortified by milk or margarine. It is therefore 
hypothesized that due to the fact that individuals with darker skins require longer 
sun exposure – as well as the evidence that subjects of African descent are often 
found to be lactose intolerant – such individuals are more prone to develop a 
Vitamin D insufficiency.115 In support of this a number of studies have been 
published providing proof of Vitamin D insufficiency, particularly in African- 
American women.116-118 
 
However, the increased rate of psychosis is not only observed in dark-skinned 
immigrants. Dealberto has therefore postulated a possible role for DNA 
methylation, (see elsewhere in chapter) specifically in light-skinned populations.37  
One possible mechanism for DNA hypomethylation is that of impaired one-
carbon metabolism. The enzyme mehtylenetetrahydrofolate reductase (MTHFR) 
has been implicated in this. Two recent meta-analyses suggested that the TT 
genotype of MTHFR inferred a greater risk for developing schizophrenia than the 
CC genotype.119;120 Those studies included in the meta-analyses, reporting on 
ethnicity, observed that this variant of MTHFR was very infrequent in subjects of 
African ancestry, leading DeAlberto to hypothesize the link to the increased risk 
for psychosis observed in light-skinned populations.37 
 
3.2.4.6 SOCIO-ECONOMIC STATUS 
 
An association between lower socio-economic status (SES) and schizophrenia 
has been suggested by a number of studies connecting the illness with being 
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born into, or raised in, an impoverished environment, with a recent meta-analysis 
reporting this effect to be at least modest in size.121 In fact, research seems to 
suggest that this is true not only for schizophrenia but for other severe mental 
illnesses as well.122  
 
A longstanding debate exists as to whether this phenomenon is indicative of 
“social stress” or “social drift”. In other words, whether lower SES precedes 
schizophrenia or whether lower SES leads to schizophrenia. Studies have found 
both these theories to demonstrate some validity, but in different populations. 123 
 
Focusing on the “social stress” theory, likelihood of exposure to a number of 
other risk factors that are associated with schizophrenia (as discussed elsewhere 
in this chapter), such as poor nutrition, poor prenatal health care and stressors 
such as inadequate housing and limited job prospects, is definitely increased in 
lower SES groupings. 
 
3.2.5 EXPOSURE TO STRESS  
 
Stress is widely accepted to be a contributor to the pathogenesis of psychosis 
and schizophrenia in particular.113;124 Animal studies have supported a role for 
social adversity as a risk factor with data showing, amongst other findings, that a 
submissive position in social hierarchy increases the reactiveness of the 
mesolimbic dopamine system and that housing a mouse with a large “bully” 
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mouse, can induce brain-derived neurotrophic factor (which controls the 
dopamine system) in the former.125;126 
 
However, despite the prominence of the stress-diatheses model, life events 
literature has provided inconsistent conclusions in relation to schizophrenia, with 
no particular pattern or type of event being consistently related to subsequent 
illness development. A detailed discussion of this literature is well beyond the 
scope of this chapter and the reader is referred to an excellent review by Gispen-
De Wied.127 
 
In terms of a possible causal link, some authors have suggested that previous 
exposure to major life events modified subsequent emotional reactions to minor 
stress, thus cumulatively increasing the risk of emotional dysfunction, which in 
turn may than open up direct emotional pathways to psychotic experiences.128-130 
 
As stated elsewhere in this chapter, DNA hypomethylation, in which stress or 
nutritional factors are postulated to modify DNA transcription, has also been put 
forward as a possible hypothesis.35;36 Currently however, this theory is not yet 
backed by any evidence directly linking stress to impaired DNA methylation. 
 
3.2.6 AUTOIMMUNE DISEASE 
 
Associations with either higher or lower than expected prevalence have been 
reported for both schizophrenia patients and their relatives for a number of 
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autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, thyroid 
disorders, and celiac disease.131-134 To date, the most consistent finding in the 
area of schizophrenia and autoimmune diseases is that of the negative 
relationship with rheumatoid arthritis.133;135;136  
 
Recently, Eaton et al. used the Danish Psychiatric Register to gather data on 
7704 schizophrenia patients.137 They found that a history of any autoimmune 
disease was associated with a 45% increase in risk for schizophrenia. In 
particular, thyrotoxicosis, celiac disease, acquired hemolytic anemia, interstitial 
cystitis, and Sjögren’s syndrome had higher prevalence rates among patients 
with schizophrenia and their family members in comparison to controls and their 
family members, respectively. 
 
One of the possible hypotheses for these findings is that schizophrenia shares a 
genetic diathesis with the family of autoimmune diseases, For example, 
association studies have highlighted the role of HLA genes for certain 
autoimmune diseases.138;139 The epidemiologic association between these 
disorders could therefore be a result of 1) direct involvement of HLA antigens or 
2) physical closeness between loci for the autoimmune disorders and 
schizophrenia loci in HLA regions. Outside the HLA region, the search for 
variants for common autoimmune diseases has not, as yet, suggested many 
clusters related to schizophrenia.140 However, there is some possible evidence 
such as linkage studies suggesting that schizophrenia and celiac disease may 
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have genes that are close to each other or identical and separate association 
studies have connected the methylenetetrahydrofolate reductase (MTHFR) gene 
to schizophrenia and to rheumatoid arthritis.141-144 
 
4. SUMMARY 
 
The aim of this chapter was to provide a brief overview on each of the topics 
discussed therein in order to introduce the reader to the difficulties inherent to 
studying a complex heterogenous disorder such as schizophrenia. It was not 
meant as a comprehensive summary and for further reading the reader is 
referred to the various texts referenced on each of the individual topics. 
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1. INTRODUCTION TO CULTURE AND MENTAL HEALTH  
 
Western medicine is rapidly expanding and the scientific treatment of mental 
illness has shown great advances in recent decades. Even so, interest in non-
western or indigenous forms of healing is probably higher than ever with calls for 
the integration of the best of both worlds into health services. In the field of 
mental health, such views are in part driven by the belief (supported by a large 
body of literature) that the way mental illness is experienced, understood and 
managed, finds different expression in different cultures. 
 
Webster’s Dictionary broadly defines culture as “the concepts, habits, skills, art, 
instruments, institutions etc. of a given people in a given period; civilisation.”1 
However, ultimately, culture cannot be static and Helman’s view of culture as “a 
set of inherited guidelines used to view and emotionally experience the world and 
shape behaviour towards it and others in it”, probably lends itself more to defining 
our understanding of the concept within the context of mental illness.2 
 
It is not within the scope of this chapter to provide a detailed discussion on the 
topic of cross-cultural psychiatry and for such an analysis it is suggested that the 
reader refer to the text, “Culture and mental health: a Southern African view” by 
Leslie Swartz.3 Although standardised “western” criteria such as the DSM-IV-TR 
has no doubt brought improved consistency to psychiatric patient management, a 
blanket application of such a theoretical framework may downplay socio-cultural 
influences on nosology.4;5 Suffice to say, that in a multi-cultural society such as 
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our own, all mental health care practitioners aiming to provide comprehensive 
care, need, on the most basic level, to at least cultivate an awareness of the 
concept and its potential impact. 
 
2. THE XHOSA – CONTEXTUAL HISTORY 
 
A considerable amount of research has been conducted into the origins and 
subsequent dispersal of African-language peoples across Sub-Saharan Africa 
and, in fact, numerous different models describing African migration routes exist.6 
However, there are some points of consensus. Most likely, from a nexus in West 
Africa (between Nigeria and Cameroon), a series of migrations occurred starting 
conservatively around 5,000 years ago. This ultimately resulted in the formation 
of an Eastern African core around 3,000 years ago, from which further 
expansions saw the initial colonisation of southern Africa during the first 
millennium AD.7 Since then, as productive subsistence economies fuelled 
population growth, a considerable number of subgroups, under different leaders, 
spread throughout southern Africa.7;8 Today these subgroups can be seen as 
local populations linked together based on linguistic, cultural, and historical 
evidence, e.g., Natal Nguni (Zulu and Swazi), Cape Nguni (Xhosa), and Sotho 
(Southern Sotho and Tswana). 
 
The Xhosa people are the second largest African culture group within South 
Africa and belong to the Nguni linguistic grouping.9 They are the southernmost 
indigenous African people and as a homogenous population with an apparently 
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common ancestry, they offer a unique opportunity for the study of an illness such 
as schizophrenia. 
 
Archaeological evidence indicates a possible Xhosa presence in the Eastern 
Cape as far back as the seventh and eight centuries. However, it was only in the 
last quarter of the eighteenth century that the settler (“trekboer”) advance into the 
South African interior began approaching the outermost fringes of the Xhosa 
settlements, leading to first large-scale contact with western civilisation.9 
 
Genealogical records take us back to the fifteenth century after which internal 
revolutions led to the Xhosa kingdom’s political fragmentation. However, cultural 
norms have remained largely intact as evidenced by comparisons between more 
current descriptions and those from early shipwreck survivors. 
 
The Eastern Cape was the region of the first continuous contact between the 
colonists and the Xhosa. The protracted so-called Xhosa wars that followed had 
tremendous longterm social and political impact in the shaping of the transformed 
South African political landscape. 
 
Prior to democracy, the nature of the socio-political situation in South Africa was 
in many ways responsible for in the Xhosa people’s relative geographic isolation 
in homelands in the Eastern Cape and townships in major cities. Ultimately, this 
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has ensured that the population displays a relatively homogenous cultural 
constitution. 
 
3. SCHIZOPHRENIA AND THE XHOSA CULTURE 
 
3.1 BACKGROUND 
 
From the outset, descriptions of the Xhosa people refer to a hospitable society, 
disposed to peace rather than war, exhibiting a fierce loyalty to their chiefs. The 
hospitable responses were strongly affected by the common emphasis placed on 
group rather than individual interests (“ubuntu”). “Ubuntu” underlined the basis of 
social law with the primary object being the preservation of tribal equilibrium.9 
Another aspect underlying their unique cultural norms, centres on a strong belief 
in supernatural powers and specifically ancestor reverence, which directly 
influences how illness (physical as well as mental) is viewed.10 It was the 
pioneering work of Vera Buhrmann that first emphasised the importance of 
ancestral reverence as part of the Xhosa cultural belief system.11 Work like hers 
finally allowed the broader society some insight into the significance of ancestral 
appeasement rituals and how misunderstanding of them could lead to the loss of 
ancestral protection and ultimately even precipitate mental illness. 
 
These cultural norms greatly influenced the experience and interpretation of 
symptoms as well as health-seeking pathways. Clearly this will impact on data 
gathering and results of studies conducted within a unique cultural grouping such 
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as the Xhosa. As previously mentioned, a full discussion on this falls outside the 
bounds of this chapter and for our purpose we will therefore focus on these 
influences specifically within the context of managing schizophrenia in the Xhosa 
population. 
 
3.2 XHOSA CULTURAL BELIEFS WITH REGARD TO 
SCHIZOPHRENIA 
 
As part of a world-wide move to a better understanding of the causes and 
presentation of mental illness, the concept of “culture-bound syndromes” was 
incorporated into the broader discussion. The term refers to any one of a number 
of recurrent, locality-specific patterns of aberrant behaviour and experiences that 
appear to fall outside of the conventional Western psychiatric diagnostic 
categories.5 Within a local context, these illness patterns are considered to 
represent specific diagnostic entities and most have local names. 
 
None of the culture-bound syndromes described within the South African context 
have been included in the DSM-IV-TR, although the so-called “brain fag” (first 
described in West African literature) has some overlap with “isimnyama 
eskolweni”.3 Nonetheless, the two Xhosa illness-terms often used to describe 
behaviour that correlates to or can be viewed as schizophrenia-like symptoms, 
“amafufunyana” and “thwasa”, are considered to be well-recognised cultural 
phenomena found in the indigenous African Xhosa population.3;12;13 
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“Amafufunyana” is broadly viewed as a negative possession state that is 
commonly associated with mental illness. Original descriptions attempted to 
outline a list of typical symptoms with emphasis placed on the hysterical, strange 
and unpredictable behaviour of the sufferer, also characterised by him/her 
speaking in a strange muffled voice in an incomprehensible language. Although 
overlap apparently existed with schizophrenia, it was viewed as a condition 
without a clear Western equivalent that could not be fitted into recognised 
Western classification systems.11;14 
 
“Thwasa” is regarded as a more positive state and within this context Buhrman 
clearly distinguished it from bewitchment.14 The condition is commonly described 
to consist of irritability, social withdrawal and auditory hallucinations and within 
the cultural context is regarded as the state of emotional turmoil a person 
experiences when called to become an indigenous healer. The belief holds that 
resisting such a calling from the ancestors may lead to illness whereas 
answering the call leads to receiving “special powers”.3 
 
In order to improve our understanding of cultural attitudes to health seeking 
behaviour, it would be invaluable to have insight into how these traditional illness 
models (“amafufunyana” and “thwasa”) are viewed and applied. Traditional 
healers play an important role in many cultures (including the Xhosa) and it is not 
uncommon in many societies for patients and/or families to first seek help from 
them prior to making contact with “Western” medicine.15;16 
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Niehaus et al. were the first to attempt to systematically study the frequency by 
which “amafufunyana” and “thwasa” are used by traditional healers to explain 
schizophrenia in the Xhosa population.17 The authors recruited 247 subjects (62 
female and 185 male) with a DSM IV-diagnosis of schizophrenia who were then 
subdivided into 3 groups, i.e. an "amafufunyana"-group, a "thwasa"-group, and a 
group of patients with diagnoses other than "amafufunyana"/"thwasa". The 
division was done on the basis of a structured interview regards the use of 
traditional treatment and diagnostic methods. Two-hundred (80.97%) of the 
participants had used such services and could be included in the analysis. Of 
these 106 were diagnosed with “amafufunyana” and only 9 with “thwasa”.  
 
The comparison between the two groups yielded no significant differences for 
either demographic characteristics or for the presence/absence of any of the core 
symptoms of schizophrenia. Interestingly, however, both a family history of 
schizophrenia (p=0.004) and of other psychiatric disorders (p=0.008) was 
significantly more common in the “thwasa” group. See table 1 for a comparison of 
some of the phenomenological characteristics of the two groups. 
 
As previously stated, a positive view is more often attached to “thwasa” in 
comparison to “amafufunyana” within the cultural context. Taking this into 
account, the authors concluded that one possible explanation for their finding of 
family history being more significantly present in “thwasa” patients, was that 
psychotic symptoms could in their case be seen as an inherited “giftedness” 
- 77 - 
rather than a sporadic illness. It would be important to note that although 
“thwasa” is not regarded as an illness in the Xhosa culture, in the case of this 
dataset, no difference could be shown between the two groups with regard to the 
core symptoms of schizophrenia. 
 
TABLE 1: COMPARISON BETWEEN "AMAFUFUNYANA" AND "THWASA" 
GROUPS 
PHENOMENOLOGICAL 
CHARACTERISTICS 
"AMAFUFUNYANA"
 GROUP  
(n=106) 
"THWASA" 
GROUP 
(n=9) 
GROUP 
DIFFERENCES 
(STATISTICAL 
SIGNIFICANCE) 
Family history of 
schizophrenia 50.9* 100 2=8.059; p=0.004
Family history of other 
psychiatric disorders 14.2 55.6 2=9.899; p=0.008
Bizarre or aggressive 
behaviour 82 88.9 NS 
Affective changes: 
Restricted 
Blunting 
Inappropriate 
 
47.2 
65.1 
16.9 
 
77.8 
55.6 
44.4 
 
NS 
NS 
NS 
Persecutory delusions 94.3 77.8 NS 
Bizarre delusions 37.7 33.3 NS 
Hallucinations (any) 80.2 88.9 NS 
NS - No significant difference detected; significance at p<0.05  
* - All values are percentages 
 
Interestingly, in comparison to the “amafufunyana”/”thwasa” groups those in the 
group that had received neither of these diagnoses were significantly more likely 
to be married (p=0.004), live in rural environment (p=0.007), have a history of an 
identifiable stressor prior to onset of illness (p=0.026) as well as a history of 
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cannabis abuse seeming to predate onset of psychotic symptoms (p=0.015). The 
authors suggest that these differences could possibly be explained by the 
presence of another more apparent reason (e.g. stressor, substance) for the 
illness or that a traditional diagnosis was possibly less likely in patients with 
higher premorbid functioning (e.g. married). 
 
International literature has shown that lay public misconceptions regarding the 
causes and treatment of schizophrenia exist worldwide.18-21 However, these 
seem to differ among different cultural groupings. Whilst studies in Germany have 
found that the public believes schizophrenia to be mainly caused by intra-
psychic, biological or psychosocial stressors, Mbanga et al. demonstrated 
dissimilar findings in their study conducted amongst the Xhosa population.19;22;23 
 
For the purposes of the above study, a trained psychiatric nurse interviewed 100 
caregivers or close family members of Xhosa schizophrenia patients, 
administering a structured questionnaire focusing on participants’ views regards 
the causes, treatment options and course of illness. The mean age of the 
participants was 61.1 (±13.0) years,  76% were female, 59.2% mothers, 21.4% 
fathers and the mean years of schooling 6 (±3.5). Respondents attributed the 
development of schizophrenia to varied number of causes (see table 2). 
 
Although some of the so-called more “biological” or “Western” causes such as 
“brain disease” (46%) or “stressful life-events” (38%) were also endorsed, 
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witchcraft or evil spirits (67%) were most commonly reported. With many 
respondents also endorsing more than one trigger, the results suggest a complex 
explanatory model for schizophrenia in the Xhosa population, with several of the 
suggested causes linking to cultural beliefs such as the phenomena of witchcraft 
as well as not breaking with traditional values. 
 
TABLE 2: PERCEIVED CAUSES OF SCHIZOPHRENIA AS REPORTED BY 
100 CAREGIVERS OR CLOSE FAMILY MEMBERS OF XHOSA 
SCHIZOPHRENIA PATIENTS 
 Yes No Unsure 
Family relationship 
problems 12* 46 42 
Work difficulties 13 68 19 
Stressful events 38 40 22 
Brain disease 46 41 13 
Heredity 34 50 16 
Lack of will power 10 72 18 
Expecting too 
much of oneself 14 82 4 
Unconscious 
conflicts 3 84 3 
Being brought up 
in a broken home 25 59 16 
Lack of parental 
affection 31 54 15 
Over-protective 
parents 19 75 6 
Loss of traditional 
values 29 56 15 
Loss of a natural 
way of life 3 84 13 
Will of God  31 49 20 
Witchcraft, evil 
spirits 67 18 15 
Being poisoned 37 48 15 
Signs of the Zodiac 2 52 46 
* - All values are percentages 
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Another aspect central to Xhosa culture, the traditional initiation ceremony 
(“umkhwetha”), also seems to influence the onset and course of schizophrenia in 
some cases. “Umkhwetha” represents a rite of passage for boys entering 
manhood and the aim of this essential process is to learn of the responsibilities 
and expectations of adulthood.10;24;25 Recently, Le Roux et al. interviewed 75 
Xhosa males diagnosed with schizophrenia to examine their perceptions of the 
role of initiation in the onset and course of their illness. In all, 10.7% perceived 
the initiation rites as a stressful event that had triggered the onset of a psychotic 
episode, and 8% felt it precipitated a relapse. These findings once again 
underline the importance of understanding the cultural background of patients. 26 
 
A further topic of considerable importance concerns the actual use of traditional 
treatment methods. Bhat and Jacobs conducted an intensive survey on the 
general use of traditional treatment methods amongst the Xhosa people in the 
Eastern Cape over a two-year period.27 They concluded that use of traditional 
medical practices could be divided into four categories: (1) Use of common 
remedies not followed by rituals, mostly practiced by common villagers; (2) Use 
of remedies considered to be family secrets handed down from one generation to 
the other (herbalists); (3) Use of remedies by traditional doctors (known as 
“amagqirha” in Xhosa) who keep in contact with their ancestors and who divine 
the cause of disease as misfortunes or who acquire the knowledge of medicinal 
plants and their application from the ancestors in their dreams and; (4) Use of 
remedies by traditional doctors (“amaxwhele” in Xhosa) who physically diagnose, 
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prescribe and sell the medicines for various ailments and who do not divine the 
causes of the illness. 
 
Furthermore, findings indicate that traditional treatments are purchased and 
consumed by a cross-section of the African population.  In their recent study  
conducted in the Eastern Cape, Cocks et al. clearly showed that contrary to 
some assumptions, traditional medicines were not only purchased by those 
groups stereotypically associated with being steeped in traditional customs and 
beliefs such as rural people, the poorly educated, the elderly and religious 
traditionalists.25 It was also apparent that allegiance to Christianity did not 
prevent patronage. In fact, Du Toit and Abdalla note that for the majority of 
Christian Africans no contradiction exists between readily accepting both 
Christian dogma and church rituals while simultaneously practicing ancestor 
reverence.28 In the Cocks study, patrons were from social groupings representing 
all levels of education, religious affiliations and income groups.25 These findings 
on the social background of customers are consistent with that of Hirst’s study of 
the clientele of traditional healers operating in Grahamstown, a university town 
some 90km from one of the Cocks study sites.29 
 
Use of traditional treatment methods is also not limited to only one population or 
illness grouping. A study of 300 physiotherapy patients in KwaZulu-Natal showed 
that 70% would choose to consult a traditional healer as their first choice.30 Also 
in KwaZulu-Natal Mkize et al. conducted a survey to investigate pathways to care 
- 82 - 
and found that traditional healers and faith healers were often the first point of 
contact.31 Of 134 patients presenting for the first time at a psychiatric clinic in 
Malaysia, 69% said that they had visited a traditional healer (bomoh) before 
consulting a psychiatrist.32 In Nigeria, a sample of 80 members of the general 
population showed a generally favourable attitude to traditional healers being 
involved in the treatment of psychiatric illness.15 
 
With regards to schizophrenia, Koen et al. reported on a sample of 236 Xhosa 
schizophrenia sufferers who were interviewed regards their use of traditional 
treatment.16 Of the 236 participants, 198 (84%) said that they had visited a 
traditional healer at some stage of their illness and had adhered to the treatment 
as prescribed by the healer. Treatments prescribed showed great variation and 
most often were: taking of an oral solution (n=109), taking of an oral 
solution/tablet to induce vomiting (n=89), washing (n=61), enema (n=33), use of 
snuff (n=23), slaughter of cattle (n=2), steam (n=24), wearing of beads (n=7) and 
cutting of own skin with a sharp instrument (n=14). Interestingly, ancestral 
appeasement methods, e.g. slaughter of cattle, were not commonly prescribed. 
The mean age of the group was 36.25 years (SD ± 9.41), with males constituting 
75% of the group. The mean number of treatments was 1.87 (SD ± 1.43) and 
60% of the group were urban dwellers. No statistically significant difference could 
be noted for any of the treatment choices when male and female or urban and 
rural groups were compared to each other. 
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Interestingly, in the previously mentioned study by Mbanga et al. 88% of family 
members and caregivers interviewed, considered psychotropic medication to be 
a recommended form of treatment for schizophrenia.23 However, the vast 
majority supported this only in conjunction with the simultaneous use of 
traditional treatment methods. Whilst many felt that traditional healers’ methods 
were essential to protect sufferers from invasion by “bad spirits”, they regarded 
Western treatment to be necessary to prevent symptoms from worsening. This 
endorsement of psychotropic medication in fact contradicts the reportedly poor 
support for Western medicine as claimed in German literature.33;34 
 
Unfortunately, despite the apparent support for psychotropic medication, the 
world-wide significant public stigma attached to the illness also seems to exist in 
Xhosa communities. In her study, Mbanga et al. reported that more than 40% of 
respondents had, in comparison to the average person, a generally negative 
view of the probands.23 Reporting on stigma, as perceived by a mixed sample of 
100 South African schizophrenia sufferers, Botha et al.’s results seemed to 
suggest that especially Xhosa-speaking patients reported experiencing a higher 
incidence of abuse as a form of stigmatisation.35 One possible explanation for 
this high perceived degree of stigma could in fact be a lack of knowledge regards 
schizophrenia and the possible belief that witchcraft or evil spirits play a 
significant role in its causation 
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It is necessary to keep some important limitations in mind when generally 
interpreting the results of the studies conducted amongst the Xhosa 
schizophrenia population and their caregivers or family members reported on 
here. Interviewers were trained mental health practitioners which could have led 
to bias towards endorsing “Western” over traditional methods. Participants were 
often older with poorer education levels and broad generalisations to the results 
to other groupings should be done with caution.  
 
However, the data show that only partial support exists for the biomedical model 
of schizophrenia in this population and culture-specific beliefs often play a 
significant role in how the illness is viewed. These include, but are not confined 
to, the acceptance of cultural diagnoses such as “amafufunyana” and “thwasa”, 
the acceptance of cultural beliefs in the causation of the illness, as well as the 
involvement of traditional healers and treatment practices in health seeking 
pathways. Whether this reflects a more holistic view of the causation of mental 
illness, or whether it comments on the reality of a country with 11 official 
languages, with practitioners unable to communicate in a patient’s home 
language, is an issue that warrants further scrutiny. Regardless, it is clear that a 
more proactive stance needs to be taken to further co-operation with reputable 
traditional healers in order to ensure a more integrated westernised/traditional 
approach in promoting health for all. 
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3.3 RESEARCH ETHICS – GENETICS, CULTURE AND 
PSYCHIATRY 
 
Putting safeguards into place to ensure ethical standards in all aspects of 
research has become a standard part of the agenda of research funding 
agencies and relevant governmental and non-governmental organizations. Long 
gone is the time when the discipline of psychiatry found it adequate to merely 
reach a consensus for research standards and then have the text translated into 
many languages and distributed. In fact, since then psychiatry has moved from 
mostly focusing on treatment and rehabilitation to also include promotion of 
mental health and therefore prevention strategies as well as the involvement of 
the patient, family, broader community and the industry in such. This change is 
also reflected in the increased debate surrounding ethical issues. 
 
Biomedical research is usually guided by the Nuremburg paradigm and the 
status and integrity of ethical guidelines based and the Nuremburg (1947) and 
Helsinki (1964) codes (and later revisions thereof) are well established. However, 
as researchers in the field of genetics have shown growing interest in samples 
from homogenous populations some sensitive ethical issues have come to the 
fore highlighting that strict adherence to the Nuremburg paradigm may not at all 
times be practical or even appropriate. For example, as described in this chapter, 
the Xhosa population place great value on communal interests rather than those 
of the individual (“ubuntu”). Therefore, the current western emphasis on the right 
of the individual to autonomy may not find favour in such a society. As stated, the 
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care of the Xhosa psychiatric patient is more often than not the concern of not 
only the mental health professional but also the family and traditional healers. 
 
Other issues associated with the Nuremburg paradigm regarding its possible 
limitations for psychiatric general and genetic research have also come to the 
fore. Not least of these are the inherent difficulties in obtaining informed consent 
from someone who suffers from a psychotic illness such as schizophrenia. At any 
given time when conducting research within a schizophrenia population some of 
the patients may be suffering an acute exacerbation of illness and this needs to 
be taken into account during the ongoing consent process. True informed 
consent implies that the choice is freely and intentionally made with rational 
understanding of that which is chosen. Clearly, in order for such to be valid the 
information needed to make the decision must be presented in a way that is 
appropriate for the particular patient (e.g. taking into account language, 
intellectual abilities, culture etc.). 
 
Once again cultural beliefs may play a role as some non-western societies 
adhere to the principal of substituted decision making with the head of a group 
(family) or even the whole group responsible for providing consent. However it 
has also been made clear that broad generalisation within a particular cultural 
grouping cannot solely dictate research practices (such as obtaining informed 
consent) within that grouping. At any give time specific individuals within the 
culture may have reached different levels of acculturation in various aspects of 
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their functioning. Furthermore, our beliefs about certain cultures are often based 
on outdated anthropological data. When all of this is taken into account it is clear 
that researchers need to factor cultural diversity into their decision making 
process. 
 
With specific reference to genetic research one must also not lose sight of the 
fact that the cultural meanings people ultimately attach to their symptoms can 
shape the final presentation of a particular disorder. Furthermore, information 
about, and even involvement of biological family members is pivotal to genetic 
research. In a worst case scenario, this could lead to revealing sensitive 
information in a way that could cause significant distress and possibly even 
precipitate relapse. 
With specific reference to genetic research one must also not lose sight of the 
fact that the cultural meanings people ultimately attach to their symptoms can 
shape the final presentation of a particular disorder.36 Furthermore, information 
about, and even involvement of biological family members is pivotal to genetic 
research.37 In a worst case scenario, this could lead to revealing sensitive 
information in a way that could cause significant distress and possibly even 
precipitate relapse. 
 
4. SUMMARY 
 
Given the historical and geographical influences that formed this group, the 
Xhosa population can be regarded as a culturally homogenous grouping with an 
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active traditional belief system. Although this system seems to raise some 
questions with regard to a population-specific course of schizophrenia, it does 
not seem to influence the presentation of the core symptoms of schizophrenia. 
The Xhosa schizophrenia population therefore presents us with an invaluable 
research opportunity to further knowledge with regard to this debilitating illness, 
all the while ensuring that possible ethical issues receive due consideration. 
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CHAPTER 4 
 
CHROMOSOMAL ABERRATIONS 
IN SCHIZOPHRENIA 
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1. BASIC INTRODUCTION TO THE CONCEPT OF 
CHROMOSOMAL ABERRATIONS 
 
The discovery of the principles of heredity by Gregor Mendel in 1865 went largely 
unnoticed until William Bateson, who first coined the term genetics, translated his 
paper from German to English in 1900. This led to increased interest and the 
seminal work on alkaptonuria by Archibald Garrod, who together with Francis 
Galton are regarded as the founders of medical genetics.1 In medical practice, 
genetics still finds its chief significance in its role in the etiology of a large number 
of disorders.2 Three main types of conditions secondary to faulty genetic 
information are recognised – (1) single gene disorders caused by mutant genes, 
(2) chromosomal disorders where aberrations affect development and (3) 
multifactorial inheritance – a combination of several genes each having a smaller 
or larger contribution (in concert with environmental effects) that together 
produce a serious defect.3  
 
In 1956, Tjio and Leven as well as Ford and Hamerton conclusively 
demonstrated (independently of each other) that the number of chromosomes in 
the normal human was 46.4;5 These chromosomes are arranged in 23 pairs and 
are made up of the two sex chromosomes (X,Y) and the so-called autosomes.6 
One copy of a pair is inherited from each parent. A chromosome is a singular 
piece of DNA, which contains many genes, regulatory elements and other 
nucleotide sequences. They also contain DNA-bound proteins, which serve to 
package the DNA and control its functions. Each chromosome has a 
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constriction point, called the centromere, which divides the chromosome into the 
so-called short “p” and long “q” arms.2 (See diagram 1) 
 
 
DIAGRAM 1: REPRESENTATION OF A CHROMOSOME 
 
The discovery by Lejuene and colleagues in 1959 that children with Down 
syndrome have 47 chromosomes instead of the normal 46 paved the way to a 
new era in medical genetics.7 Since then chromosomal aberrations have become 
well-defined causes of maldevelopment shown to be more frequent and varied 
than originally anticipated. They are regarded to be a significant cause of birth 
defects and foetal loss, present in an estimated 0.7 percent of live births and 
nearly half of all spontaneous first-trimester abortions.8;9 
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On a basic level, chromosomal aberrations can be divided into structural or 
numerical abnormalities.2 Numerical abnormalities involve the loss or gain of one 
or two chromosomes (aneuploidy) or the gain of a whole chromosome set 
(polyploidy). Examples of aneuploidy would include the well-known Down 
Syndrome (trisomy 21), Edwards Syndrome (trisomy 18) and Patau Syndrome 
(trisomy 13). True polyploidy rarely occurs in humans; although it is seen in some 
tissues (especially in the liver).10 
 
Structural abnormalities result from chromosomal breakage, followed by 
reconstitution in an abnormal combination. These breaks usually occur 
spontaneously at a low frequency, but can also be induced by a variety of agents 
such as radiation, viral infections and many chemicals. The changes in 
chromosomal structure resulting from breakage may be either stable (e.g. 
deletions, duplications, inversions, translocations, insertions or isochromosomes) 
or unstable (e.g. dicentrics, acentrics and rings).6 
 
Chromosomal inversion involves fragmentation of a chromosome by two breaks, 
followed by reconstitution with inversion of the section of the chromosome 
between the breaks (e.g. AAAbcdEEE becomes AAAdcbEEE). Inversions are 
described as either paracentric (centromere outside the inversion) or pericentric 
(inversion spanning the centromere). As such, inversions alone do not appear to 
lead to an abnormal phenotype in man, although in theory they could if the break 
was within a gene or its regulatory sequences. Rather, the medical significance 
- 98 - 
of inversions lies in the fact that the subsequent generation is exposed to the 
consequences of a crossing over between a normal and an inverted 
chromosome. For example, in 1975 a large pedigree from Newfoundland was 
described in which there were several carriers of an inversion of the long arm of 
chromosome 3, leading to children being born with a syndrome of congenital 
defects including hirsutism, micrognathia and mental retardation.11 
 
Two main types of chromosomal translocation have been described – reciprocal 
and Robertsonian. Reciprocal translocation is the exchange of blocks of 
chromatin between two non-homologous chromosomes, a process that requires 
breakages in both chromosomes with repair in an abnormal arrangement. 
Robertsonian translocation involves two acrocentric chromosomes which fuse at 
the centromere region and lose their heterochromatic short arms.2 
 
Chromosomal deletion refers to loss of a part of the chromosome, usually 
interstitially between two breaks, but sometimes terminally, following a single 
break and leading to the lack of the genetic information that was present in the 
lost fragment. A common example of deletion in humans is the cri-du-chat 
syndrome in which part of the short arm of chromosome 5 is deleted.2  
 
Two other significant concepts are that of genomic imprinting and the contiguous 
gene syndrome. Genomic imprinting refers to certain genes being active only on 
specifically either the inherited paternal or maternal copy of the chromosome. 
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Contiguous gene syndrome refers to disorders that are caused by the deletion of 
multiple gene loci that are adjacent to one another. These syndromes are 
characterised by multiple, apparently unrelated, clinical features caused by 
deletion of the multiple adjacent genes. Each of the individual genes within a 
contiguous region, when mutated, gives rise to a distinct feature. An example 
where both these concepts can be illustrated is via two syndromes caused by 
deletions in the chromosome 15q11-13 region.12 
 
Angelman syndrome (marked by mental retardation, movement or balance 
disorder, characteristic abnormal behaviours, and severe limitations in speech 
and language), is caused when the deletion results in the loss or mutation of the 
UBE3A gene, although possible associations with other genes have also been 
suggested.13-15 Normally people would inherit one copy of the gene from each 
parent but in the brain only the maternal copy is active.16 In most cases, this 
condition therefore results from either a deletion in or a non-transmission of the 
maternal copy, resulting in no working copies of the UBE3A gene in the brain, 
which likely causes the characteristic features of the syndrome.  
 
Prader-Willi syndrome (PWS) (marked by obesity, muscular hypotonia, mental 
retardation, short stature, hypogonadotropic hypogonadism, and small hands and 
feet), on the other hand, is caused in most cases when the paternal copy of 
chromosome 15 is partly or entirely missing as the genes necessary to prevent 
the syndrome are active only on the paternal copy.13;17 Currently, the precise 
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genes that cause this syndrome have not been identified but numerous protein 
coding genes and non-coding transcripts have been isolated from the PWS 
candidate region.18-20    
 
The aim of this introduction was to provide a very basic overview on some topics 
relevant to the concept of chromosomal aberrations.  It was not meant as a 
comprehensive summary and for such the reader is referred to the various texts 
available on this subject. 
 
2. BACKGROUND TO GENETICS OF SCHIZOPHRENIA 
 
The current model of liability to schizophrenia holds that both genetic and 
environmental risk factors contribute to the development of the illness. Although, 
to date, no risk factor of either type has yet been unambiguously identified, 
recent progress in this field would suggest that we are closer to understanding 
specific genetic influences than we are to characterising specific environmental 
ones. For example, even though epidemiological studies have identified a 
number of possible contributors such as obstetric complications, immigration, 
season of birth and use of illegal drugs (especially cannabis); the effect sizes are 
small and the direction of causation remains uncertain in most cases.21 
 
To genetically study any complex trait, including schizophrenia, there are two 
very important areas of inquiry. Firstly, it must be determined whether there is an 
additional risk for the trait in relatives of cases and, if so, whether the risk is 
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attributable to shared genetic rather than shared environmental factors. 
Secondly, linkage and association studies are needed. Linkage studies are used 
to demonstrate a relationship between a trait and a specific region of the 
genome, while association studies are more focused and used to establish 
whether a relationship exists between a trait and specific genes.  
 
Numerous family, twin and adoption studies have shown in a conclusive manner 
that schizophrenia has a high familial heritability risk and that genes have a major 
contributory role in the aetiology of the disorder.22 In fact, schizophrenia has one 
of the highest heritabilities (approaching 80%) among the complex genetic 
disorders, similar to that of type I diabetes mellitus (72-88%) and greater than 
that of breast cancer (30%) and heart disease in males (57%).21;23;24 In real 
terms, this can be interpreted to mean that a close relative of a schizophrenia 
patient has, on average, ten times the baseline population risk of developing the 
disorder. 
 
However, it is important to remember that since the heritability estimates are less 
than 100% and the concordance for monozygotic twins is approximately 50%, it 
is clear that environmental factors must play some role. Furthermore, the risks as 
a result of some gene-environment interactions are probably attributed to genes 
in most genetic epidemiology studies.25  
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The genetic heterogeneity is mirrored by clinical heterogeneity, which arguably 
reflects the heterogeneous nature of susceptibility factors for schizophrenia. Not 
only do we find multiple combinations of symptoms existing in individuals but also 
both disease course and outcome display considerable heterogeneity. Therefore, 
as previously stated, we currently cannot be certain whether this is a single 
disorder with different clinical manifestations or in fact a group of syndromes, 
each with unique or overlapping pathophysiology.  
 
3. THE SEARCH FOR GENES IN SCHIZOPHRENIA 
 
Considerable attempts have been made to elucidate the heterogeneity of the 
schizophrenia phenotype by exploring the relationships between the various 
symptom dimensions and possible subtypes. Some researchers have felt that 
genetic studies in schizophrenia using phenotypes would profit from the use of 
symptoms that are closer to their etiology than the end-stage clinical symptoms 
that are currently used by the DSM-IV-TR and the ICD10 to define schizophrenia.  
They therefore advocate the use of a system such as Leonhard’s classification of 
psychoses, which claims to define real diseases on the basis of differentiated 
and operationalised psychopathological syndromes, rather than DSM-IV-TR or 
ICD10 to define the phenotype for such linkage studies.26 
 
Clearly the identification of susceptibility genes would be of great benefit to 
further explore the validity of our current nosological categories. This should help 
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illuminate heterogeneity within the current schizophrenia concept and further the 
process of understanding its relationship to other diagnostic groups. 
 
Unfortunately, the search for chromosomal loci and genes has been a slow and 
tedious process, most probably because there are multiple susceptibility genes, 
each with small effect, which act in conjunction with epigenetic processes and 
environmental factors. Currently, the number of susceptibility loci, the disease 
risk conferred by each locus, the extent of genetic heterogeneity and the degree 
of interaction among all the loci, remain unknown quantities. 
 
To date, three main approaches have been used to seek genes for schizophrenia 
(1) molecular genetic studies, (2) studies of functional candidate genes and (3) 
identification of chromosomal aberrations associated with schizophrenia. 
 
3.1 MOLECULAR GENETIC STUDIES - LINKAGE ANALYSIS 
 
In contrast with several other complex disorders such as Parkinson’s disease 
and epilepsy, no forms of schizophrenia following Mendelian inheritance patterns 
have yet been discovered. Indeed, until recently results of linkage studies have 
been meagre as most studies neither achieved stringent “genome-wide” levels of 
significance nor replicated pre-existing findings.27 Small sample sizes, small 
genetic effects and the use of marker maps with insufficient density have 
probably all contributed to these disappointing findings. It is also important to 
remember that in human populations strict replication studies are virtually 
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impossible as samples will almost certainly differ with regards to genetic 
architecture due to ethnicity, ascertainment, variation in exposure to 
environmental risks and, where there are multiple disease loci, sampling 
variance.28;29 
 
In an attempt to address some of these issues two large meta-analysis of 
schizophrenia linkage have recently been undertaken. Badner et al. performed a 
medline search to identify all published genome scans for schizophrenia. Of 
these they included only studies where all regions and/or markers with p-values 
<.05 were reported and the specific location was given.30 Follow-up papers were 
excluded on the basis of being subject to possible publication bias (i.e. less likely 
to be published if negative). Lewis et al. included all published and presented 
(unpublished) data that represented whole genome scans of schizophrenia, 
excluding partial scans and candidate region studies.31 Ultimately the meta-
analyses reported on eighteen and twenty studies respectively of which eleven 
were reported on by both.30;31  
 
The regions (presented in descending order of significance) supported by Badner 
et al. were 22q, 8p, 13p and by Lewis et al. 2p, 5q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, 
14p.30;31 Therefore only 8p and 22q were supported by both analyses. When 
taking into account how the meta-analyses were performed, the differing results 
are not surprising. Also, the results are in keeping with Risch’s calculations that 
existing data for recurrence risk in relatives is incompatible with the existence of 
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a single locus in schizophrenia, conferring a relative risk in siblings of greater 
than three and that models with two or three loci carrying a relative risk of ≤2 are 
more plausible.32 
 
Taking the phenotypic approach, Stober et al. used periodic catatonia, a clinical 
entity derived form Leonhard’s classification of schizophrenias, to conduct a 
genome-wide linkage analysis.26;33 In periodic catatonia, the nuclear syndrome 
consists of distinct hyperkinetic and/or akinetic disturbances of psychomotor 
behaviour. These qualitative psychomotor symptoms are present in both the 
acute psychotic episode and the residual state. On the basis of their non-
parametric and parametric linkage analysis Stober et al. identified two 
schizophrenia susceptibility loci.33 One, 22q13, was supported mainly on data for 
a single large family, but the other, 15q15 (LOD score 3.57; p<.000026), met 
Lander’s criteria for linkage and was regarded as significant.34 Interestingly, on 
chromosome 15q15 the candidate segment overlaps with a putative 
schizophrenia locus defined by a neurophysiological deficit of the P50-auditory-
evoked-response inhibition in patients with schizophrenia.35 
 
3.2 CANDIDATE GENES 
 
3.2.1 POSITIONAL CANDIDATE GENES 
 
The convergence of the positive linkage findings has led to several detailed 
mapping studies of linked regions and some of these have implicated specific 
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genes. Based on current published data the most convincing of these loci seem 
to be dystrobrevin-binding protein 1 (DTNBP1) (6p22), neuregulin 1 (NRG1) 
(8p12-21), D-amino acid oxidase (DAO), D-amino acid oxidase activator (DAOA) 
(both 13q22-34), and regulator of protein signaling 4 (RGS4) (1q21-22).36 
 
3.2.2 FUNCTIONAL CANDIDATE GENES 
  
Schizophrenia candidate-gene literature reveals a large number of positive and 
negative findings and many of the initial positive associations have yet to be 
replicated.  Two genes that have been the focus of several replication attempts 
are V-AKT murine thymoma viral oncogene homolog 1 (AKT1) (14q22-32) and 
glutamate receptor metabotropic 3 (GRM3) (7q21-22).36 
 
 
3.3 CHROMOSOMAL ABERRATIONS 
 
Studies in Caucasian and Asian populations have revealed that between 2% and 
32% of schizophrenia subjects have chromosomal aberrations such as 
translocations, deletions and inversions.37;38 However, though there have been 
numerous reports of associations between schizophrenia and chromosomal 
abnormalities, none, with the exception of two, can be regarded to have provided 
any convincing evidence for the location of a susceptibility gene.39 The two in 
question are the deletions on chromosome 22q11 and the balanced 
chromosomal translocation (1;11)(q42;q14.3) disrupting two genes on 
chromosome 1 (Disruption in schizophrenia 1 (DISC 1) and 2 (DISC2)). 
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3.3.1 DISRUPTION IN SCHIZOPHRENIA 1 
 
DISC1 was first identified in an extended Scottish pedigree (see diagram 2) when 
a balanced chromosomal translocation disrupting two genes (DISC1 & DISC2) 
on chromosome 1 was discovered and then demonstrated to show linkage to a 
fairly broad phenotype, consisting of schizophrenia, bipolar disorder and 
recurrent major depression.(Blackwood 2001) Interestingly, both these genes are 
located close to the chromosome markers implicated in two Finnish linkage 
studies.40;41 
 
DIAGRAM 2: PART OF THE SCOTTISH PEDIGREE WITH (1;11)(q42;q14.3) 
TRANSLOCATION. SHOWN ARE THE 58 FAMILY MEMBERS FOR WHOM 
CARRIER STATUS AND PSYCHIATRIC PHENOTYPE HAD BEEN 
DETERMINED42 
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Currently the functions of DISC1 are not understood well and therefore those 
ascribed to it are inferences from the known functions of the proteins that interact 
with it.43 It has been suggested that DISC1 and a number of interacting proteins 
may play a role in neuronal migration, cortical layering during foetal brain 
development, hippocampal formation and probably adult neurogenesis in the 
dentate gyrus all of which is consistent with the neurodevelopmental hypothesis 
of schizophrenia.44-46 Whereas DISC1 encodes a novel multifunctional scaffold 
protein, DISC2 is a putative noncoding RNA gene antisense to DISC1 which may 
regulate DISC1 expression.47 If future investigations can elucidate the molecular 
mechanism by which DISC1 regulates the activity of these protein-binding 
partners it will ultimately lead to a better understanding of the role of DISC1 at 
the level of brain function. 
 
However, it is important to remember that translocations can exert effects on 
genes other than those directly disrupted. Thus, to implicate DISC1 and/or 
DISC2 conclusively in the pathogenesis of schizophrenia it would be necessary 
to identify mutations or polymorphisms that are associated with schizophrenia in 
another population and to show that those associations cannot be attributed to 
linkage disequilibrium with neighbouring genes. To date, four published studies 
have attempted to find such evidence.  Two, including one by the group who 
originally identified DISC1 and DISC2, have been negative but positive findings 
have been reported in a large Finnish and an US sample.48-51 All in all, DISC1 is 
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currently regarded to be one of the best replicated genetic findings with biological 
plausibility for major mental illness.52 
 
3.3.2 CHROMOSOME 22q11 DELETIONS 
 
Chromosome 22 is the second smallest of the human autosomes comprising 1.6-
1.8% of the genomic DNA.53 It was the first chromosome of which an 
operationally complete sequence of the euchromatic portion was finalized and as 
such represents a sequencing landmark in the human genome project.54 Due to 
the extensive body of literature available on this chromosome and related topics, 
a separate chapter is devoted specifically to it. 
 
4. SUMMARY 
 
Genes are the first objective clues to the primary causes of mental disorders and 
to the mechanisms of cellular pathogenesis. Although they are not the only 
etiologic factors in the pathogenesis of schizophrenia (both environment and 
epigenetic processes may also be important), the major benefit for genes is that 
they are bounded and objective and their biological effects can be more readily 
identified and quantitated. Therefore, taking all evidence into account it would be 
difficult to not conclude that genetic research about schizophrenia has, to date, 
generated a credible list of potential susceptibility genes, thereby starting to give 
us a glimpse into potential mechanisms by which these genes influence the risk 
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of disease. Ultimately, this will lead to our understanding of this disorder being 
enhanced dramatically. 
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1. INTRODUCTION 
 
The so-called 22q11 deletion syndrome (22q11DS) is the second most common 
human chromosomal anomaly (after trisomy 21) and the most frequently known 
interstitial deletion found in humans, occurring in approximately one of every 
4000 live births.1 It has been reported in association with more than 120 different 
birth defects and usually occurs as a sporadic mutation. Autosomal dominant 
inheritance is observed in 15% or less of cases.2;3 As noted in the previous 
chapter, the microdeletion at chromosome 22q11 remains one of only two (the 
other being a balanced chromosomal translocation [t(1;11)(q42.1;q14.3)]) 
reported associations between schizophrenia and chromosomal abnormalities 
that currently show any convincing evidence for the location of a susceptibility 
gene.4 
 
2. 22q11 ABERRATIONS IN HUMANS 
 
Genomic disorders are caused by an alteration of the genome that might lead to 
the complete loss or gain of a gene(s) sensitive to a dosage effect or, 
alternatively, might disrupt the structural integrity of a gene. Examples are the 
disorders caused by DNA rearrangements owing to homologous recombination 
involving region-specific low-copy repeats.5 The 22q11 region can be regarded 
as a model for these genomic disorders as it is seems particularly susceptible to 
such chromosomal rearrangements, with three different congenital malformation 
syndromes having been described thus far. These are the cat-eye syndrome 
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(CES), derivative (22) syndrome (der(22)) and what is collectively referred to in 
the literature as 22q11 deletion syndrome (22q11DS). (Originally CATCH 22 was 
suggested as an all encompassing term with the acronym representing Cardiac 
defects, Abnormal facies, Thymic hypoplasia, Cleft palate and Hypocalcaemia.6 
However, due to the emergence of more divergent clinical presentations as well 
as objections from some patient groups, this term is no longer in common use.7) 
The three disorders are most often identified by intellectual disability and/or 
congenital malformations and of the three, 22q11DS is by far the most common. 
 
2.1 22q11 DELETION SYNDROME (22q11DS) 
 
The 22q11DS is associated with a variable phenotype that can present with 
characteristic facial dysmorphology, a range of congenital abnormalities, and 
emotional (including psychosis), behavioural and cognitive deficits. Due to the 
frequency of the occurrence of certain sub-clusters of these symptoms in the 
presence of the characteristic facial dysmorphology, 22q11DS is regarded to 
encompass several distinct genetic “entities” including DiGeorge (DGS), 
conotruncal anomaly face (CAFS), and velocardiofacial (VCFS) syndromes as 
well as, in some cases, Cayler and Opitz GBBB syndromes.8-13 Numerous 
combinations of anomalies are found in sufferers of each of these syndromes but 
there are some classical findings which are summarised in table 1. 
 
The syndrome was first described in the 1950s and further delineated by 
Shprintzen et al.13;14 The first clue to the aetiology came when De la Chapelle et 
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al. reported a family with a chromosomal translocation t(20;22)(q11;q11) in which 
four subjects with unbalanced products had DGS.15 However, as routine 
karyotype analysis cannot be used to detect the deletion, it only became more 
generally identified with the availability of specialised chromosomal studies in the 
1990s.16  
 
TABLE 1: BRIEF SUMMARY OF THE CLASSICAL FEATURES FOUND IN 
EACH OF THE COMMONLY KNOWN DISTINCT ENTITIES THAT 
ENCOMPASS 22q11DS8-13 
SYNDROME CLASSICAL FEATURES 
DiGeorge   Interrupted aortic arch 
 Tetralogy of Fallot 
 Truncus arteriosus 
 Parathyroid & thymic hypoplasia 
Velocardiofacial   Velopharyngeal insufficiency 
 Learning disorder 
 Conotruncal abnormalities 
Conotruncal anomaly face  Velopharyngeal insufficiency 
 Learning disorders 
 Ventricular septal defect 
Cayler  Unilateral facial palsy (congenital hypoplasia of depressor 
anguli oris muscle) 
 Ventricular septal defect 
Opitz GBBB  Hypertelorism 
 Hypospadia 
 Swallowing difficulties 
 Cleft of lip, palate & uvula 
 Laryngotracheo-esophageal cleft 
 
Currently the deletions can be readily detected using standard fluorescence in 
situ hybridization (FISH) analysis techniques. By far the majority of patients with 
22q11DS have either a common recurrent deletion of approximately 3Mb (87% of 
cases) or a smaller, less common, 1.5Mb (8% of cases) deletion. The 1.5Mb 
deletion involves the same proximal breakpoint but a nested distal deletion 
endpoint.17 Both deletions apparently occur as a result of homologous 
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recombination between nonallelic flanking low-copy repeat (LCR) sequences 
located in 22q11.2.18;19 Although eight different LCRs are located in proximal 
22q, only a few cases of atypical deletions using alternative LCRs have been 
described.20  
 
2.2 CAT-EYE SYNDROME (CES) 
 
CES presents with borderline-to-moderate mental retardation as well as clinical 
features distinct from those found in 22q11DS that mostly show variable 
expressivity and penetrance. These include ocular colobomata, anal atresia, 
microphthalmia, congenital heart defects (most typically total anomalous 
pulmonary venous return (TAPVR)), renal malformations, craniofacial anomalies 
(e.g. preauricular skin tags and pits), male genital anomalies and skeletal 
defects.21 CES patients have a small supernumerary bi-satellited marker 
chromosome 22pter-q11 resulting from an inverted duplication of the proximal 
22q11 region. The additional CES chromosome generally arises de novo from 
either of the parents and currently no data is available on sibling recurrence risk 
or population incidence estimates. The CES chromosome contains two 22q11 
breakpoints, but the location of the individual breakpoints may differ.22 Both these 
regions occur in the same intervals as do the proximal and distal breakpoints of 
the 3Mb 22q11DS deletion.18 
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2.3 DERIVATIVE (22) SYNDROME (Der(22)) 
 
Der(22), also known as Emanuel syndrome, shares, with the distinct exception of 
the colobomata, microphthalmia and TAPVR, the features of CES as described 
above.23 In addition, mental retardation, cleft palate and hypotonia are much 
more common in der(22) than in CES.21 The syndrome is caused by a 
chromosomal translocation t(11;22) that currently represents the most common 
recurrent non-Robertsonian translocation reported in humans.24 Normal balanced 
t(11;22) translocation carriers are at risk of giving birth to offspring with der(22) 
syndrome, resulting from a 3:1 meiotic non-disjunction.25 In der(22) the t(11;22) 
breakpoint occurs in the same interval as does the nested distal 1.5Mb 22q11DS 
breakpoint.26 To date, no studies have reported any association between either 
CES or der(22) and neuropsychiatric manifestations. 
 
3. THE 22q11DS PHENOTYPE 
 
3.1 GENERAL FEATURES 
  
Initial descriptions of the 22q11DS phenotype focused mainly on the cardiac 
defects, characteristic physiognomy, palate abnormalities and intellectual deficits. 
However, it soon became clear that a number of later onset conditions such as 
hypocalcaemia, thrombocytopenia and neuropsychiatric manifestations were also 
associated with 22q11DS. In fact, the phenotype has been shown to vary 
considerably between families as well as among members of the same family.27 
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The physical structures that are primarily affected in 22q11DS are all derivatives 
of the branchial arch/pharyngeal pouch system and also all receive a contribution 
from the rostral neural crest during embryogenesis. Neural-crest cells migrate 
from a position adjacent to the neural tube and participate in the formation of 
both pharyngeal arches and their derivatives. Experiments that have been 
designed to interfere with crest functioning have led to the production of good 
phenocopies of the main features of 22q11DS.28;29 Furthermore, natural or 
induced mutations of genes thought to be involved in the control of neural crest 
development can also lead to malformations suggestive of 22q11DS.30-33 These 
findings form the basis of the hypothesis that the deletion of 22q11 disrupts the 
neural crest cells, or the cells with which it interacts, at a critical phase of 
organogenesis. 
 
As mentioned, the distinct clinical features of 22q11DS show variable 
expressivity and incomplete penetrance and there seems to be no apparent 
correlation between the severity of the pattern of the expressed phenotype and 
the extent of the deletion for 22q11DS.34 It is also important to note that profound 
neurodevelopmental, cognitive, behavioural and psychiatric symptoms have 
been shown to occur in the absence of any major physical anomalies. In fact, the 
prevalence of psychosis in those with 22q11DS is high (30%), suggesting that 
haploinsufficiency of a gene or genes in this region may confer this substantially 
increased susceptibility.35  
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Furthermore, in a fair percentage (<10%) of patients with syndromal features the 
microdeletion cannot be demonstrated indicating possible point mutations in the 
22q11 region, that have not yet been identified or possible involvement of other 
chromosomal aberrations.36-39 In particular, deletions of the short arm of 
chromosome 10 (10p) can often be detected although these are much less 
common than those of 22q11 occurring at an estimated frequency of only 1 in 
200000 live births.40 Interestingly, in comparison, 10p patients seem to present 
with a higher frequency of renal abnormalities and growth retardation as well as 
more severe intellectual disabilities but with less cardiac defects than 22q11DS 
patients.41 
 
Non-genetic causes such as exposure to teratogens during pregnancy could also 
play a role. Examples include the offspring of diabetic mothers and prenatal 
exposure to retinoids or alcohol that have been associated with similar-looking 
phenotypes, possibly through exerting effects on neural crest cell migration 
during embryonic development.42-45 
 
3.2 FACIAL DYSMORPHOLOGY 
 
Facial dysmorphology can be quite variable and is most pronounced during the 
childhood period.46 Features most helpful to assist in the diagnosis are regarded 
to be the ear shape, prominent nasal root and in the younger child, the mouth. In 
infancy, micrognathia may be present. The ears are typically low set and 
deficient in the vertical diameter with abnormal folding of the pinna. The face 
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appears long and narrow with flat cheeks. Palpebral fissures are often short and 
sometimes narrow and the root and bridge of the nose wide and prominent. The 
philtrum is often short and poorly modelled with the mouth small, the lips thin and 
the chin retracted.6;46-48 
 
3.3 CARDIAC ABNORMALITIES 
 
The congenital heart defects (CHD) found in a large number of patients, are the 
main cause of morbidity and mortality in 22q11DS. The type of CHD is variable 
but very often involves the outflow tract of the heart and the derivatives of the 
branchial arch arteries. Malformations include, among others, interrupted aortic 
arch (IAA), pulmonary atresia with a ventricular septal defect, tetralogy of Fallot 
and truncus arteriosus.49 Interestingly, it has been reported that the likelihood of 
finding a deletion is greater in cases with IAA type B (interruption between the left 
carotid and subclavian arteries) compared to those with IAA type A (interruption 
just beyond left subclavian artery).50 
 
3.4 IMMUNE SYSTEM 
 
Significant rates of immunodeficiency have been reported in 22q11DS samples, 
but the degree of severity varies considerably.51;52 Most have a mild form 
characterised by low absolute T-cell numbers and children can be susceptible to 
upper respiratory infections. However, at the other end of the spectrum the 
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immunodeficiency may be very severe, as seen in patients presenting with 
thymic aplasia or hypoplasia and absent T-cells6;53 
 
3.5 ENDOCRINE SYSTEM 
 
Hypocalcemic hypoparathyroidism as a result of absent or small parathyroid 
glands has been reported to varying degrees (40-60%) in different 
samples.6;46;47;51 This can probably be readily explained by the fact that neonatal 
presentation can resolve spontaneously and then sometimes reoccur later in life, 
or the condition could be missed as it can be latent at times.54;55 Patients are 
often short of stature and this can sometimes be linked to growth hormone 
deficiency which in some cases has been shown to be due to pituitary 
abnormalities as diagnosed on MRI.51;56 Both hyper- and hypothyroidism have 
also been reported but this phenomenon is not well characterised.47;51 
 
3.6 OTOLARYNGEAL 
 
Palate abnormalities are commonly reported with the velopharyngeal 
insufficiency and hypoplasia of the nasopharynx probably contributing to speech 
delays and the conductive hearing loss that is frequently seen.46;51 A wide 
spectrum of speech abnormalities occur, with hypernasal speech often a 
prominent feature. Expressive language skills are more impaired than receptive, 
with no correlation found between language impairment and IQ.57 
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3.7 COGNITIVE AND BEHAVIOURAL 
 
Learning disabilities were part of the original VCFS phenotype described by 
Shprintzen et al. in 1978.13 Over time a behavioural phenotype with a 
characteristic pattern of motor, cognitive, linguistic and social deficiencies, has 
become apparent. Delayed developmental milestones can be prominent.58 The 
majority of 22q11DS sufferers have mild to moderate intellectual impairment and 
verbal IQ scores tend to be higher than non-verbal. Intellectual disability is higher 
in familial deletions and more severe in the phenotype associated with the 10p 
deletion.41;46-48;58-61 Behavioural and psychiatric disorders have also been shown 
to be prevalent in the 22q11DS populations. (Discussed separately in this 
chapter) 
 
3.8 MISCELLANEOUS  
 
Structural renal abnormalities, renal insufficiency and renal tubular acidosis have 
all been reported as well as a wide range of neurological abnormalities including 
structural brain abnormalities, 7th cranial nerve palsy, hemipareses and recurrent 
seizures. Minor abnormalities of the skeletal system such as talipes equinovarus, 
polydactyly, syndactyly and abnormal vertebrae (kyphosis/scoliosis) are also 
seen.46-48;51 A number of other less common, but not isolated, abnormalities also 
occur in numerous systems. The interested reader is referred to Basset et al. for 
a more comprehensive list.47 
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3.9 VARIED FREQUENCY OF PHYSICAL ANOMALIES 
 
Available literature contains data on numerous 22q11DS patient populations with 
descriptions ranging from case reports to fairly large samples. In spite of this, the 
true frequency of individual features remains somewhat uncertain as rates vary 
with developmental stage, ascertainment and completeness of assessment.48;62 
Two of the largest groups studied to date are that of Cohen et al. who 
documented data from a sample of 126 adults (76 transmitting parents of 
affected offspring) collected via English language MEDLINE search (Jan 1966 to 
July 1998) and that of Ryan et al., whose sample was collected by submitting 
data questionnaires to 23 European centres, and consisted of 425 children, 72 
adolescents and 61 adults (27 transmitting parents of affected offspring).46;48 
(See table 2 for a comparison of major clinical findings and sex distribution in 
these two studies.) 
 
In comparison to Ryan et al., Cohen et al. reported a significantly lower rate of 
major cardiac anomalies (p<0.0001) but a significantly higher rate of a wide 
range of palate abnormalities (p<0.0001), cognitive difficulties (p<0.0008) and 
psychiatric conditions (p<0.02).46;48 Ascertainment biases and age required to 
identify manifestations not obvious at birth would most likely explain these 
differences.48 Furthermore, cardiac anomalies contribute most significantly to 
morbidity in 22q11DS patient population and this could also provide an 
explanation as to the differing rates for this group of anomalies in differing age 
groups. Interestingly, in the Cohen et al. sample, transmitting parents had 
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consistently lower levels of cardiac anomalies (p<0.0001), cleft palate (p<0.005) 
and reported psychiatric conditions (p<0.0001) than the rest of the sample.48 This 
would be in keeping with the notion that these patients represent a milder 
phenotype.46;63 
 
TABLE 2: COMPARISON OF SEX DISTRIBUTION AND MAJOR CLINICAL 
FINDINGS IN 22q11DS BETWEEN THE SAMPLES REPORTED ON BY RYAN 
et al. & COHEN et al.46;48 
Cases reporting data on the absence 
or presence of a particular finding Cases with finding present 
 
Cohen Ryan Difference Cohen Ryan Difference 
Clinical 
findings N (%) N (%)
*2X  p N (%) N (%) *2X  p 
Female 
sex 123 98 399 72 38.02 <.0001 83 67 202 51 10.97 <.0015
CHD 120 95 545 98 2.00 NS 36 30 409 75 88.65 <.0001
All palatal 
anomalies 105 83 496 89 2.79 NS 92 88 233 47 56.95 <.0001
Cleft 
palate       43 41 72 15 37.45 <.0001
VPI       49 47 161 32 7.77 <.0004
LD/MR 111 88 338 61 34.84 <.0001 104 94 268 79 12.13 <.0008
Psychiatric 
disorders 
(adults)a 
46 37 61 - - - 45 36 11 18 5.71 <.02 
*df = 1 
CHD = congenital heart defects, major anomalies only (see text) 
aIncludes any motor, language, or speech delay. 
NS = non-significant 
VPI = velopharyngeal insufficiency. 
LD/MR = learning difficulties or mental retardation. 
 
The expected sex ratio for an autosomal dominant condition is 1:1 and it is 
therefore of interest that a number of 22q11DS samples including that of Cohen 
et al. report a female excess.48 One possible explanation for this could be 
preferential maternal transmission of the deletion as has been suggested by 
some authors.6;64 In turn, the reason for this phenomenon could be impaired 
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reproductivity of males or possibly decreased survival of males into 
adulthood.27;64 
 
In the largest sample of 22q11DS adults (n=78) where patients were all 
systematically assessed by the same clinicians, Bassett et al. documented all 
features that appeared in at least 5% of the sample. The group identified 43 
lifetime features (median of nine per patient (range 3-22)) of which 12 could be 
further subdivided.47 Five of these, learning disabilities (92.3%), hypocalcaemia 
(64.1%), palatal abnormalities (42.3%), cardiovascular anomalies (52.6%) and 
thymic hypoplasia (10.3%) are characteristic features of 22q11DS. Other, less 
commonly appreciated features that were demonstrated in a significant number 
of participants were obesity (35%), hypothyroidism (20.5%), hearing deficits 
(28%), cholelithiasis (19%), dermatological abnormalities (28%) and scoliosis 
(47%).  
 
The sample was primarily collected from a congenital cardiac centre (n=35) and 
psychiatric referral sources (n=39).47 Marked ascertainment bias effects could be 
directly related to this, as, in comparison to the whole sample, each 
ascertainment subgroup had less than half of the other’s highlighted anomaly. To 
assess other possible effects of major ascertainment biases the results from two 
non-overlapping subgroups (31 with Tetralogy of Fallot; 31 with schizophrenia) 
were also determined. No other significant differences could be demonstrated 
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between the two, however due to its size, the sample would have had limited 
power to detect differences for features with lower frequencies. 
 
Better delineation of the 22q11DS phenotype is of great importance as it not only 
helps clinicians with early detection and appropriate treatment of the associated 
medical features, but also aids counselling, especially in terms of common later 
onset conditions, including psychiatric disorders. Genetic counselling is also 
crucial in families with an affected parent as the sibling recurrence risk is 50% 
and offspring are often more severely affected. Furthermore, an awareness of 
suggestive phenotypic features could help a wide variety of clinicians such as 
endocrinologists, hematologists and psychiatrists to identify 22q11DS in their 
patients.  
 
4. 22q13 ABERRATIONS 
 
For the sake of completeness it is necessary to mention the syndrome 
associated with the 22q13 terminal microdeletion that has been described in the 
literature. Patients share a common phenotype, including generalised 
developmental delay, hypotonia, compromised language development, autistic-
like behaviours, normal to accelerated growth and mild dysmorphic facial 
features. Other features that have been described with regularity are, partial 
agenesis of the corpus callosum, bilateral ureteropelvic stricture, 
gastroesophageal reflux, seizures, increased tolerance to pain and hearing 
loss.65 Males and females seem to be equally affected but currently the 
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prevalence of this condition is unknown and in all likelihood it is under-diagnosed. 
The deletion is usually a de novo finding; however, approximately 20% of 
reported cases are familial.66 
 
Using mostly FISH analyses it has been shown that the deletion varies 
considerably with sizes from 130kb to 9Mb reported.67 Statistically significant 
correlations between the size of the deletion and the degree of developmental 
delay, as well as the increased severity or higher incidence of clinical features 
such as hypotonia, have been demonstrated.66 The breakpoint has been 
demonstrated within exon 21 of the PSAP2 (SHANK3) gene. As the SHANK3 
gene encodes a structural protein of the postsynaptic density, it has been 
proposed that haploinsufficiency of this gene is a major causative factor in the 
neurologic symptoms of this syndrome.68 Due to the autistic-like behaviours that 
have been reported it has been suggested as a potential cause for this 
disorder.69 No other psychiatric associations have been reported and although 
the 22q13 area has been studied in both schizophrenia and bipolar disorder, no 
conclusive linkage has been demonstrated.70;71 
. 
5. 22q11DS AND NEUROPSYCHIATRY 
 
Although few studies initially placed any focus on the presence of psychiatric 
disorders in 22q11DS, high rates of neuropsychiatric disorders were often 
reported in such samples.72-76 Interestingly, one of the first clues that psychiatric 
symptomatology may be associated with the microdeletion was when children 
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with 22q11DS were demonstrated to show affective flattening and monotonous 
speech as part of the phenotype although they did not meet criteria for a specific 
psychotic illness.77 Specifically in children, attention-deficit hyperactivity disorder, 
primarily the inattentive subtype, is one of the most common psychiatric 
problems associated with 22q11DS, with reported rates of 37-41%.78;79 Autistic 
spectrum disorders (ASD) also seem to appear commonly, with for example, 
Fine et al. reporting approximately 11% of children in their sample (n=98) to be 
autistic, and showing greater developmental delays than those without ASD.80 
Both bipolar disorder and depression have also been reported to be common in 
children with 22q11DS.81 It has also been suggested that more careful scrutiny of 
pre-adolescents reveals psychotic manifestations to be present earlier than 
typically reported, possibly accompanied by manifestations such as reduced 
verbal IQ performance and decreased adaptative social skills.82 In their study, 
Gothelf et al. compared a group of 31 adolescents with 22q11DS with a control 
group (n=29) at baseline and five-year follow-up.83 Although baseline 
neuropsychiatric profiles had been similar, at follow-up, 32.1% of the 22q11DS 
subjects had developed psychotic disorders in comparison to only 4.3% of the 
control subjects. 
 
In adult samples, between 22% and 31% have been shown to meet criteria for 
schizophrenia or schizoaffective disorder.47;74;84 Murphy et al. reported on an 
adult sample of 50 VCFS patients showing a prevalence of 24% for 
schizophrenia, whilst Bassett et al. reported a prevalence of 22.6% in their 
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sample of 78 22q11DS patients.47;84  This finding would be in keeping with the 
fact that the mean age of onset for these disorders is early adulthood in the 
general population. It would also fit with the estimation that 1 in 4 children with 
22q11DS will develop schizophrenia in their lifetime.85 
 
In addition to schizophrenia, high rates of obsessive compulsive disorder (OCD) 
and bipolar disorder have also been reported. Gothelf et al. showed a lifetime 
prevalence for OCD 32.6% of participants (n=43) and Papolos et al. a rate of 
more than 40% for bipolar-spectrum disorders (n=25).73;79 These findings stand 
in contrast to the only mildly elevated (3%) reported rates of schizophrenia co-
morbid with mental retardation.86 Also, co-morbid primary psychiatric illness (and 
especially psychosis), is rarely, if ever, reported in other genetic syndromes with 
behavioural phenotypes (e.g. Fragile X, Rett’s and Turner Syndrome).87 Also 
neither Bassett et al. nor Pulver et al. could demonstrate a relationship between 
the high rate of schizophrenia and the presence of a major psychotic illness in 
first or second degree relatives of 22q11DS patients.74;88 
 
6. 22q11DS AS AN ENDOPHENOTYPE IN 
SCHIZOPHRENIA 
 
Viewed from a schizophrenia population group perspective, there seems to be a 
clear increased risk for a 22q11 deletion (with reported rates of 0.3-2%) in 
comparison to that of the general population (0.016-0.025%).2;17;89;90 
Furthermore, this risk also seems to increase with earlier age of onset 
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(childhood-onset of schizophrenia (COS)) (5-6% in cases with onset before the 
age of 13 years).90;91 It has also been suggested that differing prevalence rates 
are seen in diverse population groups.17;89;92;93 Importantly, seen together, these 
studies suggest an approximate 25-fold risk for schizophrenia in patients with 
22q11 microdeletion, therefore representing the highest known genetic risk factor 
for this illness (comparable to having two parents with schizophrenia and second 
only to having an affected monozygotic twin). 
 
As such, 22q11DS has in fact been proposed as a disease model for a 
genetically mediated subtype of schizophrenia. In order for such a model to be of 
value to researchers and clinicians it would not only be important to demonstrate 
that the schizophrenia phenotype is similar to that of other forms of schizophrenia 
but also that specific features can be identified which will help us find patients 
with the 22q11DS subtype of the illness. In a COS sample, Sporn et al., found no 
differences between those with or without 22q11DS in terms of age of onset, IQ, 
premorbid functioning or severity of psychosis, however, the 22q11DS group did 
exhibit significantly less negative symptoms.90 Furthermore, both groups had 
similar total cerebral grey matter, lateral ventricle volumes and rate of 
progressive reduction of grey matter.  
 
In their large adult group comparison, Bassett et al., compared 16 schizophrenia 
patients (without concurrent mental retardation), known with 22q11DS, to a group 
of 46 schizophrenia controls.94 No differences could be demonstrated in terms of 
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age of onset, lifetime or cross-sectional core positive and negative symptoms of 
schizophrenia or global functioning between the two groups. This was in keeping 
with previous studies with the exception of  Murphy et al. who found a relatively 
later age of onset and fewer negative symptoms to be associated with 22q11DS 
schizophrenia.84;88;95;96 One possible reason for this difference may be found in 
the fact that a much larger percentage of this group were parents (54% 
compared to the 18.8% of Bassett et al.) possibly indicating a group with a milder 
form of schizophrenia.84;88  
 
Furthermore, although their sample seemed to have a lower lifetime incidence of 
co-morbid substance use as well higher excitement factor scores, Bassett et al. 
could not demonstrate the presence of any specific features of this schizophrenia 
subtype that could be used to help identify patients with 22q11DS. The current 
set of screening criteria, based mostly on characteristic physical phenotypic 
features (as suggested by a number of studies) is therefore still the most reliable 
method to identify these patients.88;97-99 (See table 3.) In the absence of these, 
clinicians therefore need to focus on careful history-taking and searching for 
subtle physical and cognitive features in order to identify such individuals.  
 
It is also important to be aware that some of the phenotypic features may be 
influenced by age or the parkinsonistic side-effects of antipsychotic medications 
(e.g. hypotonia may be obscured and kyphosis/scoliosis may be worsened).100 
As with other genetic syndromes, developmental delays, suggestive medical and 
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family history as well as some laboratory results (e.g. low platelet count, low 
calcium) may, when present as a pattern of several features, help increase 
suspicion for the presence of 22q11DS.97 
 
TABLE 3: PROPOSED SCREENING CRITERIA TO IDENTIFY PATIENTS 
WITH SCHIZOPHRENIA AT INCREASED RISK FOR 22q11DS97 
Presence of two or more of the following features: 
1 Hypernasal speech, history of speech therapy, velopharyngeal 
incompetence, cleft palate (usually submucosal) 
2 Characteristic facial features: e.g., long, narrow face, narrow palpebral 
fissures, flat cheeks, prominent nose tip, small ears, small mouth, retruded 
chin3 Learning difficulties, history of special education, mental retardation 
(borderline to mild) 
4 Congenital heart defect: e g., ventricular septal defect, tetralogy of Fallot, 
right aortic arch, double aortic arch 
5 Other significant congenital anomaly: e.g., talipes (club foot), polydactyly 
(extra finger or toe), kyphosis/scholiosis, renal anomaly, hypospadias  
6 History of hypocalcemia (neonatal, childhood, adolescence or adult onset) 
and/or hypoparathyroidism 
7 History of athymia (absent thymus gland) or severe immune deficiency in 
infancy 
 
Neurocognitive dysfunction has long been regarded as a core component of 
schizophrenia.101 Chow et al. described the neurocognitive profiles of patients 
with 22q11DS with or without schizophrenia demonstrating no significant 
difference in mean IQ (71.6 versus 74.8) or academic achievement.102 However, 
the schizophrenia group performed significantly worse on tests of motor skills, 
verbal learning and social cognition whilst attentional dysfunction seemed to be a 
more general feature of 22q11DS. Thus, the differences between the groups 
mimicked characteristics found between schizophrenia and non-schizophrenia 
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control populations, further supporting 22q11DS as a model for 
neurodevelopmental investigations of schizophrenia. 
 
Some other hypotheses also strengthen the argument that 22q11DS-related 
schizophrenia is relevant to identifying a susceptibility locus. Firstly, we find 
evidence from research on animal models – please see elsewhere in this 
chapter. Secondly, results from a number of structural neuro-imaging studies 
have indicated that similar brain abnormalities, such as enlarged ventricles, 
reduced total brain volume and increased prevalence of midline brain 
abnormalities, exist in both schizophrenia and 22q11DS.103-105 Also, cortical grey 
matter loss such as seen in COS has been demonstrated in brain imaging 
studies of non-psychotic children with 22q11DS.106  
 
Thirdly, non-22q11DS-related schizophrenia has been suggested to have 
neurodevelopmental origins as evidenced by the increased prevalence of minor 
physical anomalies, as well as the presence of developmental delays, minor co-
ordination deficits, blunted affect and other abnormalities of early 
neurodevelopment.107;108 In comparison 22q11DS, in addition to major features, 
has a number of minor dysmorphic features that overlap with those found in 
schizophrenia. Intellectual deficits can often be demonstrated in 22q11DS and 
the midfacial and cardiac abnormalities found might result from disturbed 
development and migration of neural crest cells. In combination these could point 
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to common developmental mechanisms based partly on disturbed cellular 
migration. 
 
Due to the considerable heterogeneity displayed by the illness, identifying a 
22q11DS subtype of schizophrenia could have several advantages. Firstly, it 
could serve as a neurodevelopmental model of the illness and lead to a better 
understanding of the pathogenesis, including an improved determination of 
possible environmental risk factors that interact with genetic risk. Secondly, 
identifying such a subtype would be a very important step towards reducing the 
heterogeneity associated with the disorder. And thirdly, finding the location of a 
gene for even a rare subtype of the illness would provide us with a vital piece of 
the puzzle in our search to determine the genetic aetiology of schizophrenia.    
 
 
7. POSSIBLE SCHIZOPHRENIA CANDIDATE GENES IN 
THE 22q11 REGION 
 
With at least one schizophrenia patient having been described as carrying the 
smaller 22q11 deletion, the 1.5Mb deletion has been defined as the 
“schizophrenia critical region”.17 The relatively small size of the implicated region 
may be considered to be an advantage and as the majority of genes in this 
region are known, this locus is amenable to molecular genetic analysis.   This 
area most likely contributes via hemizygous deletion (30 genes are located in 
area) to the development of schizophrenia in approximately 2% of cases, while 
non-deletion variants in one or more of the individual genes from this locus may 
- 143 - 
make a larger contribution to susceptibility to schizophrenia in the wider 
population and could explain the increased risk for schizophrenia associated with 
this locus.85 
 
Eight genes from the regions deleted in 22q11DS have been reported as 
candidate genes in association with schizophrenia. These are COMT (currently 
most widely studied), PRODH, ZDHHC8, CLDN5, DGCR14, DGCR2, TBX1 and 
GNB1L. 
  
7.1 COMT 
 
COMT encodes catechol-O-methyl-transferase, an enzyme that is critical for 
dopamine catabolism. As far back as 1976, Groshong et al. reported an 
association between higher COMT enzyme activity in the blood of schizophrenia 
patients and dopaminergic dysfunction.109 It has been shown that dopamine 
levels in the prefrontal cortex (PFC) are critical for modulating cognitive function 
and that COMT, in turn, is important for modulating PFC dopamine levels, 
particularly under conditions that pertain during the performance of PFC-
dependant tasks.110;111 Stable deficits in cognitive functions referable to the PFC 
and cortical physiological abnormalities during performance of such tasks, have 
been consistently reported in studies of schizophrenia.112;113  
 
A common COMT polymorphism creates a valine-to-methionine (Val158/108Met) 
substitution at codon 108 or 158. The Val and Met isoforms represent high- and 
- 144 - 
low-activity enzymes, respectively.114 When specifically looking at PFC functions, 
individuals homozygous for the high-activity Val allele perform worse in tests of 
cognition and working memory.115;116 In 22q11DS patients similar results were 
found, with Met-polymorphism-hemizygous individuals shown to perform better 
on a composite measure of executive functioning.117 However, it was also 
associated with cognitive decline and increased severity of psychosis in patients 
with 22q11DS.118 
 
Unfortunately, association studies between the functional COMT polymorphism 
and schizophrenia have, to date, generated mostly conflicting results.119 The 
major evidence for a positive association between the high activity Val allele and 
schizophrenia is derived from a large population-based study of Ashkenazi Jews 
of European ancestry.120 However, although one recent meta-analysis also 
supported the fact that the Val allele may be a weak risk factor for schizophrenia, 
at least in those of European ancestry, another meta-analysis concluded that 
available evidence did not support a single locus effect for the Val/Met 
polymorphism on schizophrenia risk.121;122 
 
Therefore, the current direction of research in this area centres around the 
premise that other functional alleles exist in COMT beyond the Val/Met. 
Investigators have expanded their analysis to additional markers and haplotypes 
and although the largest study to date did not find any evidence in favor of 
association, other studies have supported an association for COMT that appears 
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stronger with haplotypes than with the Val/Met locus alone.123-127 Clearly, the 
relationship is a complex one and currently a definitive answer as to whether or 
not COMT can be regarded to be a susceptibility gene for schizophrenia, still lies 
beyond our grasp. 
 
7.2 PRODH 
 
PRODH encodes proline dehydrogenase (POX), a mitochondrial enzyme 
involved in proline catabolism and glutamate biosynthesis. Using a relatively 
dense genetic map of 72 single nucleotide polymorphisms (SNPs) distributed 
across the entire 1.5Mb region of 22q11 associated with susceptibility to 
schizophrenia, Liu et al. identified two independent peaks of association, one at 
the proximal and one at the distal end of the locus.128 The proximal peak of 
association was due to overtransmission of a haplotypic variant of PRODH. Li et 
al. analyzed the PRODH gene in patients with schizophrenia and their families in 
China and found an association with two haplotypes.129 Some patients with 
22q11DS have been shown to have elevated levels of plasma proline, a finding 
that has also been demonstrated in schizo-affective and bipolar disorder, but not 
in schizophrenia.130-132 However, Jacquet et al. identified a family of two 
schizophrenia subjects with a heterozygous deletion of the entire PRODH gene 
and consequently hyperprolinemia.131 One could hypothesize that there are at 
least two ways in which decreased PRODH activity could possibly contribute to 
schizophrenia susceptibility. Firstly, L-proline itself may serve as a direct 
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modulator of glutaminergic transmission in the brain and secondly, PRODH has 
been implicated in the initiation of apoptosis.133 
 
7.3 ZDHHC8 
 
As discussed in the previous paragraph, the Liu et al. study also revealed a distal 
independent peak of association.128 Statistical evidence strongly implicates the 
ZDHHC8 gene as the prime candidate for this region. With at least two yeast 
ZDHHC proteins, ERF2 and AKR1, being transmembrane palmitotyltransferases 
(PMT), it is regarded as likely that ZDHHC8 is also a PMT with a yet unidentified 
substrate. Palmitoylation is a posttranslational modification of proteins with the 
lipid palmitate and recent work has shown that palmitate reversibly modifies 
numerous classes of neuronal proteins, including those important for neuronal 
development, neurotransmitter receptors and synaptic scaffolding indicating that 
palmitoylation may play an important role in synaptic transmission.134 Through 
screening for association with schizophrenia one SNP (rs175174A/G), 
associated with a relative abundance of unspliced transcripts, localised to intron 
4 of ZDHHC8 was identified. Mukai et al. demonstrated an association between 
the A allele and schizophrenia in women, but other studies could either not 
confirm the association of rs175174 with schizophrenia, or could confirm it with 
rs175174G, but not the A allele.127;135-139 Currently, the role of ZDHHC8 in 
schizophrenia remains unclear. 
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7.4 CLDN5 & DGCR14 
 
A weak association between schizophrenia and SNPs in CLDN5, which encodes 
claudin-5, has been reported.140;141 Claudin proteins are a component of tight 
junctions that play crucial roles in response to changing natural, physiologic and 
pathologic conditions. Associations of promoter polymorphisms of DGCR14 have 
also been reported, but the relation between this or claudin-5 and schizophrenia 
is not yet known.142 
 
7.5 DGCR2 
 
DGCR2 encodes a putative adhesion receptor protein and association between 
its polymorphisms and schizophrenia have been noted, with the expression of 
DGCR2 found to be elevated in the dorsolateral prefrontal cortex of 
schizophrenica patients relative to matched controls. A possible explanation for 
this increase could be patient exposure to antipsychotic drugs, as significantly 
elevated levels of DGCR2 transcripts were found in rats exposed to such 
medication.120 
 
7.6 TBX1 & GNB1L  
 
TBX1 is a member of the T-box transcription factor family and GNB1L encodes 
an evolutionarily conserved peptide of unknown function and is essential to 
embryonic development. Both genes have been shown to play a role in prepulse 
inhibition and as GNB1L and TBX1 lie only 17 kb apart, it is strongly considered 
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that the engineered mutation of either gene may affect expression of its 
neighbour. Importantly, TBX1 point mutations were identified in five individuals 
with classic 22q11DS but without the common chromosomal deletion, suggesting 
TBX1 as a major contributor to 22q11DS.143 A recent comparison between a 
large Caucasian control (n=436) and patient (n=446; psychotic and affective 
disorders) sample demonstrated no evidence for significant group differences in 
TBX1 variation.144 Similarly, no significant difference in the genotype or allele 
distributions could be found between 328 Chinese schizophrenia patients and 
288 controls for any of the TBX1 polymorphisms, nor was there any haplotype 
association.145 However, Williams et al. recently found evidence for a male-
specific genotypic association for TBX1/GNB1L in 662 schizophrenia cases and 
1416 controls from the UK and replicated this finding in two independent case-
control samples.146 
 
8. CHROMOSOME 22: ANIMAL MODELS 
 
The usefulness of an animal model in the study of a human illness is directly 
related to its ability to mimic the aetiology, underlying pathophysiological 
mechanisms and responsiveness to treatment of the illness as well as, in the 
case of neuropsychiatric disorders, its psychological constructs.147 Specifically in 
the case of schizophrenia, the clearly observed heterogeneity in symptoms, 
course and aetiology presents a particular challenge. Furthermore, the 
development of a valid animal model could be confounded by the uniquely 
human nature of the illness which includes defects of perception, thinking and 
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emotion.108;148 Initially, animal models in schizophrenia have had either a 
pharmacological or developmental focus. (See summary in table 4.)  
 
TABLE 4: SUMMARY OF WELL-CHARACTERISED PHARMACOLOGICAL 
AND DEVELOPMENT MODELS OF SCHIZOPHRENIA AND RELATIONSHIP 
TO SCHIZOPHRENIA-RELATED BEHAVIOURS151 
Pharmacological 
models Hyperactivity 
Social 
interaction 
deficits 
Disruption 
of prepulse 
inhibition 
Disruption 
of latent 
inhibition 
Cognitive 
deficits 
Increased 
sensitivity 
to DA 
agonists 
Increased 
sensitivity 
to NMDA 
agonists 
Treatment with 
DA agonists Yes Yes Yes Yes Yes - - 
Treatment with 
NMDA agonists Yes Yes Yes No Yes - - 
Developmental 
models  
Neonatal hippo- 
campal insult Yes Yes Yes Yes Yes Yes Yes 
Social isolation 
 Yes Yes Yes Yes No Yes Yes 
Prenatal MAM 
administration Yes Yes Yes Yes Yes Yes Yes 
Prenatal 
immunological 
activation 
Yes Yes Yes Yes Yes Yes Yes 
MAM = Methylazoxymethanol acetate 
NMDA = N-methyl-D-aspartate 
 
The dopamine (DA) hyperfunction hypothesis of schizophrenia is supported by 
the fact that DA agonists can both exacerbate psychotic symptoms in patients 
with schizophrenia and also induce them in normal controls.149 In rodents, DA-
releasing drugs have been shown to produce disruption of prepulse inhibition 
(PPI) and latent inhibition as well as cognitive deficit models of schizophrenia. 
Hyperactivity has also been seen, which has been likened to the psychomotor 
disturbance of schizophrenia, but this model has been criticised as not 
representing a core feature of the illness. Due to the simpatomimetic effects of N-
methyl-D-aspartate (NMDA) receptor antagonists dysregulation of glutaminergic 
transmission has also been hypothesized in schizophrenia.150 In rodents, NMDA 
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antagonists have been shown to not only produce hyperactivity, PPI and 
cognitive deficit symptoms of schizophrenia, but also social interaction deficits. 
 
Targeted brain lesions have been used in attempts to model neurodevelopmental 
aspects of schizophrenia. Although an in-depth discussion of the literature on 
animal adult and neonatal lesion studies is not within the scope of this chapter 
(see full review Lipska148), numerous interesting results have been obtained, for 
example, that rodents with neonatal hippocampal lesions demonstrate delayed 
onset of hyperdopaminergic behaviour, disrupted PPI and social interaction.  
 
The construction of mice with targeted mutations has specifically enhanced our 
ability to uniquely identify the functional significance of the targeted genes and 
their encoded proteins. Due to their high fertility rate and short life span, mice are 
regarded as particularly appropriate animal models. These mouse models for 
schizophrenia susceptibility genes are not only useful in helping us to understand 
how these genes contribute to the pathophysiology of the illness, but they may 
also help us to address potential interactions between these genes. Although 
complex disease manifestations such as delusions and hallucinations can not be 
modelled in mice, certain endophenotypes which can be modelled relatively 
accurately in mice, could be of particular value. Examples of these would be 
sensory gating, working memory and attention, all of which several studies have 
suggested could contribute to schizophrenia susceptibility.152-154 They are often 
present in childhood, prior to the full phenotypic expression of the illness and can 
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also be seen in first-degree, clinically unaffected relatives of schizophrenia 
patients.153;155 Mouse models afford us an opportunity to conduct thorough and 
detailed evaluation of cellular and molecular neuropathology as well as the 
possibility to quantify brain mRNA transcripts using microarray technology.156 
(See table 5 for summary of behaviours exhibited in some schizophrenia 
susceptibility genes’ mutant mice models.) 
 
Therefore, taking into account the robust association between the 22q11 
microdeletion and the risk of developing schizophrenia coupled with our precise 
knowledge of the human/mouse sequence and chromosomal synteny at this 
locus, we are presented with a unique opportunity to use mouse models to 
understand the biological basis of the increased psychosis risk associated with 
this genetic lesion.  
 
The syntenic region of the human 22q11 locus lies on mouse chromosome 16. 
With the exception of CLTCL1, all the human genes are represented albeit with 
some minor changes in gene order. In order to help narrow the search for 
causative genes that can be associated with psychiatric disorders, Maynard et al. 
undertook a comprehensive expression profile of 22q11 orthologues in the 
mouse.157 They determined the CNS expression of 32 of these orthologues of 
which 25 are mapped to the proximal 1.5Mb regions consistently deleted in 
22q11DS. None of these were found to be uniquely expressed in the developing 
or adult mouse brain. However, of the 32, 27 are localised in the embryonic 
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forebrain as well as other sites phenotypically associated with 22q11DS (i.e. 
aortic and branchial arches and limb buds). These are expressed at apparently 
constant levels in the foetal, postnatal and adult brains except for three – TBX1, 
ProDH2, T10 – which  increase in adolescence and decline in maturity. Whereas 
the others are present fairly constantly throughout the critical processes of 
neuronal proliferation, migration and circuit differentiation these three could be 
particularly important during the refinement and stabilisation of synaptic 
connections.158 Previous reports have indicated that synaptic refinement is most 
likely compromised in patients with schizophrenia.159;160 
 
By using gene targeting and chromosomal engineering the 22q11 deletion (so-
called Df1) has been modelled in mice.161 Mice heterozygous for the deleted 
region (Df1/+) developed identical 22q11DS cardiovascular abnormalities and in 
certain genetic backgrounds thymic and parathymic defects.162 Interestingly, the 
conotruncal defects of mice hemizygous for the 1.5Mb deletion can be partially 
rescued by a human BAC containing TBX1 (a gene highly expressed in the 
pharyngeal arches during mouse embryonic development), whilst mice 
heterozygous for the null mutation in TBX1 develop conotruncal defects.163;164 
This suggests that TBX1 could be responsible for some (or many) of the physical 
features associated with the deletion.  
 
However, due to the variable expressivity of these features, one has to conclude 
that additional modifiers are involved. VEGF which encodes vascular endothelial 
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growth has been reported as a modifier of cardiovascular birth defects in 
22q11DS.165 The Vegf164 isoform in mice causes birth defects similar to that of 
22q11DS and knocked-down VEGF levels enhanced pharyngeal arch artery 
defects induced by TBX1 knockdown in zebrafish. FGF8 that encodes fibroblast 
growth factor 8 has been shown as a potential modifier of 22q11DS with Fgf8 
mutants displaying the complete array of cardiovascular, glandular and 
craniofacial phenotypes seen in human 22q11DS. 
 
The prepulse inhibition (PPI) of the acoustic startle reflex is considered an 
intermediate phenotypic marker of sensorimotor gating in schizophrenia. In a 
longitudinal study of 22q11DS children and their unaffected siblings, the 
22q11DS group showed significantly less PPI with analyses suggesting that this 
deficit did not reflect developmental delay.166 Unfortunately, specificity of reduced 
PPI to individual psychiatric disorders is low as it is associated with 
schizophrenia, OCD, Asperger syndrome and others.152 Paylor et al. mapped PPI 
deficits in a panel of mouse mutants and revealed that either TBX1+/- or 
GNB1L+/- mice had reduced PPI.167  Expression of TBX1+/- is limited to the 
brain vasculature of fullterm mice embryos or adult mice. Hanson and Gottesman 
have proposed a role for microvasculature in the pathophysiology of 
schizophrenia as such damage could satisfy both the developmental and 
degenerative models of the illness.168 Furthermore, TBX1+/- mice, in response to 
amphetamine, did not display behavioural differences in comparison to wild-type 
littermates, suggesting the possibility that the haploinsufficiency of TBX1 does 
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not contribute to the behavioural abnormalities associated with 22q11DS other 
than PPI deficits in mice.169 
 
Individuals with reciprocal duplication of the chromosome region deleted in 
22q11DS have been identified and display a phenotype ranging from mild to 
severe, sharing a tendency for velopharyngeal insufficiency with DGS/VCFS, 
whilst displaying other distinctive characteristics.18;170-172 Although their 
neuropsychiatric disorders have not been fully characterised they display 
impulsivity, aggression, social immaturity, attention span and cognitive deficits. 
Mice that overexpress a 200kb region of human 22q11.2 showed spontaneous 
sensitisation of hyperactivity and a lack of habituation that could be modified by 
antipsychotic drugs.169 
 
Mouse models for individual candidate genes of the 22q11 region could also help 
to increase the understanding of these genes and more specifically their impact 
on schizophrenia. Mice homozygous to a mutation in the mouse orthologue of 
the human PRODH gene have been shown to have hyperprolenaemia 
comparable to that seen in some individuals who carry the 22q11 microdeletion, 
providing a accurate model of not only a susceptibility gene but also an 
susceptibility allele.173 These mice also exhibit deficient PPI, although not to the 
same degree as mice that carry long-range deletions who have normal proline 
levels.174 
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TABLE 5:  
SCHIZOPHRENIA-RELATED BEHAVIOURAL PHENOTYPES AS 
DEMONSTRATED IN MICE MUTANT FOR SCHIZOPHRENIA 
SUSCEPTIBILITY GENES151 
Human Gene 
Chromosome 
Location Function in Humans Mutant mouse model 
Evidence for a schizophrenia-
related behavioural phenotype 
Synapse formation; neuronal 
migration, synaptic plasticity 
Heterozygous NRG-1 KO; EGF-
like domain; mixed 129/SvEv-
C57BL6 background 
Open-field hyperactivity 
Heterozygous NRG-1 KO (TM 
domain);  C57BL6 background 
Open-field hyperactivity, impaired 
exploration and habituation to 
novel environment; disrupted PPI, 
reduced forebrain NMDA receptor 
density 
Heterozygous NRG-1 KO (IG 
domain); C57BL6 background 
Disruption of latent inhibition 
Heterozygous Erb2, ErbB3,  
ErbB4 KO; mixed 129/SvEv 
C57BL6 background 
Open-filed hyperactivity in ErbB4 
mutants 
Heterozygous ErbB4 KO; 
C57BL6 background 
Open-field hyperactivity; PPI 
disruption 
Homozygous CNS-specific ErbB4 
KO;C57BL6 background 
Disruption of spatial learning and 
memory in water maze in 
heterozygous males 
Neuregulin – 1 
(NRG1) 
8p21-p22 
Regulation of NMDA & AMPA 
receptor function and NMDA & 
GABA receptor submit 
expression 
FVB Background No evidence  
Regulator of G 
protein signalling 
4 (RGS4) 
1q21-q22 Regulation of G protein coupled 
receptors 
Homozygous RGS4 KO; mixed 
129-B6D2 background,  
Backcrossed C57B16 three times 
No evidence: intact PPI, spatial 
learning and memory 
Dysbindin 
(DTNBP1) 
6p22.3 Regulation of synaptic structure 
and signalling 
Homozygous DTNBP1 KO (sdy 
mutant); mixed DBA/21; PWK 
background 
No evidence: intact PPI 
Catechol-O-
methyl 
transferase 
(COMT) 
22q11 Involved in DA metabolism, 
particularly in prefrontal cortex 
Homozygous COMT KO: mixed  
129J-C57B16 background 
No evidence 
Regulation of cortical Ach 
function 
PPI disruption Proline 
dehydrogenase 
(PRODH) 
22q11 
Metabolic precursor or glutamate 
in subpopulation of glutamate 
neurons 
Homozygous PRODH KO; 
129SvEv background 
Altered glutaminergic 
neurotransmission in 
hippocampus; Evidence for 
epistatic interaction between 
PRODH and COMT at 
behavioural and transcriptional 
level 
Conditional fore-brain restricted 
inducible mutant DISC1 
transgenic mouse; strain 
unknown 
Increased locomotion in novel 
environment impaired spatial 
learning and memory; disrupted 
PPI 
Conditional inducible mutant 
DISC1 transgenic mouse; strain 
unknown 
Reduced sociability; impaired 
latent inhibition; disruption of 
spatial working memory 
Disrupted in 
schizophrenia 1 
(DISC-1) 
1q42 Neuronal migration, neuronal 
differentiation 
DISC1 transgenic mouse; strain 
unknown 
Enlargement of lateral ventricles 
 
Small-scale transcriptional profiling (which could help provide an unbiased 
evaluation of the transcriptional programmes affected by the disruption of a gene) 
that was done in the cortex of PRODH-deficient mice showed fewer than 10 
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genes as differentially expressed.85 Interestingly, COMT was listed as one of the 
upregulated genes and follow-up behavioural analysis of these mice revealed a 
pronounced hyperresponsivity to dopamine. This could be particularly important 
in the light of the fact that dopaminergic hypersensitivity in schizophrenia is a 
well-established concept.175 The transcription therefore revealed a previously 
unsuspected interaction between PRODH and COMT, implying that if COMT 
upregulation is one of the mechanisms employed to control cortical dopaminergic 
hypersensitivity then schizophrenia patients with a 22q11 microdeletion are at a 
particular disadvantage because they are deficient in both genes. 
 
In a knockout mouse model of ZDHHC8, female mutant mice displayed 
significantly lower PPI as well as profound deficits in indices of fearfulness in 
comparison to wild-type littermate controls.127 Furthermore, these mice appeared 
to be less sensitive to stimulation of locomotor activity induced by a 
psychomimetic suggesting that ZDHHC8 could, at least in part, be affecting 
behaviour through interference with glutamatergic transmission. 
 
9. SUMMARY 
 
The 22q11 deletion syndrome is a multi-system disorder that currently represents 
the most common microdeletion found in humans. It presents with a variable 
phenotype that includes specific congenital heart and velopharyngeal defects, 
cognitive deficits and/or behavioural abnormalities coupled with facial 
dysmorphologies. Significant rates of co-morbid neuropsychiatric disorders have 
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been reported including attention-deficit/hyperactivity disorder, autism, obsessive 
compulsive disorder and in 30% of cases, schizophrenia. On the other hand 
schizophrenia samples have shown reported rates of 0.3-2% for 22q11DS (with 
ethnic differences possibly accounting for the variation), suggesting that a 
deletion of 22q11 may represent one of the highest known risk factors for this 
illness. As such, 22q11DS has been proposed as a disease model for 
schizophrenia with support being found in a) neuro-imaging studies, b) evidence 
suggesting common neurodevelopmental mechanisms and c) animal models. 
Identifying a 22q11DS subtype of schizophrenia could lead to a breakthrough in 
the search for schizophrenia genes. Eight genes (COMT, PRODH, ZDHHC8, 
CLDN5, DGCR14, DGCR2, TBX1, GNB1L) from the region deleted in 22q11DS 
have been reported as candidate genes for association with schizophrenia. Of 
these, COMT has been by far the most studied but, to date, the complex 
relationship between COMT and schizophrenia has not yet been untangled. 
Thus, although analyses of 22q11DS have contributed to our understanding of 
the genetics and molecular pathogenesis of schizophrenia, more studies are 
needed if critical questions relating to this devastating illness are to be answered. 
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CHAPTER 6 
 
USING DYSMORPIC FEATURES 
AS AN ENDOPHENOTYPE IN 
SCHIZOPHRENIA
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1. THE USE OF ENDOPHENOTYPES IN SCHIZOPHRENIA 
RESEARCH 
 
Current knowledge strongly supports the notion that schizophrenia seems to be a 
heterogeneous illness resulting from a complex interplay between genetic and 
environmental risk factors. However, as delineated in a previous chapter, despite 
the apparent genetic contribution, the specific mechanism or gene has yet to be 
found.   
 
Furthermore, schizophrenia shows considerable clinical heterogeneity as 
reflected by an early description of this disease entity: "Dementia praecox, a 
number of disease entities".1 This clinical heterogeneity arguably reflects the 
heterogeneous nature of susceptibility factors for schizophrenia.  Not only do we 
find multiple combinations of symptoms existing in individuals, but also both 
disease course and outcome, display considerable heterogeneity. As has been 
explained before, we can’t currently be certain whether this is a single disorder 
with different clinical manifestations or in fact a group of syndromes, each with 
unique or overlapping pathophysiology.  
 
Considerable attempts have been made to elucidate the heterogeneity of the 
schizophrenia phenotype by exploring the relationships between the various 
symptom dimensions and possible subtypes. In the search for the susceptibility 
genes it has become apparent that one possible method would be to consider a 
role for endophenotypes.  
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Whereas genotypes can be measured with techniques of molecular biology, 
phenotypes in fact represent observable characteristics of an organism which are 
the joint product of both genotypic and environmental influences.2 However, as 
psychiatric illnesses such as schizophrenia have complex genetic underpinnings, 
Gottesman and Shields suggest he use of “endophenotypes”, described as 
internal phenotypes discoverable by a biochemical test or microscopic 
examination, to provide more appropriate clinical phenotypes for use in 
psychiatric genetic studies.3 
 
Despite the clear advantages that the endophenotype concept held, it was not 
immediately actively used. In fact, it is only now, with the arrival of the 21st 
century, that endophenotypes are increasingly being seen as a perhaps 
necessary mechanism for overcoming the barriers to progress in the genetic 
analysis of a complex disorder such as schizophrenia.4 Several approaches have 
been advocated for endophenotype analysis in schizophrenia. These include 
demographic variables, clinical symptoms, physical characteristics and 
neurodevelopmental insults.5  
 
The neurodevelopmental hypothesis of schizophrenia holds that the etiological 
origins of the disease can be traced back to disturbed early prenatal 
development.6-8 Currently, numerous diverse lines of evidence support this 
hypothesis. These include the presence of obstetric complications, 
epidemiological data (i.e. in utero disease and stress exposure), the presence of 
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pre-morbid behavioral and neuromotor deficits, the observed pattern of 
developmental brain anomalies, higher frequency of neurological soft signs and 
the increased rate of dysmorphic features (often referred to as minor physical 
anomalies) that tend to accompany the disease.9-16  
 
The specific criteria that have been suggested to try and ensure maximum 
outcomes for the use of markers in psychiatric genetics can also be applied to 
endophenotypes.17 These are that the endophenotype: (1) should be associated 
with illness in the population; (2) should be heritable; (3) should be primarily 
state-independent (i.e. manifesting itself in the individual whether or not the 
illness is active); (4) should co-segregate with the illness within families; and (5) 
should be found in non-affected family members at a higher rate than in the 
general population. Taking this into account, one possible candidate 
endophenotype that suggests itself in schizophrenia, could be the presence, or 
absence of observable differences in anthropometric proportions, the so-called 
minor physical anomalies. 
 
2. ANTHROPOMETRY – A BRIEF INTRODUCTION 
 
Anthroposcopy, derived from the greek anthropos (human) and skopein 
(examine), refers to the practice of judging the body’s build by inspection. 
However, such mere visual assessment, one of the oldest methods of 
examination still used in medicine today, is not wholly reliable because it is highly 
subjective. Examiners are very much influenced by their own aesthetic 
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perceptions and a great deal of experience is essential to relatively compare 
features that are not objectively measured. Therefore, in order to be able to 
effectively use data collected from bodily observations the biological science of 
anthropometry (greek: anthropos + metron (measure)), the measuring of size, 
weight and proportions of the human body, was developed.18 
 
Measurements of the human face have been performed since ancient Greece 
and quite a number of aspects of ancient measurements can be found in modern 
clinical anthropometry.18 In fact, Egyptian artisans seemed to have been the first 
to use a crude system of measurement to depict human figures. However, as no 
well-defined landmarks can be found throughout known examples of Egyptian 
art, the existence of standards, as such, has not been proven.19 The Greek 
sculptor, Polycleitus (c.450-c.420 BC) seems to have been the first to document 
and use defined measurements. He reported the height of the face to be one-
tenth of the length of the body, the whole head one-eight of it and the head and 
neck together to be one-sixth of the length of the whole athlete.19 For his part, 
Aristotle (384-322 BC), not only emphasised the proportions of aesthetics, but 
tried to use his observations on human structure to prove that certain groups of 
people were superior to others, also publishing on this topic.20 These include 
Physiognomica, describing the science of reading one’s character from one’s 
bodily features, and Historia Animalium with its descriptions of features and 
judgments regarding the alleged qualities of people with these features. 
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The so-called neoclassical canons of facial proportion were derived by artists and 
anatomists such as Da Vinci and Dürer.21 Leonardo da Vinci (1452-1519) 
extensively reported on ideal proportions for bodies and faces equating a well-
proportioned face to one where (a) the size of the mouth equaled the distance 
between the parting of the lips and the edge of the chin, (b) the distance from 
chin to nostrils, nostrils to eyebrows and eyebrows to hairline are all equal, and 
(c) the height of the ear equals the length of the nose.22 Albert Dürer (1471-1528) 
supported Da Vinci in believing that the face could be divided into three equal 
lengths – forehead,  nose, mouth + chin – with further division of the latter into 
four equal parts.23 Even though these artists’ (and others’) canons correlate and 
are still used in facial analysis, studies using anthropometry have in fact revealed 
little applicability for these neoclassical canons to Caucasian, Asian, Caribbean 
or African-American populations.21;24-27 
 
Physical anthropology has its roots in the 18th and 19th centuries, with most of the 
so-called facial measurements being taken directly from skulls and only very few 
soft-tissue measurements performed. As in the case of Aristotle, the 
measurements were used predominantly to prove that certain groups of people 
were superior to others. For example, Cesare Lombroso (1836-1909) described 
how gangsters, murderers, alcoholics, epileptics and dwarfs could be 
distinguished from “normal” people by using anthropometric assessments.28 
Unfortunately, because little quantitative data were available, investigators of this 
era often manipulated results to endorse their own stereotyped hypotheses.29 
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During the first decades of the 20th century cephalometric radiology, a technique 
using oriented radiographs for the purpose of head measurements was 
developed.30 This technique became a vital research tool, used in the pioneering 
Bolton Study, which pursued dentofacial roentgenographic studies of healthy 
children from birth to adulthood, collecting 22 800 recordings of 5 400 children 
over a period of 36 years.31 
 
Ultimately, the honour of being the father of modern facial soft-tissue 
anthropometry lies with Leslie Farkas. By measuring and comparing more than 
hundred dimensions and proportions in hundreds of people, he defined the 
standards for almost every soft-tissue measurement in the head and face.18 He 
clearly showed that the historical tendency to divide facial measurements into 
perfect proportions merely reflected the search for perfection as in reality these 
proportions are only present incidentally and by no means reflect the norm.21 
 
3. USING CLINICAL ANTHROPOMETRY 
 
The development of the field of clinical anthropometry has been of particular 
value to two groups; craniofacial surgeons and clinical geneticists. These groups 
have widely divergent goals, with the surgeons hoping to restore normality to the 
abnormal face whilst the geneticists aim to diagnose a wide range of conditions. 
However, both groups need a consistent system of measurements in order to 
use collected data as by far the majority of observed anomalies are quantative 
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traits (i.e. graded on a continuum) with only a few being qualitative traits (e.g. 
preacuricular skin tags). 
 
At present, various methods of medical craniofacial anthropology exist, including 
direct anthropometry (in which measurements are taken directly from the subject) 
and three indirect methods; photogrammetry, soft-tissue facial profile 
cephalometry and computer-imaged three-dimensional craniofacial surface 
scans. All these methods share three basic elements of examination (1) location 
of craniofacial surface landmarks, (2) execution of measurements, and (3) 
evaluation of the findings using normative data.32  
 
With regard to craniofacial landmarks, forty-seven have been described.18  
(Please see appendix A for a full description of these.) Most can be identified 
visually or their location can be defined with respect to the lateral view of the face 
or the base view of the nose or at underlying bony areas identified by palpation. 
At present, 132 measurements are listed in direct anthropometry and the 
reliability of the measurements depend on technical precision in locating 
landmarks, maintaining required craniofacial orientation and patient compliance. 
Ultimately the interpretation of group results relies heavily on the availability of 
proper population norms for both individual measurements as well as their 
mutual relationships. Particularly, it has been shown that significant racial and 
ethnic morphometric differences exist, but some norms are available for North 
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American Caucasians, young adult African-Americans as well as Chinese 
subjects.18;33 
 
Both the direct and the indirect measurement methods have their pros and cons 
with all the indirect methods involving a substantial cost investment.32 
Advantages of direct methods include access to measurements of areas covered 
by hair (e.g. circumference, width, length and height of head) or areas that would 
be distorted by indirect anthropometry (e.g. the depth of the face in 
photogrammetry); measurements that require special positions of the head (e.g. 
base view when measuring the soft nose structures and the nasal root depth) 
and those that require a special technique such as pressing the tip of the 
instrument to the underlying bone surface when a measurement is made 
between bony landmarks (e.g. the width of the face between the zygions). 
Disadvantages of the direct methods include the prolonged time needed to 
perform the examination, requirement of a certain level of skill in performing the 
measurements and a dependence on the co-operation of the examinee. 
Currently however, of the methods available, only direct anthropometry can be 
done in the absence of highly specialised and expensive equipment and is 
therefore readily available to researchers in general. 
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4. THE USE OF DYSMORPHIC FEATURES AS AN 
ENDOPHENOTYPE  
 
Minor physical anomalies (MPAs) may be regarded as a collective term for the 
mild dysmorphic features representing subtle alterations in the developments of 
various bodily structures in the mouth, eye, ear, global head, hand and feet 
areas.34 Once formed, MPAs persist into adult life and are detected easily by 
simple visual examination and in themselves are considered to be of little 
functional or cosmetic consequence. As such their presence is regarded as being 
on a spectrum from normal to indicating major congenital disorder. Although 
hypotheses still differ as to the exact timing of MPA development, it is still most 
commonly believed that they are formed during periods of abnormal ectodermal 
development (due to genetics or a teratogen such as maternal alcohol abuse 
and/or smoking or influenza during pregnancy).35 
 
The brain and the face both develop from common embryonic ectoderm during 
the first or early second trimester and their morphogenesis is interlinked.36 
Furthermore, although the relationship between prenatal development of the 
brain and craniofacial structure is not fully understood, these processes appear 
to occur in tandem.37 Therefore, with the structures involved in their expression 
typically sharing their embryonic origin with that of the brain, MPAs are regarded 
to be potentially valuable indices of disturbances in early neurodevelopment.38 
They may therefore represent risk markers for underlying disease susceptibility 
timed according to the normal developmental chronology of the embryo.39 This 
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could be especially true when multiple MPAs occur together in a given individual 
and/or when the individual is already at high risk. (e.g. first degree relative of an 
affected individual).40 
 
In fact, MPAs have been shown to provide important clues in specific 
malformation diagnosis, brain pathology and timing of adversity and therefore 
have increasingly been the target of studies in a range of mental, behavioural 
and physical disorders.40;41 An excess of MPAs have been demonstrated in 
autism, hyperactivity, epilepsy, mental retardation, poor motor co-ordination, 
attention deficit disorder, foetal alcohol syndrome, cerebral palsy and 
schizophrenia.42;43 
 
5. MINOR PHYSICAL ANOMALIES IN SCHIZOPHRENIA 
 
The presence of an increased rate of dysmorphic features in some individuals 
with psychoses in comparison to normal individuals was already documented 
long before modern conceptions of schizophrenia started to form.1;44 More 
recently, numerous studies have confirmed physical deviations in schizophrenia 
populations in comparison to healthy controls, patients with other DSM Axis I 
diagnoses and non-schizophrenic twins from disconcordant twin pairs.16;43;45;46 
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5.1 MEASUREMENT OF DYSMORPHIC FEATURES 
 
5.1.1 SCALES AND TECHNIQUES 
 
As previously mentioned, direct measurement techniques are most readily 
available to general researchers. To date, the Waldrop Physical Anomaly Scale 
has been the most frequently used instrument in the assessment of dysmorphic 
features as a sign of neurodysontogenesis and the vast majority of schizophrenia 
studies have also used this scale (or a modification thereof).47-50 The original 
scale was developed for use in Down’s Syndrome and consisted of 18 items (see 
table 1) from six body regions (head, eyes, ears, mouth, hands, feet) mostly 
scored qualitatively as present (1) or absent (0), but in some instances in a 
graded manner according to severity (1) or (2).49 
 
Although widely used, the Waldrop has been criticised for inherent limitations 
involving both content and form.14;15;51;52 Trixler et al. specifically fault the 
Waldrop for not making a distinction between minor malformations (MM), which 
arise during organogenesis, and phenogenetic variants (PV), which appear after 
organogenesis.52 In other words, MM are always abnormal and can point to 
problems during organogenesis, but PV are developmentally identical to normal 
variants. However, other authors argue that more knowledge about the timing 
and exact nature of the development of MPAs will not necessarily lead to 
improved knowledge regarding the influence of it on the later development of 
schizophrenia.53 
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A further common criticism concerning the Waldrop is the fact that it has low 
internal consistency, probably due to heterogeneity of the anomalies in terms of 
location, character, period of prenatal origin, time and adversity-specific 
vulnerability, phase specificity of risk factors, developmental heterochronia and 
induction processes.54 However, from an embryological point of view, many of the 
Waldrop items (especially the craniofacial features) are closely related to 
underlying brain development, lending some legitimacy to the use of this tool in 
psychiatric research.37;55  
 
In order to address some of the issues, specifically with regards to schizophrenia 
research, attempts have been made to expand the Waldrop. Ismail et al. added 
23 items to the original 18, focusing on documented MPAs that belonged to the 
same body regions as those measured in the original in order to gain more data 
without having the subject remove further clothing during the examination.50 
Interestingly, they note that although both the original and their new items 
independently show significantly higher rates of MPAs in schizophrenia patients 
in comparison to control subjects, the original Waldrop appears to function well in 
identifying minor physical anomalies that are especially strongly associated with 
schizophrenia.50 
 
In their modification, Gourion et al. placed focus on craniofacial asymmetry.47 
This addition was based on recent findings indicating significantly decreased 
brain asymmetry and increased prevalence of atypical handedness in 
- 196 - 
schizophrenia as well as a relationship between cerebral structural measures 
and dermatoglyphic abnormalities.47;56;57 (See table 1 for clarification of specific 
items used on the original and expanded versions.)  
 
TABLE 1: MINOR PHYSICAL ANOMALIES EXAMINED BY THE ORIGINAL 
WALDROP AND MODIFIED BY ISMAIL ET AL. AND GOURION ET AL. 47;50 
 
WALDROP ISMAIL GOURION 
Head 
Head circumference abnormal 
Fine, electric hair 
Hair whorls abnormal 
Eyebrows fused 
Frontal bossing 
Nostrils anteverted 
Micrognathia 
Widening nose basis 
Facial symmetry 
Eyes 
Epicanthus 
Telecanthus 
Heterochromia 
Ptosis 
Colobomata 
 
Ears 
Low-seated ears 
Adherent earlobes 
Malformed ears 
Asymmetric ears 
Soft, pliable ears 
Pre-auricular skin tag 
Pre-auricular sinus 
Ear lobe skin tag 
 
Mouth 
High/steepled palate 
Furrowed tongue 
Tongue with texture spots 
Cleft lip 
Cleft uvula 
Thin upper lip 
 
Hands 
Curved fifth finger 
Abnormal palmar crease 
Clinodactyly 
Tapered fingers 
Overlapping fingers 
Small fingernails 
Hyperconvex fingernails 
Single crease 5th finger 
Asymmetric hands 
Feet 
3rd toe longer than 2cnd   
Partial syndactyly 
Gap between 1st & 2cnd toe 
 
Overlapping toes 
Absent 4th or 5th toe 
Deep creases on soles 
Hyperconvex toenails 
Asymmetric feet 
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In spite of modifications, some authors still contend that a detailed 
anthropometric scale is of greater value than a scale such as the Waldrop as it 
provides more information regards the location and exact nature of MPAs in 
schizophrenia.51  Such a scale should therefore not only include qualitative 
measurements but also quantitative measurements obtained using direct 
measurement techniques (see earlier in chapter for a more detailed discussion 
on the different techniques used to obtain quantitative anthropometric 
measurements). An example is the Lane dysmorphology scale, consisting of 70 
items that include both linear and angular craniofacial measurements as well as 
scoring of individual dysmorphic features.51 This scale has been used 
successfully to readily distinguish schizophrenia patients from controls.51;58 
 
Unfortunately, one major problem for general researchers using either the 
Waldrop (or modification thereof) or a comprehensive scale such as the Lane, is 
that these scales require either well-trained examiners of significant periods of 
face-time per subject, making them potentially difficult-to-use tools, both time and 
labour-wise. A possible solution to this dilemma can be found in limiting the 
examination to a small number of pre-determined quantitative head/facial 
measurements.  To optimise reliability, measurements should be chosen that (1) 
have reliable landmarks, (2) can be conducted using easily available tools such 
as a cloth tape measure and calipers and (3) can readily be taught to examiners. 
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Working from this premise, a number of studies have been conducted that 
included only a select group of quantitative facial measurements. It has been 
demonstrated that this method can be used to successfully differentiate between 
schizophrenia subjects and non-psychiatric controls.59 Importantly, this 
differentiation has not only been demonstrated in Caucasian populations but also 
in a Mestizo sample as well as an predominantly African-American sample.60;61 
 
5.1.2 INABILITY TO BLIND RATERS 
 
A major criticism of investigations of MPAs in adults with schizophrenia has 
always been that such assessments can never be conducted in a truly blinded 
fashion due to the face-to-face approach needed. In order to try and minimise 
such bias different samples have employed different methods. These include 
inter-rater reliability assessments, using assessors unable to communicate in the 
participants’ language and using assessors blinded to any other part of the 
interview.58;60;62  
 
5.2 RELATIONSHIP BETWEEN SCHIZOPHRENIA AND MINOR PHYSICAL 
ANOMALIES 
 
To date, numerous studies have examined the relationship between MPAs and 
schizophrenia.8 In most cases the studies fall into one of two categories; either 
they report on a comparison of the frequency of MPAs between schizophrenia or 
at-risk cases and healthy controls or they report on an exploration of the 
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relationship between MPAs and other putative indices (e.g. cognitive, 
morphology). 
 
5.2.1 INCREASED FREQUENCY OF MPAs IN SCHIZOPHRENIA SUBJECTS 
 
In the case-control studies (for which mean total MPA scores can be calculated) 
that used the Waldrop to report on differences between schizophrenia subjects 
and healthy controls, schizophrenia subjects have been consistently observed to 
have more MPAs than controls.8 In fact, the magnitude of the case-control 
difference has been shown to be quite large, providing support for MPAs as a 
reliable discriminator between schizophrenia cases and controls.  
 
In one such study, Sivkov and Akabaliev specifically investigated a role for MPAs 
as a potential discriminator between schizophrenia patients and normal 
subjects.63 They found that a total MPA-score (on a 19-item Waldrop) higher than 
4 could be regarded as the cut-off score that optimally discriminates between the 
two groups with a sensitivity of 76.3% and a specificity of 72%. Furthermore, they 
also demonstrated that the schizophrenia group showed a significantly higher 
percentage of subjects with large total MPA scores, possibly supporting the 
hypothesis that MPAs might reflect extragenetic stressful events. 
 
Moving beyond the Waldrop, other researchers have focused also on quantitative 
measurements. Various studies, using both direct and indirect anthropometric 
measurement techniques, have demonstrated that these techniques can also be 
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used to successfully differentiate between schizophrenia subjects and non-
psychiatric controls.51;58-61;64;65 A number of studies have also supported the 
contention that head and face MPAs can best be used to discriminate between 
schizophrenia patients and controls.39;53;66;67 Compared to controls, patients have 
been shown to have more brachycephalic skulls (wider skull base, shorter lower 
facial heights, longer facial depths).51;59 Recent research has shown that middle 
cranial fossa size and shape influence skull base shape and facial measures.68 
Interestingly, the middle cranial fossa cradles the anterior portion of the temporal 
lobe, an area of interest in schizophrenia with research consistently identifying a 
decrease in temporal lobe volume in patients versus controls.69 
 
5.2.2 RELATIONSHIP BETWEEN MPAs AND OTHER INDICES IN 
SCHIZOPHRENIA SUBJECTS  
 
5.2.2.1 FAMILY MEMBERS OF SCHIZOPHRENIA PATIENTS 
 
Findings from studies of MPAs in relatives of schizophrenia patients are mixed. 
Whilst some studies report that relatives have no MPA elevations, showing 
frequencies similar to healthy controls, others reveal that relatives have clearly 
increased rates of MPAs in comparison to controls, although not to the same 
degree as patients.47;50;53;70-72  
 
In their comparison of 21 normal siblings to 60 adult schizophrenia patients as 
well as 75 normal no-related subjects Ismail et al. demonstrated that although the 
siblings also had significantly higher rates of MPAs (schizophrenia > sibs > 
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controls), no correlation was found for the level or type of MPAs within the same 
family.50 One possible interpretation could be that schizophrenia subjects and 
their family members are subjected to one or more genetic or shared 
environmental factors that increase the risk for developing both MPAs and 
schizophrenia but that the ultimately increased rate of MPAs in patients (versus 
siblings), could signal an accentuated effect of such factor(s) in those who later 
develop schizophrenia.  
 
This evidence was further supported by that of Gourion et al. who investigated 18 
trios (two non-psychotic parents and schizophrenia proband) and found no direct 
evidence for an intra-familial transmission of level or type of MPAs.47 
Furthermore, Cantor-Graae et al. demonstrated increased MPAs in monozygotic 
twins discordant for schizophrenia specifically showing that although both twins 
had increased rates in comparison to normal subjects there was a trend toward 
higher MPA rates in the ill comparatively to the well co-twin.45 Interestingly, data 
from Griffiths et al. seem to indicate sporadic cases of schizophrenia may 
manifest more MPAs than those from multiplex families.73 This supports the 
notion that an abnormality of prenatal development seems to be particularly 
implicated in sporadic schizophrenia.  
 
5.2.2.2 GENDER 
 
Research has shown the male foetus to have a higher sensitivity to adversities of 
the ectodermal activity and a greater overall vulnerability.74 Within this context 
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there seems to be increasing evidence for sex differences in the epidemiology of 
schizophrenia, as suggested by associations such as earlier onset, poorer 
premorbid function and poorer outcome in males that hint to a greater 
vulnerability of the male brain for the neurodevelopmental disruption leading to 
schizophrenia.75;76  
 
A possible role for gender in MPAs has also been investigated but to date results 
remain inconclusive with a number of schizophrenia studies reporting no sex 
differences, others an excess in MPAs in females and yet more others an excess 
in males.42;45;47;63;71-73;77-80 However, most of these studies just focused on mean 
total MPA score rather than investigating a possible relationship for MPAs from 
specific regions and/or individual MPAs. 
 
In this regard Akabaliev and Sivkov reported results not only showing that male 
schizophrenics had significantly higher total MPA scores (compared to females 
and controls), but also that females scored significantly higher for ear and mouth 
anomalies.77 Interestingly these are structures that undergo complex 
morphogenesis. The ear derives from six rudiments, the palate requires exact 
spatial relationships for its proper formation and the tongue originates from 
derivatives of the three distinct embryonal layers—ectoderm, mesoderm, and 
endoderm.35 Due to their complex development, these structures would be more 
prone to malformations due to prenatal adverse events and the higher scores in 
females suggest either more severe or different in nature extragenetic effects. 
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The head and eye regions were more dysmorphic in male schizophrenics, which 
might reflect the inexorably intertwined development of brain and skull and 
greater susceptibility of the male brain to neurodevelopmental disruptions. 
Akabaliev and Sivkov therefore contended that in the total etiological panorama 
of schizophrenia, gender could conceivably still provide insight into some of the 
unanswered questions within the multifactorial-polygenetic threshold model of the 
disorder. 77 
 
Clear gender differences have also been demonstrated in samples using 
quantitative rather than qualitative techniques. Using 3D craniofacial 
morphometrics, Henessey et al. demonstrated gender-specific differences in 
directional asymmetry in male and female schizophrenia subjects, both in relation 
to controls but also in relation to each other.65 Compton et al. conducted direct 
craniofacial measurements on a predominantly African-American sample 
revealing gender-specific differences in comparison to controls and each other 
for both male and female subjects.60 
 
5.2.2.3 BRAIN CORRELATES 
 
Reports that morphological abnormalities of the brain are already present in the 
early stages of schizophrenia have lent support to the neurodevelopmental 
hypothesis.81 A number of attempts have been made to demonstrate correlations 
between MPAs and morphological abnormalities of the brain. Initially no 
significant relationship could be demonstrated for either CT or MRI for general 
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schizophrenia groups.42;82 However, Hata et al. theorised that they would be 
more likely to demonstrate this difference in a subgroup of schizophrenia patients 
with early (before age of 18) onset schizophrenia (EOS).83 They performed MRIs 
on 27 EOS patients and demonstrated a significant correlation between total 
MPAs and ventricular enlargement.  
 
Furthermore, in a recent MRI study by Dean et al., the authors demonstrated that 
total MPA score in group of first episode psychosis patients was significantly 
associated with a reduction of grey matter volume in the prefrontal cortex and 
precuneus and with a grey matter excess in the basal ganglia, thalamus and 
lingual gyrus.84 Importantly, the areas highlighted have previously been 
implicated in the pathogenesis of psychosis.85-88 
 
5.2.2.4 SYMPTOM DIMENSIONS 
 
Both schizophrenia sufferers and their non-psychotic relatives have been shown 
to have significantly increased rates of cognitive dysfunction on formal 
testing.89;90 These findings on cognitive dysfunction were supported by Ismail et 
al. but they could not demonstrate any significant correlation between MPAs and 
these in either schizophrenics or their non-psychotic siblings.53 Their findings are 
in keeping with most previous studies, supporting the notion that MPAs as a 
group should preferably be considered as markers of generalised early 
neuromaldevelopment rather than markers of specific dysfunction.38;78;91 This 
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hypothesis is further supported by several studies reporting no association 
between MPAs and positive, negative, or disorganised symptoms.42;43;92 
 
5.2.2.5 ETHNICITY 
 
The distribution of MPAs as a marker of disturbed neurodevelopment across 
ethnic groups has received very little attention. An excess of psychosis has been 
demonstrated in particular ethnic groups but published data has been unable to 
link this to neurodevelopmental abnormalities.93;94 One could hypothesize that 
MPA rates in such groups would therefore possibly be lower than in other 
groups. However, in their recent study comparing four ethnically diverse 
(Caucasian, African Carribean, Black African, Other) groups of first episode 
psychosis patients, Dean et al. showed that the rate of MPAs (using an abridged 
version of the Lane scale) was consistently higher amongst those with psychosis 
than amongst controls and that this association existed irrespective of ethnicity.95   
 
Another recent US study compared an ethnically-mixed sample of Caucasian 
and African-American schizophrenia patients with controls and found MPAs 
(using only quantitative measurements) to be elevated in the patient group as a 
whole.96  However, no attempt was made to ethnically stratify the sample in order 
to make inter-group comparisons. Quantitative measurements were also used to 
demonstrate increased rates of dysmorphic features for schizophrenia subjects in 
comparison to controls in a small Mestizo (admixture Spanish, Indian, Black) 
sample and a larger predominantly African-American sample.60;61 
- 206 - 
5.2.2.6 AGE 
 
Studies broadly examining a relationship between age of onset and MPAs have 
mostly yielded negative results, however studies focusing specifically on a 
comparion between MPAs in early onset (under age of 18) schizophrenia (EOS) 
versus later onset have shown an increased rate in EOS.42;43;82;97;98 Such results 
would possibly support the hypothesis that EOS represents a subset of patients 
in which neuromaldevelopment is significantly involved. 
 
No studies have specifically focused on MPAs in schizophrenia patients above 
the age of 60. Lloyd et al. used the Lane dysmorphology scale to compare rates 
of MPAs between healthy older (>60) and younger individuals and found the 
older group to significantly differ on four items i.e. higher frequency of absent 
trichions due to alopecia, shorter and broader palates and greater right and left 
ear protrusions.99  The authors concluded that changes associated with normal 
ageing (hair loss and loss or extraction of teeth followed by longstanding 
pressure from dentures leading to the observed palate shape) made at least two 
of these items invalid comparisons and that a separate scale needs to be 
validated for the elderly. However, Henriksson et al. recently did a statistical 
analysis using a comparative age-breakdown of participants in a number of large 
studies reporting significant differences in MPA rates between controls and 
schizophrenia subjects.100 They demonstrated that no statistically significant 
differences could be observed between MPA rates and age for any of the study 
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groups and concluded that current data did not support increased age to be a 
confounding factor in the study of MPA rates in schizophrenia. 
 
The question has also been posed as to whether MPAs present at an early age 
could in fact predict future psychiatric illness. Schiffman et al. assessed subjects 
at age 11-13 years, before onset of mental illness, collecting follow-up data on 
their adult psychiatric outcome 20 years later.101 Presenting with a higher number 
of MPAs in childhood significantly differentiated between those who developed 
schizophrenia spectrum disorders (SSD) and those with no mental illness. 
Furthermore, for those individuals with a parent suffering from schizophrenia, a 
higher number of MPAs in childhood significantly differentiated between those 
who developed SSD and those with no mental illness as well as those with other 
psychopathology. The results seem to support a neurodevelopmental hypothesis 
for SSD. For high-risk individuals, MPAs seem to either signify a stressor 
relevant to those at genetic risk to develop schizophrenia or that high-risk status 
does in fact increase the risk for neuro-maldevelopment. 
 
5.2.2.7 NEUROLOGICAL SOFT SIGNS 
 
Neurological “subtle” or “soft” signs (NSS) are abnormalities that illustrate 
generalised and nonspecific neurological pathology. As is the case for MPAs, 
several studies have reported an increased prevalence of NSS in patients 
suffering from schizophrenia.102-104 The presence of MPAs and NSS have also 
both separately been found to be predictive of future schizophrenia.101;105 
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Gourion et al. examined a group of schizophrenia subjects, their non-psychotic 
parents and normal controls for both MPAs and NSS.72 Total MPA and NSS 
scores could be positively correlated; these results being in keeping with the 
expectation that these two variables could reflect an early developmental insult. 
These findings were supported by that of John et al. who demonstrated in a small 
sample that schizophrenia and control subjects were most accurately classified 
(82.9%) when MPAs and NSSs were considered jointly rather than 
independently106 Both groups of authors therefore concluded that the co-
assessment of these markers could be useful as a composite phenotype for 
genetic studies. 
 
6. SUMMARY 
 
Due to the complex genetic and clinical heterogeneity exhibited in schizophrenia, 
the use of endophenotypes has long been considered a viable option in the 
search for susceptibility genes. The quantitative and qualitative measurement of 
anthropometric proportions to demonstrate the presence or absence of 
dysmorphic features (so-called minor physical anomalies (MPAs)) represents 
one such endophenotype.  The presence of MPAs act as biologically-timed 
markers of developmental disturbance within a foetus and craniofacial anomalies 
are of special interest as the brain and the overlying face both develop from 
common embryonic ectoderm. Although some of the current evidence is 
contradictory and more research is needed, the presence of an excess of MPAs 
in schizophrenia subjects, in comparison to normal controls, has repeatedly been 
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demonstrated. The use of MPAs as endophenotype fits in well with the 
neurodevelopmental hypothesis of schizophrenia and seems to be particularly 
appropriate in our setting as not only can these measurements be done 
inexpensively, but observers can be relatively easily trained to perform these 
measurements. 
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APPENDIX A: LANDMARKS FOR HEAD AND FACIAL 
MEASUREMENTS 
 
In direct measurements of the head and face, 47 landmarks are used: 6 on the 
head, 6 on the face, 8 on the orbits, 11 on the nose, 6 on the lips and mouth, and 
10 on the ears. 
 
 
 
HEAD 
 
Vertex: (v) Highest point of the head when normally oriented.  The vertex is not 
identical to the bregma, the bony landmark in the middle of the top of the skull, 
where the coronal and sagittal sutures cross. 
Glabella: (g) Most prominent midline point between the eyebrows and is identical 
to the bony glabella on the frontal bone.   
- 224 - 
Opisthocranion: (op) Point situated in the occipital region of the head and is 
most distant from the glabella, that is, it is the most posterior point of the line of 
greatest head length.   
Eurion: (eu) Most prominent lateral point on each side of the skull in the area of 
the pariental and temporal bones.   
Frontotemporale: (ft) Point on each side of the forehead, laterally from the 
elevation of the linea temporalis.   
Trichion: (tr) is the point on the hairline in the midline of the forehead.  It cannot 
be determined on a balding head. 
 
FACE 
 
Zygion: (zy) Most lateral point of each zygomatic arch and is identified by trial 
measurement, not by anatomical relationship.  It is identical to the bony zygion of 
the malar bones. 
Gonion: (go) Most lateral point on the mandibular angle close to the body 
gonion.  It is identified by palpation.   
Sublabiale: (sl) Determines the lower border of the lower lip or the upper border 
of the chin.  It corresponds with the mentolabial ridge of anatomists, a point 
marked as inferior labial point, supramentale, submental point or labiomentale.   
Pogonion: (pg) Most anterior midpoint of the chin, located on the skin surface in 
front of the identical bony landmark of the mandible. 
Menton/Gnathion: (gn) Lowest median landmark on the lower border of the 
mandible.  It is identified by palpation and is identical to by bony gnathion.  This 
landmark is the lowest point used in measuring facial height. 
Concylion laterale: (cdl) Most lateral point on the surface of the condyle of the 
mandible.  It is identified by palpation at each temporomandibular joint when the 
jaw is open.   
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ORBITS 
 
Endocanthion: (en) Point at the inner commissure of the eye fissure.  The soft 
endocanthion is located lateral to the bony landmark that is used in 
cephalometry. 
Exocanthion: (ex) Point at the outer commissure of the eye fissure.  The soft 
exocanthion is slightly medial to the bony exocanthion. 
Center point of the pupil: (p) Determined when the head is in the rest position 
and the eye is looking straight forward.  Identification is easiest when the patient 
is reclining, the eye fissures are horizontal and the eyes are gazing straight 
forward. 
Orbitale: (or) Lowest point on the lower margin of each orbit.  It is identified by 
palpation and is identical to the bony orbitale. 
Palpebrale superius: (ps) Highest point in the midportion of the free margin of 
each upper eyelid. 
Palpebrale inferius: (pi) Lowest point in the midportion of the free margin of 
each lower eyelid. 
Orbitale superius: (os) Highest point on the lower border of the eyebrow, close 
to the highest bony point of the upper margin of each orbit, where the bony 
supraorbitale landmark is located. 
Superciliare: (sci) is the highest point on the upper borderline in the midportion 
of each eyebrow. 
 
NOSE 
 
Nasion: (n) Point in the midine of both the nasal root and the nasofrontal suture. 
The slight ridge on which it is situated can be felt by the observer’s fingernail.  
This point always is above the line that connects the two inner canthi.   
Sellion: (se) Deepest landmark located on the bottom of the nasofrontal angle.  
The point usually occurs somewhere between the level of the supratarsal fold 
and eyelash. 
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Mazillofrontale: (mf) Base of the nasal root medially from each endocanthion, 
close to the bony maxillofrontale of the medial margin of each orbit, where the 
mazillofrontal and nasofrontal sutures meet.   
Alare: (al) Most lateral point on each alar contour. 
Pronasale: (prn) Most protruded point of the apex nasi, identified in lateral view 
of the rest position of the head.  In the case of the bifid nose, the more protruding 
tip is chosen. 
Subnasale: (sn) Midpoint of the angle at the columella base where the lower 
border of the nasal septum and the surface of the upper lip meet.  The landmark 
is identified in base view of the nose, or from the side.   
Subalare: (sbal) Point at the lower limit of each alar base, where the alar base 
disappears into the skin of the upper lip.  The landmarks indicate the labial 
insertion of the alar base. 
Alar curvature: (ac) Most lateral point in the curved base line of each ala, 
indication the facial insertion of the nasal wingbase. 
Highest point of the columella: (c’) is the point of each comumella crest, level 
with the top of the corresponding nostril. 
Alare’: (al’) Marking level at the midportion of the alae where the thickness of 
each ala is measured. 
Subnasale’: (sn’) Midpoint of the columella crest where the thickness of the 
columella is measured.  When measuring the width of the nostril floor between 
the subalare and the crest of the columella, the sn’ point designates the 
columella crest at the bottom line. 
 
LIPS AND MOUTH 
 
Crista philtri: (cph) Point on each elevated margin of the philtrum just above the 
vermilion line.   
Labiale superius: (ls) Midpoint of the upper vermilion line. 
Labiale superius’: (ls’)Laterally from the midpoint, also located on the upper 
vermilion line vertically beneath the right and left subalare points. 
- 227 - 
Labiale inferius: (li) Midpoint of the lower vermilion line. 
Stomion: (st) Imaginary point at the crossing of the vertical facial midline and the 
horizontal labial fissure between gently closed lips, with teeth shut in the natural 
position. 
Cheilion: (ch) Point located at each labial commissure. 
 
EARS 
 
Superaurale: (sa) Highest point on the free margin of the auricle. 
Subaurale: (sba) Lowest point on the free margin of the ear lobe. 
Preaurale: (pra) Most anterior point of the ear, located just in front of the helix 
attatchment to the head. 
Postaurale: (pa) Most posterior point on the free margin of the ear. 
Otrobasion superius: (obs) Point of attachment of the helix in the temporal 
region.  It determines the upper border of the ear insertion. 
Otobasion inferius: (obi) Point of attachment of the ear lobe to the cheek.  It 
determines the lower border of the ear insertion. 
Porion: (po) Highest point on the upper margin of the cutaneous auditory 
meatus. This point is a few millimeters medial to the bony portion. 
Tragion: (t) Notch on the upper margin of the tragus. 
Points establishing the medial longitudinal axis:  (1) uppermost point is 
determined by halving the upper portion of the ear (i.e., the portion above the 
upper insertion point of the ear), and (2) the lowest point is the middle of the free 
border of the ear lobe.   
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METHODOLOGY
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1. VISUAL METHODOLOGICAL OVERVIEW 
SUBJECT RECRUITMENT 
 
A convenience sample of 112 Xhosa schizophrenia patients participating in a 
substudy of a large international genetic study were recruited. 
SUBJECT INTERVIEW 
 
DSM-IV-TR; DIGS (including SANS + SAPS); Interview augmented with 
information obtained from family members and patient records. 
PROCEDURES 
 
Using sliding calipers 9 sets of 
head and facial measurements 
were performed. 
SAMPLES 
 
Blood samples (for karyotyping 
and/or FISH analysis) as well 
as urine samples (for drug 
screening) were obtained. 
STATISTICAL ANALYSIS 
 
Descriptive statistics were compiled with reference to demographic, 
clinical and morphological variables. Comparisons between mean 
differences for these variables were made. 
INTERPRETATION 
 
FISH analysis and karyotyping results as well as comparative analysis of 
variables were interpreted within the context of current knowledge. With 
reference to information gained from this study future possibilities for studies 
within this population group were discussed. 
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2. STUDY SUBJECTS 
 
2.1 OVERVIEW 
 
Over a period of 24 months, a group of potential participants, all of Xhosa 
(African population of the Nguni language group) ethnicity and known to have a 
diagnosis of schizophrenia, were recruited from in and outpatient hospital 
services and community clinics in the Western Cape Province of South Africa for 
participation in an international genetic study. Participants were initially identified 
by hospital or community mental health workers and were at various stages of 
illness and treatment. Subjects who met inclusion and exclusion criteria and were 
able to give informed consent (consent obtained from caregivers in the event of 
diminished capacity) were included in the study group. 
 
During the course of the above-mentioned study a number of subprojects were 
also initiated concurrently, using convenience samples from the larger study 
population. All of the subjects who presented for assessment for one such study 
(over a six month period) were approached in consecutive order by a Xhosa-
speaking social scientist to discuss possible participation in this study. Of the 112 
patients approached, all agreed to participate. Once again subjects were 
screened as to meeting inclusion and exclusion criteria and informed consent 
was obtained prior to any study procedures being initiated. Blood samples of fifty 
consecutively recruited participants from the total study population of 112 were 
selected for karyotyping. 
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2.2 INCLUSION CRITERIA 
 
(a) Adult male and female subjects known with a diagnosis of schizophrenia 
according to DSM-IV-TR criteria1;  
(b) Known Xhosa ethnicity (this was defined as all four grandparents being of 
Xhosa origin).  
(c) Current stage of illness did not exclude a subject from participation. 
 
2.3 EXCLUSION CRITERIA 
 
(a) Known organic aetiology that could significantly impact on diagnosis. 
 
3. SUBJECT ASSESSMENT 
 
3.1 STRUCTURED ASSESSMENT TOOLS 
 
Once informed consent was obtained, a trained clinician administered a 
standardised interview (DIGS – Diagnostic Interview for Genetic Studies; Version 
2.0) in either English or Xhosa (with the help of an experienced Xhosa-speaking 
social scientist).2 The DIGS is a comprehensive clinical assessment interview 
specially developed for diagnosing major mood and psychotic spectrum 
disorders and also includes the SANS and SAPS (Schedules for the Assessment 
of Positive and Negative Symptoms).3;4 The SANS and SAPS each assess 
symptom complexes to obtain clinical ratings of negative and positive symptoms 
respectively in patients with schizophrenia. They are – SANS – (1) affective 
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blunting; (2) alogia (impoverished thinking); (3) avolition/apathy; (4) 
anhedonia/asociality; and (5) disturbance of attention; and SAPS – (1) 
hallucinations; (2) delusions; (3) inappropriate behaviour; (4) thought disorder. 
Ratings are made on each symptom cluster, after consideration has been given 
to each of the items contained within the various complex scores. Anchor points 
are given for each item. (0 = not at all; 1 = questionable; 2 = mild; 3 = moderate; 
4 = marked; 5 = severe). The DIGS (including the SANS and SAPS) has 
previously been used as interview tool for studies in the Xhosa population and it 
has been shown that the core symptoms of schizophrenia were found to be 
similar to those of Caucasian samples.5-7 The interview was augmented with 
information gathered from family members of participants as well as that 
obtained from hospital records.  
 
3.2 FOCUS OF ASSESSMENT 
 
Information with reference to relevant demographic characteristics, previous and 
current medical history and history of substance use/abuse was obtained. In 
terms of psychiatric history, full data with regard to current and previous episodes 
of illness, number of episodes and hospitalisations (as well as duration), “trigger” 
factors, current and previous medications, age of onset, family history, presence 
of previous and current risk behaviours (e.g. suicidality) and co-morbid diagnosis 
was collected.  
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3.3 SAMPLE COLLECTION 
 
Blood samples (for karyotyping and/or FISH analysis) as well as urine samples 
(for drug screening (cannabis, opioids, cocaine, metaqualone, methamphe-
tamine)) were obtained from each participant. 
 
3.4 MORPHOLOGICAL ASSESSMENT 
 
In a previous study conducted by our group digital still images were captured and 
then evaluated by an experienced clinical geneticist who performed a Modified 
Waldrop Scale (MWS) assessment on each.8 However, one of the objectives of 
the current study was to obtain information that could contribute to the 
development of a simple, user-friendly, “risk profile” screening tool for use by 
community mental health workers. As such, we decided that due (1) to the 
complexity of training lay individuals to use the MWS and, (2) the cost in 
providing a digital camera for many different sites the previous procedure would 
not be feasible for the current project.  
 
Therefore, a decision was taken to rather perform head and facial measurements 
using sliding calipers. Nine sets of measurements were captured; please see 
diagram for the landmarks used. In the case of depth measurements only the 
right side of the face was used.  
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The nine sets of measurements used were: (1) Head circumference (2) Trichion 
(tr) to Glabella (g); (3) g to Nasion (n); (4) g to Subnasale (sn); (5) g to Stomion 
(st); (6) g to gnathion (gn); (7) Tragion (t) to tr; (8) t to sn; and (9) t to gn. Please 
see diagram below identifying these landmarks. To optimize quality, we selected 
measurements with reliable landmarks. These measurements form part of those 
suggested by Lane et al and have previously been used for measurements in 
schizophrenia subjects.9;10 
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4.  ANALYSIS  
 
4.1 KARYOTYPING AND FISH 
 
Fluorescence In Situ Hybridisation (FISH) analysis was done using a 
DiGeorge/VCFS region probe (LSI TUPLE 1 SpectrumOrange/ARSA (22q13.3)). 
Karyotyping (resolution of appropriate 500 Giemsa-band stage) was performed 
according to standardised UNISTEL laboratory protocol. Please see Appendix A 
for these protocols. 
 
4.2 STATISTICAL ANALYSIS 
 
Descriptive statistics were compiled for each of the subgroups (total sample, 
sample karyotyped, participants with chromosomal aberrations) with reference to 
demographic, clinical and morphological variables using the Software Package 
for Social Sciences (SPSS) (V10.0). Comparisons between mean differences for 
demographic and clinical variables including living arrangements, marital status, 
employment status, level of qualification, number of admissions, duration of 
illness, substance use, lifetime illness features as well as the nine morphological 
measurements were made. Student T-Tests were used as appropriate. 
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5. ETHICAL CONSIDERATIONS 
 
This study formed part of a large multi-national effort to study genetic risk factors 
in schizophrenia and as such was approved by the Committee for Human 
Research of the University of Stellenbosch. (97/005).  
 
All study procedures and aims were explained in lay terms to subjects in their 
home language (via an interpreter when necessary) and if appropriate to their 
caregivers/legal guardians. Informed consent was only accepted if the patient 
was able to understand and communicate this understanding to the researchers.  
Legal guardians/caregivers gave consent, in addition to the patient's consent, if 
any doubt existed as to his/her ability to offer informed consent. Participation did 
not lead to any costs for the participants. 
 
All participation was voluntary and refusal to participate or withdrawal would in no 
way affect a participant’s right or access to future treatment. Any request for 
withdrawal of participation would immediately be implemented. The study 
findings would be available to all participating individuals, if requested. 
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APPENDIX A: UNISTEL STANDARD OPERATING 
PROTOCOLS 
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UNISTEL STANDARD OPERATING PROTOCOL: KARYOTYPING 
 
Chromosome preparation from peripheral blood lymphocytes: 
 
Culture Procedure: 
 
Set up cultures twice a week – Tuesdays and Fridays. 
 
1. Place PBMax in incubator (37°C) at least 2 hours prior to setting up of cultures 
(8ml/blood specimen) 
2. Switch on the Laminar flow cabinet 20 minutes before setting up of cultures and 
clean the Laminar flow cabinet with ethanol. 
3. Take blood specimens, PHA and enough syringes and needles and wipe it with 
ethanol before putting it in the flow cabinet. 
4. Prepare the culture tubes by writing the patient lab number and the culture 
number on both tubes (A and B cultures). Write the numbers on the cap of the 
tube as well. 
5. Place 4ml of PBMax medium in every tube.  Add 50 µl PHA to culture A and 
100µl PHA to culture B. 
6. Add 0.5ml blood to each prepared culture tubes in the case of an adult and 0.3ml 
if it is a baby or a cordocentesis. 
7. Mix the contents of each culture tube gently by inverting it a few times. 
8. Incubate the cultures at 37°C in a slanting position. (48 hours for cultures set up 
on Tuesday and 72 hours for cultures set up on Fridays.) 
 
Cell-Syncronisation: 
 
1. Clean the Laminar flow cabinet with ethanol and take the MTX out of the freezer 
and let it thaw.  Everything that goes in to the flow cabinet must be cleaned with 
ethanol. 
2. Add 25µl MTX sterile to the cultures at 15H00 on Mondays (cultures set up on 
Fridays) and Thursdays (cultures set up on Tuesdays. 
3. Mix the cultures and incubate it for a further 16-18 hours.   
4. Wash out the MTX block on Tuesday (cultures set up on Fridays) and Friday 
(cultures set up on Tuesdays) mornings. 
5. Place PBMax medium in incubator at 37°C and thaw the thymidine. 
6. Clean the Laminar flow cabinet with ethanol. 
7. Centrifuge the cultures at 1500 rpm for 8min.  Discard the supernatant and add a 
mixture of medium and thymidine (3 ml PBMax and 30µl thymidine per culture).  
8. Incubate the cultures for 4¾ hours in a slanting position at 37°C in the incubator 
in the harvesting laboratory. 
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Preparations for Harvesting: 
 
1. Place KCI in the incubator (37°C) at least 1 hour before harvesting. (8ml per 
culture) 
2. Make up die fixative at least half an hour before harvesting and put in freezer: 
1 Glacial Acetic Acid: 3 Methanol (20ml per tube + 20ml) 
1 Glacial Acetic Acid: 6 Methanol (10 ml per tube) 
 
Harvesting: 
 
1. Add 100µl Colcemid to each culture tube and mix by gently inverting a few times 
and incubate at 37°C for 30 minutes in a slanting position. 
2. Check to see if the number on the tube correlates with the number on the cap of 
the tube. 
3. Centrifuge the culture at 1200 rpm for 10 min and remove the supernatant with an 
aspiration pump until ± 2 ml of fluid remains.  Mix up cell pellet gently. 
4. Add 8ml KCI, mix well and place in the incubator (37°C) for 15 min. 
5. Add 5 drops of 1:3 fixative to each tube and mix gently. 
6. Centrifuge at 1200 rpm for 10 min.  Aspirate supernatant and mix up cell pellet. 
7. Gradually add 5 ml 1:3 fixative to cultures and mix thoroughly. 
8. Centrifuge at 1200 rpm for 10 min.   Aspirate supernatant and mix up cell pellet. 
9. Repeat this procedure 4 times.  After the fourth centrifuge and aspiration of the 
supernatant 1:6 fixative must be added to the cultures. 
10. Centrifuge at 1200 rpm for 10 min.  Aspirate supernatant and mix up cell pellet. 
11. Gradually add 5 ml 1:6 fixative to cultures and mix thoroughly. 
12. Centrifuge at 1200 rpm for 10min.  Aspirate the supernatant and remove as much 
of it as possible. 
13. Place in freezer for slide preparation the next day or for at least 30 minutes. 
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UNISTEL STANDARD OPERATING PROTOCOL: FISH 
 
PROCEDURE: FISH (Fluorescent in situ hybridization) – FISH procedure 
 
1. SCOPE 
This SOP is applicable to all staff of the FISH Division, the QA manager and all 
staff of UML allowed to give out and discuss the results of this test with either the 
referring clinician or the patient. 
 
2. PURPOSE 
This SOP describes the complete procedure for testing human DNA for the 
presence/absence of specific genes, whole chromosomes, translocations, inversion 
or duplications. 
 
3. FREQUENCY 
This SOP is used as often as required for routine testing of referred samples, as 
often as required for testing new probes/other chemicals/equipment used in this 
procedure, and as often as it is required for evaluating and validating (a) any new 
variations in this procedure or (b) any other procedure developed to replace or 
complement this procedure. 
 
4. BACKGROUND 
FISH (Fluorescent in situ hybridization) is a cytogenetic technique that can be 
used to detect and localize the presence or absence of specific DNA sequences on 
chromosomes.  It uses fluorescent probes that bind to only those parts of the 
chromosome with which they show a high degree of sequence similarity.  
Fluorescence microscopy can be used to find out where the fluorescent probe 
bound to the chromosome.  FISH is often used for finding specific features in 
DNA.  The features can be used in genetic counseling, medicine and species 
identification. 
 
5. PROCEDURE 
5.1 Materials required 
 
All chemicals are to be made up fresh on the day of preparation: 
 
1. Sterile distilled deionised (SDD) water prepared according to UnistelSOP. 
2. Distilled deionised (DD) water prepared according to UnistelSOP. 
3. Patient DNA, Prepared according to UnistelSOP. 
4. 70% ethanol, 90% ethanol and 100% ethanol 
5. HCI 
6. 20xSSC (Nacl, Tri-NaSitrate and distilled water) made up according to 
UnistelSOP. 
7. Phosphate buffer (PBS) 
8. MgCl² 
9. PFA 
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10. Pepsin 
11. Methanol 
12. Acetic acid 
13. KCL 
 
5.2 Equipment required 
 
1. Incubator 37°C 
2. Water bath 73°C 
3. Yellow 20µl Gilson pipette tips 
4. Blue 1000µl Gilson pipette tips 
5. Transparent 20µl Gilson pipette tips 
6. 20 clean Hellendahl containers (individually marked for dedicated chemicals 
used) 
7. Four heat resistant plastic containers 
8. 100µl Gilson Pipette 
9. 2µl Gilson Pipette 
10. 20µl Gilson Pipette 
11. 1000µl Gilson Pipette 
12. Microscope cover glasses 24x50mm 
13. Microscope cover glasses 22x22mm 
14. Minute/second count down timer 
15. Plastic tweezers 
16. Fluorescent microscope 
17. Fluorescent microscope filters (red, gold, aqua, green, and dapi) 
18. Fan 
19. Eppendorphs 
20. Clean glass slides 
21. Warm fan 
22. Light microscope 
 
5.3  Preparation of samples 
 
The following samples can be prepared for the FISH technique: 
 
 EDTA or heparinised blood 
 EDTA or heparinised bone marrow 
 Amniotic fluid 
 Products of conception 
 Semen (sperm) 
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5.4.1 Preparation of FISH samples 
 
Place KCI in the incubator (8ml per tube) at least 1 hour before harvesting 
Make up fixative at least half an hour before harvesting and put in the freezer. 
1 Glacial Acetic Acid: 3 Methanol (Make up 10ml per tube + 20ml) 
 
1. Check to see that the number on the tube correlates with the number on the cap of 
the tube. 
2. Centrifuge the amniotic fluid, culture at 1200 rpm for 10 min and remove the 
supernatant with an aspiration pump until ± 2 ml of fluid remains.  If there are 
signs of blood in the pellet, it must be documented. 
3. For the blood and bone marrow, mix well and decant 2 ml into a clean dry tube. 
4. The products of conception must be biopsied according to UnistelSOP and stored 
in culture medium. 
5. Then the samples are ready for preparation. 
6. Add warm (37°C) 8 ml KCI, mix well and place in incubator (37°C) for 20 min. 
7. Remove tubes from the incubator 
8. Add 5 drops of 1:3 fixative to each tube and mix gently. 
9. Centrifuge at 1200rpm for 10 min.  Aspirate the supernatant and mix up cell 
pellet. 
10. Add 5ml 1:3 fixative and mix thoroughly. Place cultures overnight in refrigerator. 
 
Next day: 
 
Make up fresh fixative at least half an hour before harvesting and put in freezer. 
1 Glacial Acetic Acid: 3 Methanol (15ml/tube) 
 
1. Centrifuge cultures at 1200 rpm for 10 min. 
2. Aspirate supernatant and mix up pellet. 
3. Add 5 ml fixative and mix thoroughly 
4. Repeat this 3 times.  After the third 5 ml fixative is added, the cultures are 
centrifuged and the supernatant is aspirated (as much as possible) depending on 
the size of the pellet. 
5. Samples are now ready for slide preparation. 
 
5.5  Making of the slides 
 
1. Place all sample tubes in a Perspex container. 
2. Reconcile all samples with their relevant request forms. 
3. Ensure that lab numbers on the sample tubes correspond to the lab numbers on the 
patient forms. 
4. Use the slides that have been cleaned in an ethanol ether solution.  As per 
UnistelSOP. 
5. Only make on slide at a time 
6. Write the corresponding lab number (e.g. BF11111) on the frosted side of the 
slide in pencil 
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7. Using a 50µl pipette and designated pipette tips draw up a well suspended pipette 
tip full of sample. 
8. For bone marrow and blood samples distribute sample evenly over the slide. 
9. For amniotic fluid samples make two designated concentrated areas of cells on 
either side of the slide 
10. Place slides on a flat surface in front of a warm dryer to dry. 
11. Evaluate the dry slide under the phase contrast microscope.  If more cells are 
needed place more sample drops on the slide and let dry. 
12. Store the remaining sample in the fridge for at least 6 months. 
 
5.6  Preparation of solutions to be used for one FISH procedure 
 
Always make up fresh solutions to be used on the same day for the FISH slide treatment 
procedure. 
 
1. Mark and fill three Hellendahl containers respectively 10% methanol, 70% acetic 
acid: methanol (70 ml acetic acid + 30 ml Methanol) and 100% methanol. 
2. Mark one glass staining dish Pepsin, and fill with a solution consisting of 100 ml 
phosphate buffer (PBS) 100µl HCR and 18µl Pepsin (to be added later). Place 
container with solution in a 37°C incubator to warm up. 
3. Mark and fill four Hellendahl containers respectively. 
Two containers marked PBS (phosphate buffer prepared according to 
UnistelSOP) 
PBS + MgCl² (95ml PBS and 5 ml MgCl² prepared according to UnistelSOP) 
PFA paraformimide prepared according to UnistelSOP) 50 ml PFA + 45 ml PBS 
and 5 ml MgCl²) 
4. Mark and fill three Hellendahl containers respectively 100% ethanol, 90% ethanol 
(90 ml ethanol + 10 ml distilled water) and 70% ethanol (70 ml ethanol + 30 ml 
distilled water) 
5. Discard all solutions after use, rinse containers under tap and let dry overnight. 
6. Remove the aliquoted Pepsin, 20X SSC and FA from the freezer to defrost. 
 
5.7 FISH Procedure 
 
1. Place cooled down, dry slides in 100% Methanol container for 10 min 
2. Move slides to the 70% acetic acid: methanol solution for 1 min 30 seconds 
3. Move slides to a 100% methanol container for 2 min 
4. Remove slides and let dry in front of a fan for 10 min 
5. After 10 min in front of fan, add 18µl defrosted and well mixed Pepsin to the 
PBS/HCI staining container, add slides to the solution and place at 37°C for 15 
min 
6. After 15 min, remove slides and place in PBS for 5 min. 
7. Move slides to PBS/MgCl solution for 5 min 
8. Move slides to PFA solution for 5 min 
9. Move slides to PBS solution for 5 min 
10. Remove slides from the PBS solution 
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11. Place them in the 70% ethanol solution (70 ml ethanol + 30 ml dH²O) for 3 min 
12. Move slides to the 90% ethanol solution (90 ml ethanol + 10 ml dH²O) for 3 min  
13. Move slides to the 10% ethanol solution for 3 min 
14. Remove slides from the 100% ethanol and place in front of a fan for 10 min to dry 
15. The slides are now ready for denaturation and probing. 
 
5.7.1  Denaturation 
 
The probes are light sensitive!  When working with the probes, ensure that the light is 
turned OFF at all times. 
There are two different types of probes that require two different types of 
denaturation procedures. 
Some probes can be co-denatured with DNA but others (most of the probes) need to 
be denatured separately from the DNA. 
 
5.7.2   Separate denaturation technique 
 
1. Turn main lights off 
2. Turn on the water bath and set to 73°c 
3. Make up the Hybridization solution according to the following formula 
4. 70µl deonised Formamide + 20µl sterile dH²O + 10µl 20 X SSC 
5. (This is enough solution to denature one slide of DNS, make up enough for all the 
slides to be denatured) 
6. Mix the denatured solution well 
7. Place 10µl denaration solution on every slide, cover with a long cover slip 
8. Place the slide on a hot plate 75°C for 3 min 
9. After 3 min remove the cover slips and place the slides immediately in 4°C 70% 
ethanol solution for 3 min. 
10. Move slides to the 90% ethanol solution (90 ml ethanol + 10 ml dH²O) for 3 min 
11. Move slides to the 100% ethanol solution for 3 min 
12. Remove slides from the 100% ethanol and place in front of a fan for 10 min to dry 
13. Slides are now ready for probing 
 
5.8 Probing 
 
Remove all the required probes from the freezer and allow to reach room temperature.  
Probes will be applied and handled in two different ways. 
 
5.8.1  Probes for separate enaturation 
This method is used for the single copy probes 
 
1. Ensure the lights are turned off at all times when working with the probe 
2. Ensure probes and hybridization buffer are at room temperature 
3. Centrifuge the probe and the hybridization buffer to ensure it is mixed well 
4. Mark eppendorf’s with the corresponding probe name 
5. Prepare the probe mix according to the following formula: 
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 7,0 µl hybridization buffer 
 2 µl sterile distilled water 
 0,6 µl desired probe 
6. Mix well and denature the probe by floating the eppendorf containing the probe 
mix in a water bath at 73°C for 5 min 
7. After 5 min remove the eppendorf and place the denature probe on the 
corresponding already denatured slide, cover with a 21mm x 50mm cover slip. 
8. Remove most of the air bubbles and place in a humidity camber in an incubator at 
37°C 
9. Allow to re-anneal overnight in a dark incubator at 37°C 
 
5.8.2  Probes for co-denaturation 
 
This method is used for the multiple copy probes 
 
1. Ensure the lights are turned off at all times when working with the probe 
2. Ensure probes are at room temperature 
3. Centrifuge the probe to ensure it is mixed well 
4. Measure 5µl of required probe and place in the middle of a 24mm x 24mm cover 
slip. 
5. Invert the already prepared Fish slide onto the cover slip with the probe. 
6. Ensure there is not air bubbles trapped under the cover slip. 
7. Seal all 4 sides with glue 
8. Place on a hotplate at 75°C for 5 min to denature 
9. After 5 min remove slides immediately and place in a humidity camber in a 37°C 
incubator 
10. Allow to re-anneal overnight in the dark. 
 
6.  Post-hybridization washes. 
There are two types of post-hybridization washes, a different wash for both the single 
copy probes (a less stringent wash) and the multiple copy probes ( a more stringent 
wash). 
 
6.1  More stringent wash for the multiple copy probe. 
 
1. Label three plastic coplin jars respectively 
 0,4 x SSC/0,3% Tween 
 2 x SSC/),1% Tween 
 PBS 
2. In the 0,4 x SSC/0.3% Tween container make a solution containing: 
2.1 53.9 ml dH²O + 14 ml 2 x SSC + 2.1 ml 10% Tween 
2.2 Place in a water bath at 68°C 
2.3 Allow 20 min to warm up 
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3. In the 2 x SSC/),1% Tween container make a solution containing: 
3.1 69.3 ml 2 x SSC + 700 µl 10% Tween 
3.2 Leave at room temperature 
 
4. Fill the PBS container with PBS and leave at room temperature 
5. Once the 0,4 x SSC/0,3% Tween solution reached 68°C 
6. remove the slides from the humidity camber in the incubator 
7. Carefully remove the glue without disturbing the cover slips 
8. Carefully remove the coverslips by lifting them off with a razor blade 
9. Once all the cover slips have been removed, place the slides back to back and into 
the warmed up 0,4 x SSC/0,3% Tween solution for 3 min 
10. After 3 min remove the slides and place it into the 2 x SSC/0,1% Tween solution 
at room temperature for 3 min 
11. After 3 min remove the slides and place it into the PBS for 3 min  
12. Slides are now ready for mounting. 
 
6.2  Less stringent wash for the single copy probe 
 
1. Label 7 Hellendahl containers respectively 
 Mark three Hellendah containers 50% FA/SSC 
 Mark two containers 2 X SSC 
 Mark one container 1 X SSC 50µl 10% Tween 
 PBS 
 
2. In the three containers marked 50% FA/SSC make a solution containing 50% 
Formamide and 50% 2 X SSC 
2.1 Measure 150 ml Formamide and 150 ml 2 X SSC mix well and divide 
between the three containers. 
2.2 Place containers in a water bath at 42°C and allow to warm up 
 
3. Fill the two containers marked 2 X SSC with 2 X SSC and place in the water bath 
at 42°C and allow to warm up. 
4. In the container marked 1 X SSC/500µl 10% Tween make a solution containing: 
4.1 100 ml 2 X SSC and 500µl 10% Tween 
4.2 Place in the water bath to warm up 
5. Once the solutions have reached 42°C the wash can begin 
6. Remove the slides from the humidity camber in the incubator 
7. Carefully remove the cover lips by lifting them off with a razor blade 
8. Once all the cover slips have been removed, place the slides back to back and into 
the warmed up 50% FA/SSC solution for 5 min 
9. After 5 min move the slides to the next 50% FA/SSC solution for 5 min 
10. After 5 min move the slides to the next 50% FA/SSC solution for 5 min 
11. After 5 min remove the slides and place it into the 2 X SSC solution for 5 min 
12. After 5 min move the slides to the next 2 X SSC solution for 5 min 
13. After 5 min remove the slides and place it into the 2 X SSC and 500µl 10% 
Tween solution for 5 min 
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14. After 5 min move the slides to PBS at room temperature for 3 min 
15. Slides are now ready for mounting 
 
 
7.  Counter staining and mounting of the slides 
 
The counter stain contains Dapi which stains the DNA blue and is extremely poisonous, 
gloves must always be warn when working with Dapi. 
 
1. The Dapi/Antifade is made up according to UnistelSOP and stored in 
eppendorphs in the dark at 4°C 
2. Remove the Dapi/Antifade solution and allow it to reach room temperature 
3. After moving slides from the PBS during the post-hybridzation washes, allow 
most of the PBS to run of the slide by blotting it on absorbent paper 
4. Drop 2 drops of Dapi/Antifade solution on the slide and cover with a 24mm X 
50mm cover slip 
5. Invert slide cover slip at the bottom onto an absorbent paper to remove excess 
Dapi/Antifade solution 
6. Ensure all air bubbles are removed 
7. Seal the sides of the cover slip onto the slide with clear cutex 
8. Place in front of a fan and allow cutex to dry 
9. Analyze 
 
8.  Analysis of the results 
 
There are different FISH probe manufacturers, this results in different color 
combinations.  There are also different types of probes such as break apart and dual 
fusion dual color probes.  Therefore it is not possible to write a standard operating 
procedure for the analysis of the FISH probes.  Always consult the probe description 
insert to ensure that the correct signal pattern is observed during analysis. 
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LSI DiGeorge/VCFS Region Probe 
(LSI TUPLE 1  Spectrum Orange/ARSA(22q13.3)) 
(SpectrumGreen Control Probe) 
32-191028-20 Assays 
 
The LSI DiGeorge/VCFS Region Probe may be used to identify deletions of band 
22q11.2 found in DiGeorge and velocardiofacial (VCFS) syndromes.  Deletions of 
22q11.2 are commonly referred to as the CATCH-22 region because of their association 
with syndromes of various phenotypes.  The Vysis LSI DiGeorge-BCFS Region Dual 
Color Probe is a two color probe mixture that contains the SpectrumOrange TUPLE 1 
(HIRA) probe (3 non-coding region of TUPLE 1, D22S553, D22S609 AND D22S942) 
and the SpectrumGreen LSI ARSA (Arylsulfatase A) gene control probe that maps very 
close to the telomeric end of 22q at 22q13.3.  The 110kb TUPLE 1 probe does not 
contain the more telomeric loci D22S941 and D22S943. It is not known if the TUPLE 1 
probe contains the gene DVL22. 
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CHAPTER 8 
 
RESULTS
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1. DEMOGRAPHIC CHARACTERISTICS 
 
Our sample comprised of 112 Xhosa participants with a diagnosis of 
schizophrenia.  All patients were recruited from the Greater Cape Town area in 
the Western Cape, South Africa. Twenty one subjects were female and ninety-
one male with the mean age at interview being 36.2 years (SD 11.85; range 17-
64). The majority were single at the time of interview (n=86; 76.8%) with only 
15.2% (n=17) married and the remainder being either divorced (n=2), separated 
(n=3) or widowed (n=4).  
 
Only one participant was employed and of the remaining one hundred and 
eleven, 75.9 % (n=85) were receiving a disability grant. Most of the participants 
(n=70; 62.5%) had not progressed beyond a primary school level of education. 
See chart 1 for full description. Hundred and one of the subjects were right-
handed. 
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CHART 1: NUMBER OF PARTICIPANTS REACHING EACH LEVEL OF 
EDUCATION 
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2. GENERAL ILLNESS FEATURES 
 
The mean age of onset for the illness was 23.38 years (SD 7.17; range 12-55). 
The number of hospitalisations ranged from 0-13 with 2.94 (SD 2.52) being the 
mean. As to number of episodes the mean was 3.19 (SD 2.24; range 0-10). 
Sixty-seven (59.8%) reported no family history of psychiatric illness. History 
regarding the duration of the prodromal period was available for only fifty-one of 
the subjects with the reported time varying from an acute onset of symptoms to 
up to three hundred weeks.  
 
Thirty (26.78%) of the participants reported one or more possible stressor as 
precipitating events prior to the onset of the illness. Of these the death or serious 
illness of a close family member (n=8), participation in an initiation ceremony 
(n=5) and general family hardship (financial and other) (n=6) were most often 
cited. Two subjects also related it to giving birth, two to their participation in 
events relating to the political struggle and two to academic demands. 
 
3. LIFETIME CLINICAL FEATURES 
 
3.1 RESIDUAL SYMPTOMS 
 
Only two of the participants denied experiencing any residual symptoms. For the 
remainder it was difficult to accurately determine the duration of such symptoms 
as sixty-six were unable to venture any clear guestimate as to the length of the 
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period. Three of the participants were acutely psychotic at the time of the 
interview. 
 
3.1.1 HALLUCINATIONS 
 
Hallucinations of an auditory nature were by far the most common with 110 
(98.2%) subjects admitting to experiencing such over the lifetime of their illness. 
Seventy-eight (69.6%) heard two or more voices and conversing voices (n=67; 
59.8%) and those of a commentary nature (n=63; 56.3%) were also reported to 
occur by the majority of participants. A significant number of participants 
experienced auditory hallucinations of a threatening nature (n=44; 39.3%) and 
noises (n=22; 19.6%) and command hallucinations (n=57; 50.9%) were also 
found to be quite frequent. A fair percentage of participants also reported 
disturbances in one or more of the other sensory modalities. See chart 2 for a full 
breakdown. 
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CHART 2: PERCENTAGE OF PARTICIPANTS WITH LIFETIME HISTORY OF 
A PARTICULAR PERCEPTUAL DISTURBANCE 
 
 258
3.1.2 DELUSIONS 
 
Persecutory delusions were by far the most common, with 90.2% (n=101) of 
participants reporting a lifetime history of these. Delusions of reference (n=64; 
57.1%), mind-reading (n=46; 41.1%) and those with a religious (n=41; 36.6%) or 
grandiose (n=47; 42%) content were also reported to occur frequently. 
Interestingly, delusions of a bizarre nature were only reported by 7 participants 
(6.3%). See chart 3 for a full breakdown. 
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CHART 3: PERCENTAGE OF PARTICIPANTS WITH LIFETIME HISTORY OF 
A PARTICULAR TYPE OF DELUSION 
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3.1.3 BEHAVIOUR 
 
A lifetime history of some form of inappropriate behaviour was reported for 90.2% 
(n=101) of the participants. Incidents of verbal or physical aggression were by far 
the most common (n=85; 75.9%). Sexually disinhibited behaviour was reported 
for 11.7% (n=13) of the sample. Catatonic symptoms (chart 4) were reported in 
only 9 (8.1%) of the participants.  
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CHART 4: PERCENTAGE OF PARTICIPANTS WITH LIFETIME HISTORY OF 
A PARTICULAR TYPE OF CATATONIC BEHAVIOUR 
 
Eleven participants admitted to having made one or more suicide attempts during 
the course of their illness. Methods varied from ingesting different substances 
(pills (n=2), paraffin, washing powder, bleach) to the more violent (cutting own 
throat (n=2), hanging (n=2), throwing himself in front of a train). One participant 
was reported by family to have made a number of attempts by unknown method. 
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3.1.4 THOUGHT DISORDER 
 
A lifetime history of thought disorder could be documented for seventy-six 
(67.9%) of the participants. Incoherence was the specific form of thought disorder 
most commonly documented. (n=41; 36.6%). See chart 5 for a full breakdown. 
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CHART 5: PERCENTAGE OF PARTICIPANTS WITH LIFETIME HISTORY OF 
A PARTICULAR TYPE OF THOUGHT DISORDER 
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3.2 COMORBID FEATURES 
 
3.2.1 DEVELOPMENTAL AND MEDICAL HISTORY 
 
Eighty (72%) participants reported no significant co-morbid medical illness. For 
the remainder a history of pulmonary tuberculosis (n=13; 11.7%) was by far the 
most common. Others included, head injury (n=2), orthopaedic trauma (n=2), 
hypertension (n=2), known to be HIV-positive (n=2), meningitis (n=1), epilepsy 
(n=1) and a visual impairment (n=1). None of the illnesses had a temporal 
relationship to the onset of schizophrenia. 
 
One case of prolonged labour was reported whilst generally poor school 
performance was reported in two cases. It was also noted that one participant 
only started speaking at the age of five. 
 
3.2.2 SUBSTANCE USE 
 
Seventy-seven (68.8%) of the participants admitted to smoking regular tobacco 
frequently. Twenty participants (17.9%) met lifetime criteria for alcohol abuse and 
a further two (1.8%) that for dependency. With regard to cannabis, forty-six 
(41.1%) met lifetime criteria for abuse and nine (8%) for dependence. Only one 
(0.9%) met criteria for both alcohol and cannabis dependence with 13 meeting 
criteria for both alcohol and cannabis abuse (11.6%). Twenty-two (19.8%) 
participants tested positive for cannabis on a urinary drug screen performed on 
the day of the interview. Previous mandrax abuse (in conjunction with cannabis 
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abuse) was reported for two participants and mandrax and cocaine abuse (in 
conjunction with alcohol abuse) for one. No tests for other drugs of abuse were 
found to be positive on the drug screen. 
 
3.2.3 COMORBID MOOD AND ANXIETY DISORDERS 
 
Twelve participants (10.7%) could be diagnosed with a suspected co-morbid 
mood disorder at some time during their illness. Of these, major depressive 
disorder was the most prevalent, occurring in eight of the participants with 
adjustment disorder with depressed mood (n=2) and mania (n=2) representing 
the other diagnoses. 
 
Nine participants (8%) were suspected to have a co-morbid anxiety disorder at 
some stage. Probable post traumatic stress disorder and panic disorder occurred 
in three participants each, with a further two admitting to criteria for obsessive 
compulsive disorder and another exhibiting an array of mixed anxiety symptoms. 
 
3.2.4 ABNORMAL INVOLUNTARY MOVEMENTS 
 
The Abnormal Involuntary Movement Scale (AIMS) was completed for ninety-six 
(86.4%) of the participants. The mean score was only 0.71 (SD 2.48; range 0-
17). Clear tardive dyskinesia could be documented for seven (6.25%) of the 
participants. 
 
 263
4. TREATMENT 
 
At the time of interview, information for only three (2.67%) of the participants was 
not available with regard to at least the name of the primary antipsychotic drug 
they were being treated with. All participants professed to be treatment-
compliant. Besides the three, no information was available for a further three as 
to the name of a second drug they were on and for a further two as to the name 
of a third drug. A second drug could be documented for 76 (67.85%) and a third 
for 31 (27.9%) of the participants. Thirty-six participants were receiving two 
different antipsychotics and three were on a combination of three different 
antipsychotics. See chart 6 for a full breakdown. 
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CHART 6: NUMBER OF PARTICIPANTS REPORTING CURRENT USE OF 
EACH TYPE OF MEDICATION 
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With the exception of clozapine (n=12; 10.9%) none of the subjects in this 
sample were on an atypical antipsychotic. Interestingly, three of the patients were 
still on thioridazine which had already been withdrawn from the market at the 
time of the interviews. Other than antipsychotics the only medications reported by 
participants were anticholinergics (n=47; 42.3%), mood stabilisers (n=10; 8.92%), 
antidepressants (n=3), thiamine (n=3) and reserpine, phenytoin, lorasepam (n=1 
each). 
 
5. HEAD AND FACIAL MEASUREMENTS 
 
In accordance with the previously described procedure (see methodology) a total 
of nine head and facial measurements were taken for 69 (61.6%) of the 
participants. Please see table 1 for full results (divided into male and female 
groups) as well as the diagram below for orientation to the landmarks used. 
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TABLE 1: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN 
(REPORTED IN MILLIMETRE) 
 MALES (n=53) FEMALES (n=16) 
ITEM MEASURED M
EA
N
 
ST
D
 D
EV
 
M
EA
N
 
ST
D
 D
EV
 
Head circumference 578.19 19.00 578.66 19.46 
Trichion(tr) to Glabella (g) 57.55 10.49 56.09 6.90 
Glabella to Nasion (n) 20.50 9.20 21.84 9.99 
Glabella to Subnasale (sn) 58.03 5.64 55.62 5.08 
Glabella to Stomion (st) 83.93 5.75 78.24 8.65 
Glabella to Gnathion (gn) 129.48 10.47 119.47 9.25 
Tragion (t) to Trichion 139.26 8.10 135.77 8.18 
Tragion to Subnasale 132.55 7.44 126.17 4.61 
Tragion to Gnathion 145.63 9.13 139.34 5.01 
 
6. CLINICAL FEATURES ON INTERVIEW 
 
As part of the interview, Schedules for the Assessment of Positive and Negative 
Symptoms (SANS; SAPS) were also performed on each participant. Whereas the 
rest of the interview provided information on lifetime symptomatology and history, 
the SANS and the SAPS were used to elicit a snapshot view of the participants 
as they presented on interview. 
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6.1 SANS 
 
The calculated SANS-total mean score was 8.93 (SD 3.71; range 2-20). 
Participants achieved scores in all of the subscales (affective flattening; alogia; 
avolition/apathy; anhedonia/asociality; attention) but to differing degrees. 
 
On interview, global affective flattening could be observed for 100 (89.2%) of the 
participants. However, it was regarded to be only mild in 63 of the cases, with 22 
rated as moderate, 13 as marked and 2 as severe. Please see table 2 for a full 
results breakdown. 
 
TABLE 2: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL AFFECTIVE 
FLATTENING SUBSCALE ITEMS OF THE SANS 
AFFECTIVE FLATTENING ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Unchanging facial expression 55 27 13 1 
Decreased spontaneous movement 46 19 3 1 
Paucity of expressive gestures 50 20 4 1 
Poor eye contact 46 20 4 1 
Affective non-responsivity 43 17 4 2 
Inappropriate affect 4 6 3 1 
Lack of vocal inflections 43 19 6 1 
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Global alogia could be documented for 70 (62.5%) of the participants. Once 
again, mild cases made up the largest part of the group comprising 42 (60.0%) of 
the cases with only 12 (17.1%) reported to be either marked or severe. Please 
see table 3 for a full results breakdown. 
 
TABLE 3: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL ALOGIA 
SUBSCALE ITEMS OF THE SANS 
ALOGIA ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Poverty of speech 44 11 7 2 
Poverty of content of speech 21 34 9 7 
Blocking 1 0 1 0 
Increased latency of response 7 0 2 1 
 
Ninety-nine (88.4%) of the participants received a definite score on the global 
avolition/apathy subscale, with 44 rated mild, 38 moderate, 14 marked and 1 
severe. Please see table 4 for a full results breakdown. 
 
Ninety-five percent (n=107) of the participants were regarded to definitely qualify 
for a score on the global anhedonia/asociality subscale. Mild symptoms were 
documented in 50.5% (n=54) of these cases and marked or severe in only 12.1% 
(n=14). Please see table 5 for a full results breakdown. 
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TABLE 4: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL 
AVOLITON/APATHY SUBSCALE ITEMS OF THE SANS 
AVOLITION/APATHY ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Grooming and hygiene 45 21 2 1 
Inpersistance at work or school 34 39 14 4 
Physical anergia 31 34 15 1 
 
TABLE 5: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL ANHEDONIA/ 
ASOCIALITY SUBSCALE ITEMS OF THE SANS 
ANHEDONIA/ASOCIALITY ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Recreational interests and activities 53 36 11 1 
Sexual activity 7 6 3 0 
Ability to feel intimacy + closeness 42 41 12 1 
Relationship with friends + peers 49 41 12 1 
 
Only 14 (12.5%) participants were regarded to definitely exhibit a disturbance of 
attention making this the lowest, by far, of all five the global SANS subscales. For 
9, the disturbance was regarded to be mild, 2 moderate, 1 marked and 2 severe. 
Please see table 6 for a full results breakdown. 
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TABLE 6: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL ATTENTION 
SUBSCALE ITEMS OF THE SANS 
ATTENTION ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Social inattentiveness 10 2 1 2 
Inattentiveness during mental status 
testing 1 1 0 0 
 
6.2 SAPS 
 
The calculated SAPS-total mean score was 4.77 (range 0-15; SD 4.39). 
Participants achieved scores in all of the subscales (hallucinations; delusions; 
bizarre behaviour; positive formal thought disorder) but to differing degrees. 
 
One or more form of current perceptual disturbances were reported or could be 
observed for nearly half of all participants (n=55; 49.1%) on interview. Presence 
of and/or impairment due to these were regarded to be mild in 22.3% (n=25) of 
cases, moderate in 14.3% (n=16), marked in 9.8% (n=11) and severe in 1.8% 
(n=2).  Of these, auditory hallucinations were by far the most common (n=50; 
44.6%) with both voices providing running commentary (n=35; 31.25%) and two 
or more voices conversing (n=37; 33.0%) occurring in a significant percentage of 
participants. Please see table 7 for a full results breakdown. 
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TABLE 7: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL HALLUCINATION 
SUBSCALE ITEMS OF THE SAPS 
HALLUCINATION ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Auditory hallucinations 19 14 13 4 
Voices commenting 19 9 6 1 
Voices conversing 17 8 10 2 
Somatic/Tactile hallucinations 9 3 0 1 
Olfactory hallucinations 17 3 0 0 
Visual hallucinations 8 7 2 0 
 
Fifty-six (50.0%) participants were documented to report or observed to have the 
presence of one or more type of delusion on interview. The effect of these or 
presence thereof was regarded to be severe for 2 (1.8%) participants, marked for 
9 (8%), moderate for 24 (21.4%) and mild for 21 (17.9%). Although many 
different types of delusions could be documented persecutory delusions (n=42; 
37.5%) were the most frequent with delusions of reference (n=26; 23.2%), the 
only other type occurring in more than 15% of participants. Please see table 8 for 
a full results breakdown. 
 
Some form of inappropriate behaviour was reported or observed on interview for 
nearly a third (n=34; 30.3%) of participants. Of these aggressive or agitated 
behaviour (n=26; 23.2%) was most common with repetitive or stereotypical 
behaviour (n=5; 4.5%) least common. See table 9 for a full results breakdown. 
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The presence of some degree of formal thought disorder on interview could be 
documented for forty (35.7%) participants. Mostly this was regarded to be mild 
(n=23; 20.5%), but for 13 (11.6%) participants it could be recorded to be 
moderate and for 4 (3.6%) marked. Tangentiality (n=37; 33.0%) and derailment 
(n=33; 29.5%) were most often observed and clanging in only 1 participant. 
Please see table 10 for a full results breakdown. 
 
TABLE 8: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL DELUSION 
SUBSCALE ITEMS OF THE SAPS 
DELUSION ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Persecutory delusions 15 17 8 2 
Delusions of jealousy 1 1 0 0 
Delusions of guilt or sin 3 2 0 0 
Grandiose delusions 7 9 4 0 
Religious delusions 8 5 2 0 
Somatic delusions 4 4 0 0 
Delusions of reference 5 17 3 1 
Delusions of being controlled 5 6 3 1 
Delusions of mind reading 9 6 2 0 
Thought broadcasting 5 3 1 0 
Thought insertion 4 6 0 0 
Thought withdrawal 2 5 0 0 
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TABLE 9: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL BIZARRE 
BEHAVIOUR SUBSCALE ITEMS OF THE SAPS 
BIZARRE BEHAVIOUR ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Clothing and appearance 11 3 2 1 
Social/Sexual 9 3 6 0 
Aggressive/Agitated 9 11 5 1 
Repetitive/Stereotyped 2 1 0 2 
 
TABLE 10: NUMBER OF PARTICIPANTS EXHIBITING PRESENCE OF MILD 
TO SEVERE SYMPTOMS FOR EACH OF THE INDIVIDUAL THOUGHT 
DISORDER SUBSCALE ITEMS OF THE SAPS 
THOUGHT DISORDER ITEMS M
IL
D
 
M
O
D
ER
A
TE
 
M
A
R
K
ED
 
SE
VE
R
E 
Derailment 21 9 3 0 
Tangentiality 25 9 3 0 
Incoherence 11 3 2 1 
Illogically 10 4 1 0 
Circumstantiality 14 7 4 1 
Pressure of speech 3 2 1 0 
Distractible speech 4 1 0 0 
Clanging 1 0 0 0 
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7. FISH ANALYSIS 
 
Of the 112 participants 110 had FISH analysis performed on their blood samples. 
For the remaining two, the blood samples yielded insufficient metaphases for 
analysis and we were unable to locate either participant (due to both having 
moved) in order to collect a second sample. No chromosome 22 microdeletions 
could be detected.  
 
8. KARYOTYPING SUBGROUP 
 
Fifty participant samples were karyotyped. When compared in terms of 
demographic and clinical variables, no statistically significant differences could 
be demonstrated between the karyotyping subgroup (KSG) and the sample as a 
whole for any of the demographic, clinical or morphological measurement 
variables reported on. 
 
8.1 KSG DEMOGRAPHICS AND CLINICAL FEATURES 
 
The majority were male (n=42; 84%) and single (n=37; 73%). All were 
unemployed with thirty-one (62%) participants receiving a disability grant. In 
terms of education level only four (8%) had progressed beyond primary school. 
The mean age of onset for the illness was 23.04 years (SD 8.12; range 12-55). 
The number of hospitalisations ranged from 0 to 10 with 2.88 (SD 2.14) being the 
mean. As to number of episodes, the mean was 3.17 (SD 2.09; range 1-10). 
Eighteen (36%) reported a family history of psychiatric illness. Twelve (24%) of 
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the participants reported one or more possible stressor as precipitating events 
prior to the onset of the illness. Of these, death or serious illness of a close family 
member (n=6) was most often reported. 
 
Reported lifetime history of psychotic symptoms did not differ significantly 
between the KSG and the full sample. As with the total group, auditory 
hallucinations (n=49; 98%) were by far the most common type of perceptual 
disturbance reported. See table 11 for a full breakdown. 
 
TABLE 11: NUMBER OF PARTICIPANTS IN KSG REPORTING A LIFETIME 
HISTORY FOR ANY TYPE OF HALLUCINATION 
TYPE OF HALLUCINATION n % 
All auditory hallucinations 49 98 
Visual hallucinations 31 62 
Olfactory hallucinations 9 18 
Tactile hallucinations 11 22 
Gustatory hallucinations 6 12 
 
Persecutory delusions (n=44; 88%) were most commonly experienced; see chart  
7 for full breakdown.  Where inappropriate behaviour was reported incidents of 
physical or verbal aggression (n=40; 80%) were the most common with sexual 
disinhibition (n=5; 10%) and catatonic symptoms (n=4; 8%) also reported. 
 
Incoherence (n=17; 34%) was the type of thought disorder most often reported. 
See chart 8 for full breakdown. 
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CHART 7: PERCENTAGE OF KSG MEMBERS WITH LIFETIME HISTORY OF 
A PARTICULAR TYPE OF DELUSION 
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CHART 8: PERCENTAGE OF KSG MEMBERS WITH LIFETIME HISTORY OF 
A PARTICULAR TYPE OF THOUGHT DISORDER 
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Twenty (40%) of the KSG members reported a history of a significant medical 
illness. Of these a history of pulmonary tuberculosis (n=10; 20%) was by far the 
most common. Thirteen (26%) met criteria for lifetime alcohol abuse and one 
(2%) for dependency. Thirty-seven (73%) smoked regular tobacco and twenty-
one (44%) met lifetime criteria for cannabis abuse and four (8%) for dependency. 
Eight (16%) participants tested positive for cannabis on an urinary drug screen 
performed on the day of the interview.  
 
Thirteen (26%) of the group were suspected to have had a co-morbid mood or 
anxiety disorder at some time during their illness. Six (12%) participants admitted 
to having made one or more suicide attempts during the course of their illness. 
Three attempts were of a more violent nature (cutting own throat (n=2) and 
hanging (n=1)). The AIMS could be completed for forty-five (90%) of the group. 
Clear tardive dyskinesia could be documented for five (10%) of the participants.  
 
At the time of interview, information as to at least the name of the primary 
antipsychotic drug they were being treated with was available for all KSG 
members with the exception of one. Twelve (24%) participants were receiving 
two different antipsychotics and one was on a combination of three different 
antipsychotics. Twenty-three (46%) of the participants were receiving a depot 
antipsychotic and only 5 (10%) were on an atypical (clozapine). Other than 
antipsychotics the only medication reported by participants were anticholinergics 
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(n=20; 40%), mood stabilisers (n=4; 8%), antidepressants (n=2), thiamine (n=2) 
and phenytoin, lorasepam (n=1 each).   
 
8.2 KSG HEAD AND FACIAL MEASUREMENTS 
 
Head and facial measurements as previously described were done on all 50 KSG 
members. Please see diagram and table 12 for full breakdown. 
  
TABLE 12: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
KSG MEMBERS (REPORTED IN MILLIMETRE) 
 MALES (n=42) FEMALES (n=8) 
ITEM MEASURED MEAN STD DEV MEAN STD DEV 
Head circumference 580.45 20.01 588.88 20.53 
Trichion(tr) to Glabella (g) 56.84 10.36 57.01 5.78 
Glabella to Nasion (n) 21.25 9.74 27.31 8.74 
Glabella to Subnasale (sn) 57.68 5.39 54.51 4.70 
Glabella to Stomion (st) 84.22 5.06 75.83 9.77 
Glabella to Gnathion (gn) 128.88 10.50 115.96 10.52 
Tragion (t) to Trichion 139.26 7.99 135.26 9.92 
Tragion to Subnasale 132.85 7.66 126.63 6.04 
Tragion to Gnathion 146.25 9.64 137.89 5.54 
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8.3 KARYOTYPING RESULTS 
 
Of the fifty participants who were karyotyped, chromosomal aberrations were 
identified in five (10%). All of these participants were male. FISH analysis had 
revealed no chromosome 22 microdeletions and the aberrations were reported 
as follows: 
 
Participant FN – Male chromosome complement with double satellites was 
observed on chromosome 22. [46,XY,22pss] 
 
 
 
Participant TN – Male chromosome complement with an inversion of the 
heterochromatic area of chromosome 9. [46,XY,inv(9)] 
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Participant PGM – Male chromosome complement with an inversion of the 
heterochromatic area of chromosome 9. [46,XY,inv(9)] 
 
Participant TM – Male chromosome complement consisting of 46,XY (18 
metaphases); 47,XXY (2 metaphases); 47,XX,+acentric fragment (1 metaphase). 
The combination could point to a low-grade mosaic. The acentric fragment could 
be from the long arms of the X-chromosome. 
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Participant SK – Male chromosome complement with a variant of the 
heterochromatic portion of chromosome 1. [46, XY,1qh+] 
 
A descriptive analysis of each of these five participants follows:  
 
8.3.1 PARTICIPANT FN 
 
FN was a single (never married) male participant. At the time of the interview he 
was 35 years old and was an outpatient, with his last discharge from a 
psychiatric hospital having been approximately eight months earlier. He had a 
Grade 10 education and was unemployed, receiving a disability grant due to his 
schizophrenic illness. He had never been employed and was still living in the 
family home. Information was obtained from the patient, his father and the 
available clinic files. 
 
There was no specific history of pregnancy complications and he was a NVD at 
full-term, the third child out of a total of four. Please see pedigree. 
 
His first episode of illness occurred at the age of 19 but the duration of the 
prodromal period was unknown. No clear stressor could be associated with his 
first psychotic episode. He was treated as an outpatient at the time. He had had 
a total of four acute psychotic breakdowns including the above-mentioned and for 
the other three he needed psychiatric hospitalisation. No family history of any 
psychiatric illness was reported. 
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EPILEPSY
 
Prior to the onset of psychotic illness he had been fully treated for pulmonary 
tuberculosis and some years after the onset he was also diagnosed with 
epilepsy. At the time of the interview no convulsions had been observed for a 
period of at least two years. His sister was also known to suffer from epilepsy but 
there was no family history for any other significant medical illness. 
 
He admitted to alcohol use and smoking regular tobacco. No history (lifetime or 
current) was obtained for any substance use, abuse or dependence and his 
urinary drug screen was negative. There was no history of any co-morbid mood 
or anxiety disorder or any suicide attempts. His AIMS score was zero. 
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At the time of the interview he was being treated with a monthly antipsychotic 
depot (zuclopenthixol) and sodiumvalproate (for his epilepsy). Exact duration was 
unknown but he had been on the combination for some time. 
 
A lifetime history of auditory hallucinations (including running commentary and 
voices conversing) was reported. The participant also had a lifetime history of 
tactile hallucinations which he described as a cramping sensation that went from 
his arms to throat whereafter he then experienced a sensation of feeling 
strangled. A lifetime history of persecutory delusions as well as delusions of 
reference, guilt and jealousy could be documented. Numerous incidents of 
physical and verbal aggression during periods of acute illness were reported with 
agitation and unpredictability in between. No history of bizarre behaviour, 
catatonic symptoms or symptoms of thought disorder was reported.  
 
At the time of the interview no hallucinations, delusions or symptoms of formal 
thought disorder were reported or observed with the patient scoring zero in each 
of these sections of the SAPS. Please see table 13 for a summary of the items in 
each section of the SANS and SAPS for which the patient achieved a score. 
(Scoring key 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe) 
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TABLE 13: SUMMARY OF SANS AND SAPS ITEMS ON WHICH 
PARTICIPANT FN ACHIEVED ANY SCORE 
ITEM SCORE ITEM SCORE
AFFECTIVE FLATTENING – 
GLOBAL SCORE 4 
AVOLITION / APATHY – 
GLOBAL SCORE 3 
Unchanging facial expression 4 Grooming and hygiene 3 
Decreased spontaneous 
movement 3 Inpersistance at work or school 3 
Paucity of expressive gestures 4 Physical anergia 3 
Poor eye contact 3 ANHEDONIA / ASOCIALITY – GLOBAL SCORE 3 
Affective non-responsivity 4 Recreational interests and activities 3 
Lack of vocal inflections 4 Ability to feel intimacy and closeness 3 
ALOGIA – GLOBAL SCORE 3 Relationship with friends and peers 3 
Poverty of speech 3 BIZARRE BEHAVIOUR – GLOBAL SCORE 2 
Poverty of content of speech 3 Clothing and appearance 2 
  Aggressive and agitated behaviour 3 
 
 
TABLE 14: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
PARTICPANT FN (REPORTED IN MILLIMETRE) 
ITEM MEASURED  ITEM MEASURED  
Head circumference 570 Glabella to Gnathion  136.2 
Trichion to Glabella  68.3 Tragion to Trichion 143.1 
Glabella to Nasion  20.2 Tragion to Subnasale 133.8 
Glabella to Subnasale 67.1 Tragion to Gnathion 142.8 
Glabella to Stomion 90.6   
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8.3.2 PARTICIPANT TWO – TN 
 
TN was a single (never married) male participant. At the time of the interview he 
was 24 years old and was an inpatient, having been in hospital for approximately 
three weeks. He had a Grade 9 education and was unemployed, receiving a 
disability grant due to his schizophrenia. He had never been employed and had 
been living in a shack with four relatives in the ten months preceding his 
admission. Information was obtained from the patient, his mother and the 
available clinic files. 
 
There was no specific history of pregnancy complications and he was a NVD at 
unknown gestation, the second child out of a total of five. Please see pedigree. 
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His first episode of illness occurred at the age of 15 but the duration of the 
prodromal period was unknown. No clear stressor could be associated with his 
first psychotic episode. He reported a sexual assault in the same period but 
maintained that it had only happened after he had become ill. He was treated as 
an inpatient at the time. The patient’s mother reported that he had had numerous 
psychotic breakdowns since becoming ill, needing repeated hospitalisation but 
the exact number of episodes was unknown. No family history of any psychiatric 
illness was reported. 
 
With the exception of receiving treatment after the sexual assault, the patient had 
no medical history and there was also no family history of significant medical 
illness. 
 
He admitted to smoking regular tobacco and using alcohol but did not meet 
current or lifetime criteria for either alcohol abuse or dependence. He also 
admitted to using cannabis very regularly between 1998 and 2001 (when he 
stopped to please his mother) and met criteria for lifetime abuse (not 
dependence). His urinary drug screen was negative. There was no history of any 
co-morbid mood or anxiety disorder or any suicide attempts. His AIMS score was 
zero.  
 
At the time of the interview he was being treated with a monthly antipsychotic 
depot (zuclopenthixol) and haloperidol. He was non-compliant at the time of his 
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admission and had therefore been on this combination for approximately three 
weeks. He was known to have been previously treated with “an injection” as well 
but the name, dose and duration was unknown. 
 
A lifetime history of visual and auditory hallucinations (running commentary) as 
well as delusions (persecutory, somatic, reference) was reported. No bizarre 
behaviour but numerous incidents of physical and verbal aggression during 
periods of acute illness was reported. No history of catatonic symptoms was 
reported but a lifetime history of thought disorder (tangentiality) could be 
documented.  
 
At the time of the interview no hallucinations, delusions or symptoms of formal 
thought disorder were reported or observed with the patient scoring zero in each 
of these sections of the SAPS. Please see table 15 for a summary of the items in 
each section of the SANS and SAPS for which the patient achieved a score. 
(Scoring key 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe) 
 
TABLE 15: SUMMARY OF SANS AND SAPS ITEMS ON WHICH 
PARTICIPANT TN ACHIEVED ANY SCORE 
ITEM SCORE ITEM SCORE
AFFECTIVE FLATTENING – 
GLOBAL SCORE 3 
ATTENTION – GLOBAL 
SCORE 2 
Unchanging facial expression 2 Social inattentiveness 2 
Decreased spontaneous 
movement 2 
HALLUCINATIONS – GLOBAL 
SCORE 3 
Paucity of expressive gestures 2 Auditory hallucinations 3 
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Poor eye contact 3 Voices commenting 3 
Affective non-responsivity 3 Voices conversing 3 
Inappropriate affect 3 Visual hallucinations 3 
Lack of vocal inflections 3 DELUSIONS – GLOBAL SCORE 3 
ALOGIA – GLOBAL SCORE 2 Delusions of reference 3 
Poverty of speech 1 BIZARRE BEHAVIOUR – GLOBAL SCORE 3 
Poverty of content of speech 2 Clothing and appearance 2 
AVOLITION / APATHY – 
GLOBAL SCORE 3 Social and sexual behaviour 2 
Grooming and hygiene 3 Aggressive and agitated behaviour 3 
Inpersistance at work or school 3 FORMAL THOUGHT DISORDER – GLOBAL SCORE 2 
Physical anergia 3 Derailment 2 
ANHEDONIA / ASOCIALITY – 
GLOBAL SCORE 3 Tangentiality 2 
Recreational interests and 
activities 3 
  
Sexual Activity 3   
Ability to feel intimacy and 
closeness 3 
  
Relationship with friends and 
peers 3 
  
 
TABLE 16: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
PARTICPANT TN (REPORTED IN MILLIMETRE) 
ITEM MEASURED  ITEM MEASURED  
Head circumference 585 Glabella to Gnathion  137.6 
Trichion to Glabella  50.6 Tragion to Trichion 137.5 
Glabella to Nasion  15.5 Tragion to Subnasale 133.1 
Glabella to Subnasale  61.9 Tragion to Gnathion 150.3 
Glabella to Stomion 87.5   
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8.3.3 PARTICIPANT THREE – PGM 
 
PGM was a single (never married) male participant. At the time of the interview 
he was 36 years old and was an inpatient, having been admitted to hospital six 
months earlier. He had a Grade 7 education and was unemployed, receiving a 
disability grant due to his schizophrenic illness. He had previously been 
employed in a low-level watchman position but it had been more than a year 
since his last employment. Information was obtained from the patient, ward staff 
and the available ward files. 
 
There was no specific history of pregnancy complications and he was a NVD 
(gestation unknown), the third child out of a total of six. Please see pedigree. 
DIED AS 
INFANT
SHOT
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His first episode of illness occurred at the age of 29 but the duration of the 
prodromal period was unknown. No clear stressor could be associated with his 
first psychotic episode and he was hospitalised at the time. Including that 
episode he had had a total of five acute psychotic breakdowns needing 
psychiatric hospitalization for all. A family history of schizophrenia was reported 
for one of his cousins on his mother’s side. The patient had no personal or family 
history of significant medical illness. 
 
He admitted to smoking regular tobacco and met criteria for a lifetime (not 
current) history of alcohol abuse (not dependence). He also admitted to using 
cannabis up until two years prior to the time of the interview and met criteria for 
lifetime abuse (not dependence) and his urinary drug screen was negative.  
 
Previous symptoms suggesting mania were found documented in the patient’s 
file (euphoria, disinhibition, overfamiliarity, restlessness, lability). On the interview 
there were no symptoms suggesting a current mood episode. His AIMS score 
was zero.  
 
At the time of the interview he was being treated with clozapine and 
sodiumvalproate and he was regarded as treatment-resistant according to his 
clinical notes. The treatment had been started during his current period of 
hospitalisation and he had been on the combination for some weeks already. 
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A lifetime history of auditory hallucinations (two or more voices, voices 
conversing, noises and those of a command, commentary and threatening 
nature) as well as visual hallucinations was reported. With regards to thought 
content a lifetime history of thought withdrawal and delusions of a persecutory, 
religious, grandiose, nihilistic, reference and control nature was reported. There 
was no history of catatonic symptoms but a lifetime history of thought disorder 
(tangetiality, circumstantiality, derailment, illogicality) and inappropriate behaviour 
(verbal aggression; non-bizarre) could be documented.  
 
At the time of the interview the patient still exhibited numerous positive and 
negative symptoms. Please see table 17 for a summary of the items in each 
section of the SANS and SAPS for which the patient achieved a score. (Scoring 
key 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe) 
 
TABLE 17: SUMMARY OF SANS AND SAPS ITEMS ON WHICH 
PARTICIPANT PGM ACHIEVED ANY SCORE 
ITEM SCORE ITEM SCORE
AFFECTIVE FLATTENING – 
GLOBAL SCORE 2 
DELUSIONS – GLOBAL 
SCORE 4 
Unchanging facial expression 2 Persecutory delusions 4 
Decreased spontaneous 
movement 1 Grandiose delusions 3 
Paucity of expressive gestures 2 Religious delusions 4 
Poor eye contact 2 Delusions of control 4 
Affective non-responsivity 1 Delusions of reference 4 
Inappropriate affect 3 Thought withdrawal 3 
Lack of vocal inflections 1 BIZARRE BEHAVIOUR – GLOBAL SCORE 3 
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ALOGIA – GLOBAL SCORE 1 Social and sexual behaviour 4 
Poverty of content of speech 2 Aggressive and agitated behaviour 2 
Increased latency of response 1 Repetitive or stereotyped behaviour 1 
AVOLITION / APATHY – 
GLOBAL SCORE 4 
FORMAL THOUGHT DISORDER 
– GLOBAL SCORE 3 
Grooming and hygiene 3 Derailment 2 
Inpersistance at work or school 5 Tangentiality 3 
Physical anergia 1 Illogicality 1 
ANHEDONIA / ASOCIALITY – 
GLOBAL SCORE 2 Circumstantiality 4 
Recreational interests and 
activities 3 Pressure of speech 3 
Ability to feel intimacy and 
closeness 2 Distractible speech 1 
Relationship with friends and 
peers 2   
HALLUCINATIONS – GLOBAL 
SCORE 4   
Auditory hallucinations 4   
Voices commenting 4   
Voices conversing 4   
Visual hallucinations 1   
 
 
TABLE 18: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
PARTICPANT PGM (REPORTED IN MILLIMETRE) 
ITEM MEASURED  ITEM MEASURED  
Head circumference 570 Glabella to Gnathion  121.0 
Trichion to Glabella  60.0 Tragion to Trichion 132.0 
Glabella to Nasion  33.0 Tragion to Subnasale 140.0 
Glabella to Subnasale 62.0 Tragion to Gnathion 142.0 
Glabella to Stomion 94.0   
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8.3.4 PARTICIPANT FOUR – TM 
 
TM was a single (never married) male participant. At the time of the interview he 
was 39 years old and was an outpatient with his last discharge from a psychiatric 
hospital having been many years ago. He had a Grade 7 education and was 
unemployed, receiving a disability grant due to his schizophrenia. He had 
previously been employed as a miner but it had been many years since he had 
last worked. He had been living in a squatter camp with six relatives for the 
previous 18 years. Information was obtained from the patient, his mother and the 
available clinic files. 
 
There was no specific history of pregnancy complications and he was a NVD at 
fullterm, the eldest of two siblings and he also had two older half-siblings, sharing 
the same mother. Please see pedigree. 
EPILEPSY; CAUSE OF 
DEATH UNKNOWN
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His first episode of illness occurred at the age of 19 but the duration of the 
prodromal period was unknown. No clear stressor could be associated with his 
first psychotic episode and he not was hospitalised at the time. Including that 
episode he had had a total of at least three acute breakdowns but was only 
hospitalised for one. The patient’s halfbrother was reported to also suffer from a 
mental illness (diagnosis unknown). The patient had no personal history of 
significant medical illness but his father who passed away when the patient was 
five, was known to have had epilepsy. 
 
He admitted to smoking regular tobacco and using alcohol but did not meet 
current or lifetime criteria for either alcohol abuse or dependence. He also 
admitted to using cannabis since his teens and met criteria for both lifetime 
abuse and dependence and his urinary drug screen was positive. There was no 
history of any co-morbid mood or anxiety disorder or any suicide attempts. His 
AIMS score was zero.  
 
At the time of the interview he was being treated with a monthly antipsychotic 
depot (flupentixol) and had been on it for an extended period.  
 
A lifetime history of auditory hallucinations (including running commentary, 
threatening voices and voices conversing) was reported. A lifetime history of 
persecutory delusions as well as delusions of reference, religion and jealousy 
could be documented. Numerous incidents of physical and verbal aggression 
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during periods of acute illness were reported as well as episodes of bizarre 
behaviour specifically centered around attempts to steal washing from 
clotheslines. No catatonic symptoms were reported but the participant was 
known to display thought disorder (derailment and tangentiality) during acute 
episodes. 
 
At the time of the interview, the participant displayed some mild negative 
symptoms but with the exception of a mildly bizarre appearance as well as the 
possibility of some thought disorder, the participant scored zero in each of the 
sections of the SAPS. Please see table 19 for a summary of the items in each 
section of the SANS and SAPS for which the patient achieved a score. (Scoring 
key 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe) 
 
TABLE 19: SUMMARY OF SANS AND SAPS ITEMS ON WHICH 
PARTICIPANT TM ACHIEVED ANY SCORE 
ITEM SCORE ITEM SCORE
AFFECTIVE FLATTENING – 
GLOBAL SCORE 2 
AVOLITION / APATHY – 
GLOBAL SCORE 4 
Unchanging facial expression 2 Grooming and hygiene 4 
Decreased spontaneous 
movement 2 
ANHEDONIA / ASOCIALITY – 
GLOBAL SCORE 2 
Paucity of expressive gestures 2 Recreational interests and activities 2 
Poor eye contact 2 Ability to feel intimacy and closeness 2 
Affective non-responsivity 2 Relationship with friends and peers 2 
Lack of vocal inflections 2 BIZARRE BEHAVIOUR – GLOBAL SCORE 2 
ALOGIA – GLOBAL SCORE 2 Clothing and appearance 2 
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Poverty of speech 2 FORMAL THOUGHT DISORDER – GLOBAL SCORE 1 
Poverty of content of speech 2 Derailment 1 
Increased latency of response 1 Tangentiality 1 
 
 
TABLE 20: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
PARTICPANT TM (REPORTED IN MILLIMETRE) 
ITEM MEASURED  ITEM MEASURED  
Head circumference 610 Glabella to Gnathion  116.5 
Trichion to Glabella  62.0 Tragion to Trichion 132.0 
Glabella to Nasion  44.1 Tragion to Subnasale 146.5 
Glabella to Subnasale 57.6 Tragion to Gnathion 151.7 
Glabella to Stomion 84.0   
 
 
8.3.5 PARTICIPANT FIVE – SK 
 
SK was a single (never married) male participant. At the time of the interview he 
was 22 years old and was an outpatient, having never been hospitalised for 
psychiatric illness. He had a Grade 11 education and was unemployed and was 
not receiving a disability grant. He had never been employed and had been living 
on his own in a shack for four years. Information was obtained from the patient 
and the available clinic files.  
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There was no specific history of pregnancy complications and he was a NVD at 
fullterm, the third child out of a total of five; also having one older halfsibling 
sharing a mother. Please see pedigree. 
STABBED SHOT
 
His first episode of illness occurred at the age of 21 but the duration of the 
prodromal period was unknown. Death of a family member was associated with 
his first psychotic episode. Initially his family took him to a traditional healer who 
diagnosed amafufunyana and he received treatment. When he did not respond 
after two months he was taken to the clinic where an antipsychotic was started. 
The patient had not yet had a second acute episode at the time of the interview 
and according to the clinic notes, his psychotic symptoms had resolved 
completely approximately four months after treatment was started. According the 
patient he had a cousin who was also “mad”. 
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The patient reported a previous history of “asthma” and ten years prior to the 
onset of psychiatric illness he was fully treated for pulmonary tuberculosis. He 
was not receiving any current treatment for medical illness and there was no 
family history of significant medical illness. 
 
He admitted to smoking regular tobacco and using alcohol but did not meet 
current or lifetime criteria for either alcohol abuse or dependence. The patient 
admitted to using cannabis (but was vague as to the duration). He met criteria for 
lifetime abuse (not dependence) and his urinary drug screen was positive. As an 
adolescent the patient reportedly suffered two episodes of depression both 
related to the death of close family members. He received no treatment for these 
and had no history of any suicide attempts. No mood symptoms were associated 
with his psychotic breakdown and he has experienced none since. His AIMS 
score was two with some minimal tardive diskinesia of upper limbs observed.  
 
At the time of the interview he was being treated with haloperidol and 
orphenadrine. He had been on this combination for approximately 12 months and 
regularly attended clinic visits. 
 
A lifetime history of visual and auditory hallucinations (two voices, conversing, 
threatening in nature) as well as delusions (persecutory, grandiose, religious, 
bizarre) was reported. No bizarre behaviour but verbal aggression during his 
period of acute illness was reported. No history of catatonic symptoms was 
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reported but a lifetime history of thought disorder (incoherence) could be 
documented.  
 
At the time of the interview no hallucinations, delusions or symptoms of formal 
thought disorder were reported or observed with the patient scoring zero in all 
sections of the SAPS. Please see table 21 for a summary of the items in each 
section of the SANS and SAPS for which the patient achieved a score. (Scoring 
key 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe) 
 
TABLE 21: SUMMARY OF SANS AND SAPS ITEMS ON WHICH 
PARTICIPANT SK ACHIEVED A SCORE 
ITEM SCORE ITEM SCORE
AFFECTIVE FLATTENING – 
GLOBAL SCORE 1 
AVOLITION / APATHY – 
GLOBAL SCORE 2 
Unchanging facial expression 1 Grooming and hygiene 2 
Decreased spontaneous 
movement 1 Inpersistance at work or school 2 
Poor eye contact 1 ANHEDONIA / ASOCIALITY – GLOBAL SCORE 2 
Affective non-responsivity 1 Recreational interests and activities 2 
AVOLITION / APATHY – 
GLOBAL SCORE 2 Sexual Activity 2 
Grooming and Hygiene 2 Ability to feel intimacy and closeness 2 
Inpersistance at work or school 2 Relationship with friends and peers 2 
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TABLE 22: SUMMARY OF HEAD AND FACIAL MEASUREMENTS TAKEN ON 
PARTICPANT SK (REPORTED IN MILLIMETRE) 
ITEM MEASURED  ITEM MEASURED  
Head circumference 545 Glabella to Gnathion  121.8 
Trichion to Glabella  42.2 Tragion to Trichion 138.3 
Glabella to Nasion  12.4 Tragion to Subnasale 124.7 
Glabella to Subnasale 60.2 Tragion to Gnathion 139.7 
Glabella to Stomion 81.6   
 
 
8.4 COMPARISON 
 
No significant differences could be demonstrated for any of the demographic or 
clinical variables for the group of five when compared to the rest of the KSG 
group. See table 23-25 for comparison of selected variables. 
 
TABLE 23: COMPARISON OF SELECTED DEMOGRAPHIC VARIABLES 
BETWEEN KSG GROUP AND THE FIVE PARTICPANTS REPORTED WITH 
CHROMOSOMAL ABERRATIONS (5CA) 
  FN TN PGM TM SK KSG 
Chromosomal 
aberration 
46,XY,22pss 46,XY,inv(9) 46,XY,inv(9) 
46,XY/47,XXY/ 
47,XX+acentric 
fragment 
46,XY,1qh+   
Age illness 
onset 19   15  29 19   21 23.04 
No of 
hospitalisations  3 Numerous   5  1 0  2.88 
No of episodes  4 Numerous   5  3  1 3.17 
Family history  No No   No  Yes Yes  36% 
Stressor or 
precipitating 
event 
 No  No  No  No Yes 24% 
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TABLE 24: COMPARISON OF SELECTED CINICAL VARIABLES BETWEEN 
KSG GROUP AND THE 5CA GROUP 
  FN TN PGM TM SK KSG 
Chromosomal 
aberration 
46,XY,22pss 46,XY,inv(9) 46,XY,inv(9) 
46,XY/47,XXY/ 
47,XX+acentric 
fragment 
46,XY,1qh+   
Auditory 
hallucinations  Yes Yes   Yes Yes  Yes  98% 
Visual 
hallucinations No  Yes   Yes No  No  62% 
Olfactory 
hallucinations No  No  No  No  No  18% 
Tactile 
hallucinations  Yes No  No  No  No  22% 
Persecutory 
delusions  Yes Yes   Yes Yes   Yes 88% 
Sin/Guilt 
delusions  Yes No  No  No  No  14%  
Control 
delusions No  No   Yes No  No   26% 
Thought 
broadcasting No  No  No  No  No   26% 
Nihilistic 
delusions No  No   Yes No  No   8% 
Mind reading No  No  No  No  No   30% 
Thought 
insertion No  No  No  No  No   18% 
Erotomanic 
delusions No  No  No  No  No   4% 
Jealousy 
delusions  Yes No  No   Yes No   10% 
Religious 
delusions No  No   Yes Yes   Yes  42% 
Grandiose 
delusions No  No   Yes No   Yes  42% 
Somatic 
delusions No   Yes No  No  No   30% 
Thought 
withdrawal No  No  Yes  No  No   14% 
Delusions of 
reference  Yes  Yes Yes  Yes  No   56% 
Bizarre 
delusions No  No  No  Yes   Yes  10% 
Physical/Verbal 
aggression 
 Yes  Yes Yes   Yes  Yes  80% 
Sexual 
disinhibition No  No  Yes  No  No  10%  
Catatonic 
symptoms No  No  No  No  No  8%  
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TABLE 25: COMPARISON OF SELECTED CO-MORBIDITY VARIABLES 
BETWEEN KSG GROUP AND THE 5CA GROUP 
  FN TN PGM TM SK KSG 
Chromosomal 
aberration 
46,XY,22pss 46,XY,inv(9) 46,XY,inv(9) 
46,XY/47,XXY/ 
47,XX+acentric 
fragment 
46,XY,1qh+   
Medical illness Yes   No No  No  Yes  40%  
Alcohol abuse No  No   Yes No  No  26% 
Alcohol 
dependence 
No  No  No  No  No  2% 
Regular tobacco  Yes Yes   Yes Yes  Yes  73%  
Cannabis abuse  No  Yes  Yes  Yes Yes   44% 
Cannabis 
dependence 
No  No  No   Yes No   8% 
Co-morbid 
mood/anxiety 
disorder 
No  No   Yes No   Yes  26% 
Any suicide 
attempts 
No  No  No  No  No  12%  
 
However, when the morphological measurement variables were compared 
between groups, a significant difference was observed for the measurement 
between the glabella and the subnasale. (p=0.036) Comparison only done for 
male participants as all of the participants with chromosomal aberrations were 
male. See table 26. 
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TABLE 26: COMPARISON BETWEEN HEAD AND FACIAL MEASUREMENTS 
TAKEN ON MALES OF KSG GROUP AND THE 5CA GROUP  
(REPORTED IN MILLIMETRE) 
MEASUREMENT OTHER MALES KSG GROUP (n=37) 
CHROMOSOMAL 
ABERRATIONS (n=5) p-VALUE 
Head circumference 581.05 576.00 0.670 
Trichion to Glabella  56.86 56.62 0.962 
Glabella to Nasion  21.01 23.06 0.684 
Glabella to Subnasale  57.13 61.76 0.036* 
Glabella to Stomion 83.77 87.54 0.171 
Glabella to Gnathion  129.19 126.62 0.602 
Tragion to Trichion 139.62 136.60 0.263 
Tragion to Subnasale 132.48 135.62 0.452 
Tragion to Gnathion 146.38 145.30 0.719 
* significance at p<0.05 
 
9. SUMMARY 
 
In our study, FISH analysis of 110 participants yielded no chromosome 22 
microdeletions. Of the fifty participants who were karyotyped, chromosomal 
aberrations were identified in five (10%). These were: two cases of inversion of 
chromosome 9 [46,XY,inv(9)]; and one each of double satellites on chromosome 
22 [46,XY,22pss]; a variant of the heterochromatic portion of chromosome 1 [46, 
XY,1qh+] and a low-grade mosaic [46,XY / 47,XXY / 47,XX, +acentric fragment].  
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No significant differences could be demonstrated for any of the demographic, 
clinical or morphological measurement variables for the karyotyping subgroup 
(n=50) in comparison to the total study group (n=112). Furthermore, no 
significant differences could be demonstrated for any of the demographic or 
clinical variables for the karyotyping subgroup in comparison to the five 
participants reported with chromosomal aberrations. However, one morphological 
measurement variable (glabella to subnasale) showed a significant difference 
(p=0.036) between these two groups. 
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1. INTRODUCTION 
 
More than one hundred years ago, Emil Kraepelin, who first described dementia 
praecox (the disease concept ultimately known as schizophrenia), and thereafter 
Eugene Bleuler, who introduced the term schizophrenia, both already agreed that 
the entity they were dealing with was a familial illness. However, as families not 
only share genes but often also common environments, it was only since the 
early seventies that conclusive data from adoption, twin and family studies 
started showing a consistent pattern of results favouring an important genetic 
contribution in the development of schizophrenia.  
 
Unfortunately, in spite of compelling evidence in support of a significant role for 
genetic factors in the development of the disorder, to date, in spite of intensive 
investigation, the nature of the genetic transmission remains unknown. A simple 
single-gene explanation is regarded as highly implausible and there is no doubt 
that the demonstration of modes of transmission by a few genes of moderate 
effect (oligogenic) or many genes of small effect (polygenic) will be much more 
difficult. Nonetheless, the molecular basis of other common complex disorders 
(such as non-insulin dependent diabetes) have been demonstrated by using 
molecular genetic approaches and this remains one of the most promising 
techniques in the investigation of the biological basis of schizophrenia.  
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Current literature shows that by far the majority of molecular genetic work done in 
schizophrenia has involved Caucasian populations. Taking into account the 
evidence suggesting ethno-specific loci as well as apparent ethno-specific 
pharmacological responses to atypical antipsychotic treatment in African-
American and African samples it seems clear that indigenous African populations 
also need to be investigated.1-4 The Xhosa people are a linguistically distinct 
population grouping that diverged within the last 2 000 years. Therefore taking 
into account the seemingly uniform core symptom profile reported in both 
Caucasian and African groups (including the Xhosas), as well as the marked 
paucity of clinical and susceptibility data for Xhosa-speaking schizophrenia 
patients, this group would seem to present an invaluable opportunity for 
molecular genetic research.4-10 
 
2. CHROMOSOMAL ABERRATIONS 
 
Chromosomal abnormalities in those with mental illness are a valuable resource 
in as much as they can help us redefine phenotypes, identify candidate genes 
and refine areas of linkage.11 Literature reports on chromosomal analysis in 
schizophrenia started consistently appearing in the early 1960s. Initially these 
were mostly case reports or cytogenetic studies focussing primarily on the sex 
chromosomes, paying relatively little attention to potential autosomal 
abnormalities.12-15 
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The first large study reporting on full chromosomal analyses was that of Judd and 
Brandkamp published in 1967.16 Their study group consisted of a group of 40 
schizophrenia patients and they could only demonstrate an aberration (sex 
chromosome mosaic) in one patient. They concluded that cytogenetic methods 
available at that point in time were not sufficient to allow for the detection of 
possible genetic factors in the aetiology of schizophrenia. 
 
Fortunately, since then techniques have improved dramatically and more recent 
studies in Caucasian and Asian populations have revealed significant 
percentages of schizophrenia subjects with chromosomal abnormalities. These 
have ranged between 2% (2/100) and 32% (43/134) with others in between – for 
example 6.2% (9/134) and 13% (21/161).17-20 In our study, of the fifty participants 
who were karyotyped, chromosomal aberrations were identified in five (10%). 
These were: two cases of inversion of chromosome 9 [46,XY,inv(9)]; and one 
each of double satellites on chromosome 22 [46,XY,22pss]; a variant of the 
heterochromatic portion of chromosome 1 [46, XY,1qh+] and a possible low-
grade mosaic [46,XY / 47,XXY / 47,XX, + acentric fragment]. 
 
2.1 CHROMOSOME 9 
 
Chromosome 9 displays the highest degree of structural variability of all human 
chromosomes.21 In fact, the most common inversion seen in human 
chromosomes is the pericentric inversion of chromosome 9 [inv(9)] and as such it 
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is the most common reciprocal translocation found in humans.22 Please see 
diagram for an ideogram of normal chromosome 9 and high-resolution CTG-
banded photographs of a normal chromosome 9 and an inverted chromosome 9. 
 
Inv(9) is transmitted to offspring in a dominant fashion and the prevalence varies 
with ethnicity. Hsu et al. examined the frequency in four major ethnic groups 
reporting an incidence of 0.73% (17/2334) in Caucasians, 2.42% (42/1737) in 
Hispanics, 0.26% (1/384) in Asians and 3.57% (64/1795) in African-Americans.23 
Another study, by Serra et al., examining 7613 newborns estimated the 
prevalence of inv(9) to be 0.85% in European newborns.24 Later studies showing 
incidences of 1.2% (16/1350) in Taiwanese foetuses and 1.65% (25/1513) in 
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Japanese newborns, indicated that the incidence in Asian populations could 
probably be estimated at approximately 1.5%.25;26 
 
In addition to inv(9) occurring commonly, no specific phenotype has been 
demonstrated to be associated with this particular chromosomal rearrangement. 
This has lead to inv(9) generally being regarded to be a normal variant rather 
than an abnormal karyotype and, in fact, in our sample it was reported as such 
by Unistel.27 However, Kiss and Osztovics found this aberration to be present in 
1.9% of a group of dysmorphic children (younger than one year) and postulated 
that it was in fact not a normal variant, but rather that it might play an important 
role in the aetiology of unspecified dysmorphic syndromes.28 
 
There is also some evidence linking inv(9) to subfertility and recurrent abortions 
and a number of cases have been documented where patients with inv(9) 
exhibited psychiatric symptoms.29;30 These include Kumar et al. reporting on a 
patient with a personality disorder (diagnosed with a hysterical, immature and 
psychopathic personality) and Miyaoka et al. reporting on a case of a patient 
diagnosed with psychosis not otherwise specified.31;32 Furthermore, an unusually 
increased prevalence (9.7%) of inv(9) in a sample of male patients with “paranoid 
psychosis” was already reported more than 20 years ago.33   
 
Our study shows an incidence of 4% (2/50) for inv(9). This is a similar 
percentage to that reported in a number of other schizophrenia studies such as 
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Nanko et al. 3.4% (4/116); Kunugi et al. 4.5% (6/134) and Demirhan et al. 5.2% 
(7/134).17;18;34 In contrast, both Gorwood et al. (0/25) and DeLisi et al. (0/46) 
reported no incidences of inv(9) in their samples.35;36 Interestingly, an 
international two-stage genome scan for linkage with schizophrenia performed by 
Moises et al. obtained a positive result (p=0.009) for a marker (D9S175) on the 
pericentric region of chromosome 9.37 Also, Levinson et al. conducted a genome 
scan and found a suggested linkage (p<0.05) between schizophrenia and a 
marker (D9S257) located 20cM from the centromere of chromosome 9.38 
 
Therefore, though current evidence seems to indicate that inv(9) is unlikely to 
have a major effect on the development of schizophrenia, it may be an risk-
increasing factor. Inv(9) has been characterised using fluorescence in situ 
hybridisation (FISH) analyses, indicating that there are several different forms of 
inv(9) which have differential breakpoints.39 Localisation of these breakpoints on 
chromosome 9 may ultimately lead to the cloning of schizophrenia-susceptibility 
genes.  
 
2.2 X CHROMOSOME ANEUPLOIDES  
 
The occurrence of sex chromosome aneuploides are well documented and a 
great variety of mosaics have been described in humans.40 Incidences at birth of 
the various sex chromosome abnormalities have been reported at between 0.1 
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and 1.3%. Well-known examples of these include both Klinefelter and Turner 
syndromes. 
 
Several lines of evidence seem to suggest that the sex chromosomes have a role 
in the expression of schizophrenia with an apparent excess of sex chromosome 
aneuploidies (XXY, XXX, and possibly XYY) having been reported in 
schizophrenia populations.41 This hypothesis seems to find further support in the 
gender differences in response to treatment, age at onset of illness and 
prognosis reported in schizophrenia.42 Also, some data seem to support an 
increased concordance for sex in sibling pairs with schizophrenia although 
results reported so far have been inconclusive.43 
 
It has long been observed that the risk for schizophrenia does not follow the 
simple dominant or recessive form of Mendelian inheritance.44 As such, risk 
among relatives of probands is shown to be greatly reduced in second- and third-
degree relatives in comparison to siblings. Furthermore, in contrast to the 
accepted Mendelian pattern of transmission, there is an unequal distribution of 
risk between categories of first degree relatives (e.g. greater risk to children than 
siblings) and the persistence of a high prevalence in the face of a substantial 
fecundity disadvantage.45 Thus, though schizophrenia has been considered a 
“complex genetic disorder” with heterogeneity and environmental or epigenetic 
factors contributing to its origin, no robust genetic locus or clear environmental 
factor has yet been identified.  
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 After taking all the evidence into account, a pseudoautosomal location at the 
telomeric extremity of the short arms of the X and Y chromosomes was first 
proposed for a schizophrenia susceptibility locus by Crow in 1988.46 However, 
consensus was soon reached that linkage within the short arm pseudoautosomal 
region could be excluded.41 On the other hand, a number of regions of homology 
between the X an Y chromosomes outside the pseudoautosomal regions have 
been described and these were next considered as a possible susceptibility 
locus.47 A number of studies followed but even at best the evidence remains 
weak.48 
 
Our study showed one X-chromosome low-grade mosaic [46,XY/47,XXY/ 
47,XX,+acentric fragment] translating into a 2% prevalence. Other schizophrenia 
samples have shown percentages of 1.7% (2/113), 2% (5/250) and 8.6% 
(14/161).18;20;41 Numbers drop when persons with mosaics of the sex 
chromosomes are excluded; these authors argue that this is appropriate as we 
are dealing with a very heterogeneous group with varying degrees of mosaicism 
and therefore the abnormal cell line could be present to varying degrees in 
different tissues, including the brain. Unfortunately, large-scale studies have 
failed to show any evidence of consistent linkage between sex chromosome 
aneuploidies or particular regions on the X chromosome and risk for 
schizophrenia.49;50 
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However, there is also the possibility of finding a susceptibility gene that is more 
strongly linked to an intermediate phenotype predisposing to schizophrenia 
susceptibility. With regard to the X chromosome, one such phenotype is reduced 
cerebral asymmetry, for which a multipoint QTL analysis for degree of 
handedness produced a LOD of approximately 3.0 within the Xq21.3 region.51 
Also, evidence from studies of the parental origin of Turner syndrome (XO), 
shows that a gene on the X chromosome relates to social ability and is subject to 
differential imprinting.52 Such a gene, accounting for the cerebral anomalies 
present in the sex chromosome aneuploidies, could also relate to psychosis. 
Thus, while no variant in DNA sequence on the X chromosome is currently linked 
to schizophrenia, the possibility cannot be excluded that an important mechanism 
on the X chromosome related to its susceptibility could still be found. 
 
2.3 OTHER AUTOSOMAL ABNORMALITIES 
 
As stated in a previous chapter, in spite of numerous reports of possible 
associations for chromosomal aberrations with schizophrenia, to date, bar the 
exception of two, none can be regarded to have provided convincing evidence for 
the location of a susceptibility gene.53 The two being (a) the chromosome 22q11 
microdeletions and (b) the balanced chromosomal translocation 
(1;11)(q42;q14.3) disrupting two genes on chromosome 1 (Disruption in 
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schizophrenia 1 (DISC 1) and 2 (DISC2)). Please review the chapters on 
aberrations and chromosome 22 for a summary of evidence currently available. 
 
2.3.1 CHROMOSOME 22 
 
In our sample karyotyping revealed one chromosome 22 complement with 
double satellites [46,XY,22pss] that was reported as a normal variant. FISH 
analysis revealed no chromosome 22q11 deletions for any of the participants in 
our study.  At first glance, this seems to stand in contrast to previous findings 
suggesting 22q11 deletion syndrome to be the highest known genetic risk factor 
for schizophrenia. However, available data lends support to a notion that differing 
prevalence rates are seen in differing population groups. In strong contrast to 
reported Caucasian sample prevalence rates of ±2%, Arinami et al. could only 
demonstrate a 0.3% prevalence in their large Japanese case sample (300 
unrelated patients and controls each).19;54;55 Furthermore, in the only other 
sample to date reporting on a black African population, Riley et al. failed to find 
evidence to support the linkage of chromosome 22 markers to schizophrenia in 
their sample (22 families (Xhosa, Zulu, Sotho and Tswana)).4 This data were 
further supported by the findings of Takahashi et al. who demonstrated 
significant linkage for chromosome 22 markers with schizophrenia in their family-
based association study for both European-American (34 pedigrees) and 
Chinese (52 pedigrees) samples but not for an African-American sample (29 
pedigrees).56 
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 Interestingly, one of the reported Caucasian samples consists of an Afrikaner 
(population group that cohabitates with the Xhosa population in South Africa) 
schizophrenia group. This sample showed a prevalence of 2.4% (2/85) for 
chromosome 22q11 deletions.55 The same research group has reported on de 
novo copy number mutations (CN) in an Afrikaner cohort consisting of 152 
sporadic schizophrenia or schizo-affective disorder patients and 159 controls.57 
Their results showed that confirmed de novo (CN) mutations could significantly 
be associated with schizophrenia (p=0.00078) and were collectively ≈8 times 
more frequent in sporadic (but not familial) cases with schizophrenia than in 
unaffected controls (15/152 vs 2/159). Of particular note was that 3 of the 15 
were de novo 22q11.2 microdeletions (1.8% rate) with sizes consistent to the two 
predominant sizes (3 Mb or 1.5 Mb) reported in the literature. They concluded 
that these results once again confirmed the importance of microdeletions in the 
22q11.2 locus as the only known recurrent CN mutation associated with 
schizophrenia.19  
 
Furthermore, the prevalence of obsessive-compulsive symptomatology (OCD) in 
an Afrikaner schizophrenia sample (which included the above 85) was reported 
to be 13.25% (53/400), which also seems distinctly different to that of the 1.7% 
OCD prevalence seen in our study sample.58  Other independent samples of 
Xhosa schizophrenia subjects also reported very low prevalences of OCD (0.5%; 
3/509) and hoarding behaviour (3.9%; 4/102) respectively.59;60 This is of special 
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interest as OCD has been associated with 22q11-13 deletions.61 Taken together, 
our findings therefore support available data that seem to suggest that current 
evidence does not support the linkage of markers on chromosome 22 to 
susceptibility to schizophrenia in black African populations. 
 
2.3.2 CHROMOSOME 1 
 
A recent large meta-analysis of schizophrenia linkage by Lewis et al. showed 
support for chromosome 1q as an area of interest.62 By far the most attention has 
focused on the balanced translocation (1;11)(q42.1;q14.3) first identified in a 
large Scottish family and referred to as “Disruption in Schizophrenia 1” (DISC1).63 
In fact, it generated enough interest to be included as part of Science magazine’s 
nominations for the “Scientific Breakthroughs of the Year, 2005”.64 To date, it has 
been implicated through genetic analysis in not only schizophrenia but also 
schizo-affective and bipolar disorders as well as major depression.65 
Furthermore, causal relationships between DISC1 and measurable trait variables 
as well as DISC1-binding with a number of proteins known to be involved in 
essential processes of neuronal function have been demonstrated.65;66 
 
One participant in our study was reported to demonstrate a normal variant of the 
heterochromatic portion of chromosome 1 [46, XY,1qh+]. Since this variant was 
only identified in one patient and literature does not show a previously reported 
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association, it would be difficult to establish current relevance for it in 
schizophrenia.  
 
2.4 SIGNIFICANCE OF FINDINGS 
 
The chromosomal aberrations detected in our sample were all reported as 
normal variants by UNISTEL. Normal variants are wide-spread in human 
populations and have no apparent effect on phenotype. These variants are 
mostly found in some specific chromosomal regions including the highly variable 
regions on chromosomes 1, 9 and 16, the distal two thirds of the long arm of the 
Y chromosome and the short arms and satellites of the acrocentric 
chromosomes.23  
 
One could therefore ask what the relevance of our findings are? Firstly, it would 
be important to reiterate that although the findings are reported as normal 
variants, they may in fact not be normal, but rather have, as yet undetected, 
significance. In order to truly exclude a possible link to psychiatric illness, groups 
of individuals with such variants need to undergo proper psychiatric evaluation in 
a structured manner.  
 
There can be no doubt that the search for schizophrenia susceptibility genes has 
been, and remains, a difficult task. It has been less than a decade since linkage 
and association studies have started to produce replicated data for linkage 
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regions and genes. Detection techniques are rapidly becoming more 
sophisticated and, very importantly, more non-Caucasian samples are being 
recruited.  As such, the fact that a particular chromosomal aberration has not yet 
been linked to schizophrenia cannot be interpreted to conclusively mean that the 
aberration is a normal variant with no likelihood for association.  
 
Therefore, although chromosomal aberrations in schizophrenia may be due to 
chance, the alternatives have to be considered. Aberrations may be involved with 
causing schizophrenia by disrupting an important locus, they may represent 
linkage to a susceptibility locus or they may provide a permissive genetic 
environment for mutations elsewhere in the genome to become expressed as 
psychotic illness.67  In a genetically complex illness such as schizophrenia, it is 
much more difficult to either confirm or disprove these possibilities, than in a 
single gene disorder (e.g. Huntington’s Chorea).  
 
Furthermore, even if none of our detected aberrations can be shown to 
individually have a major effect on the development of schizophrenia, they may 
still be risk-increasing factors. An example of a mechanism that could 
encompass several chromosomal associations, is the disruption of transcription 
factors that interact with genes important in brain development. Retinoic acid 
signaling could be involved in such a process, because it seems to play an 
important role in forebrain, limb, face development as well as the development 
and functioning of the dopamine system.68;69  
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 Previous samples of chromosomal aberrations in schizophrenia populations 
reported on in the literature have included all aberrations found in their 
results.17;18;20  To our mind, it would therefore be premature to dismiss any of our 
findings as non-significant and therefore we have included all five of the patients 
in our karyotyping subgroup. 
 
3.  MORPHOLOGY 
 
3.1 COMPARITIVE DISCUSSION 
 
Our dataset reporting on selected craniofacial measurements represents the first 
in an African schizophrenia population. As described in the methods section, nine 
sets of measurements (from those suggested by Lane et al. and previously 
chosen in schizophrenia subjects) were used: (1) Head circumference (2) 
Trichion (tr) to Glabella (g); (3) g to Nasion (n); (4) g to Subnasale (sn); (5) g to 
Stomion (st); (6) g to gnathion (gn); (7) Tragion (t) to tr; (8) t to sn; and (9) t to 
gn.70;71 Please see diagram for location of the landmarks used. 
 
The anthropometric study of facial morphology in groups differing in ethnicity and 
race has revealed that significant inter-group differences exist.72 Most of the 
normative data of facial measures currently available, comprise of studies done 
on Caucasian, and more specifically North American, groups. However, some 
African-American data on normal controls are available.73-75 Please see table 1 
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for data comparison between some of the larger studies and our dataset. As 
there was no significant difference between the karyotyping subgroup (KSG) and 
the whole group, we will use the KSG dataset for comparison purposes. 
 
TABLE 1: COMPARITIVE MEASUREMENTS BETWEEN OUR SAMPLE AND 
THOSE REPORTED FOR THREE AFRICAN-AMERICAN CONTROL 
SAMPLES (REPORTED IN MILLIMETRE(mm)) 
OWN DATASET FARKAS73 PORTER75 PORTER74  
MALE 
n = 42 
FEMALE 
n = 8
MALE 
n = 50
FEMALE 
n = 50
MALE 
n = 109 
FEMALE 
n = 108
HEAD CIRC 580.45 578.88 573.6 547.0 -- -- 
G – TR 56.84 57.01 61.8 55.7 60.2 55.7 
G – N  21.25 27.31 11.8 11.4 11.1 13.2 
G – SN 57.68 54.51 68.6 64.6 62.4 62.0 
G – ST  84.22 75.83 89.8. 84.1 -- -- 
G – GN  128.88 115.96 137.7 127.9 136.5 129 
T – SN 132.85 126.63 132.6 125.4 -- -- 
T – GN  146.25 137.89 149.5 138.1 -- -- 
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From the comparison it is clear that although both male and female participants 
have similar face width (tragion to subnasale; tragion to gnathion) as reported in 
the African-American datasets they clearly have decreased anterior facial height 
(AFH) measurements, i.e. glabella to gnathion. Although females comparatively 
show a slightly increased glabella to trichion measurement (upper portion of face) 
their overall AFH is still decreased and for males all three parts of the face show 
decreased measurements. Comparatively, both males and females demonstrate 
an increased measurement from the glabella to the nasion but the overall 
distance between glabella and subnasale (middle portion of the face) is still 
significantly shorter.  
 
At first glance, the glabella to nasion measurement could give cause for concern 
as to a possible technique error, as our value is nearly double that reported in the 
comparative datasets. However, another African-American dataset reports 
measurements closer to our own for both males (15.7) (n=33) and females (19.2) 
(n=32) and as in our dataset the female measurements are, in fact, the longer of 
the two.76 (Please see table 2.) 
 
As before, our sample still shows decreased AFH whilst the width measurement 
is similar. Such inter-ethnic differences in craniofacial measurement between 
African-American samples have previously been reported, with the various racial 
admixtures given as a possible explanation.77 These differences have also been 
demonstrated in Caucasian samples comprised of differing European ethnicity.72 
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TABLE 2: COMPARITIVE MEASUREMENTS (mm) BETWEEN OUR SAMPLE 
AND AN AFRICAN-AMERICAN (A-A) CONTROL SAMPLE76  
 G – TR G – N G – SN G – GN T – SU 
XH MALE 56.84 21.25 57.68 128.88 132.85 
A-A MALE 64.6 15.7 73.6 137 133.6 
XH FEMALE 57.01 27.31 54.51 115.96 126.63 
A-A FEMALE 59.5 19.2 63.3 127.2 123.3 
 
It would be interesting to speculate why there is such a clear difference between 
our sample and the known African-American samples. One possibility that must 
be considered is technique error. It has been suggested that inexperienced 
anthropometrists often prefer to use rulers rather than calipers.78 However, rulers 
often cannot be placed directly on the facial landmarks, whereas callipers can. 
Caliper-derived data is believed to be more accurate and allows easier 
comparison to the existing sets of normative data.78 Our sets of measurements 
were specifically chosen for ease of landmark identification and ultimately the 
data obtained follows the same general pattern as that reported in previous 
samples. Therefore, whilst technique error as a possibility cannot be completely 
excluded, we probably need to look elsewhere for an answer. 
 
Another possibility to consider is that African-American population groupings in 
fact represent an admixture of Caucasian, Native American and African 
groups.79;80 Their craniofacial morphology may therefore not resemble that of 
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native African people (e.g. the Xhosa) who have remained fairly unmixed and 
might exhibit unique features.   
 
Although no studies are available for normal controls in the Xhosa population 
reporting on facial measurements using the same methods we employed, there 
are some data in African populations that was acquired using cephalometric 
techniques. Specifically, a recent study evaluated cephalograms of 101 adult 
ethnic Shona subjects and compared their findings with existing norms in African-
American and North American Caucasian populations.81 The Shona are the 
native people of Zimbabwe and as a group contributed, via migration, to the 
ultimate formation of some of the latterday South African ethnic groupings, 
including the Xhosa. Both the Shona and the Xhosa are descended from the 
Eastern Bantu language migration grouping.82 Using markers that can be roughly 
correlated to the nasion, gnathion and subnasale, Dandajena et al. demonstrated 
that both total AFH and lower AFH were significantly shorter for Shona males 
and females in comparison to African-American norms. Thus, their results 
supported the trend exhibited in our own. 81 
 
It would also be important to remember that the comparative samples reported 
on here are those of normal controls. Numerous studies have shown differences 
do exist between schizophrenia and control samples with regard to the presence 
of minor physical anomalies.83 Although fewer studies are available that report 
specifically on quantitative facial measurements in schizophrenia subjects, some 
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have been conducted, with majority of the available data being for Caucasian 
patients. Importantly, existing data has specifically reported decreased glabella to 
subnasale measurement in schizophrenia subjects in comparison to normal 
controls.71 The general premise of shorter lower facial heights was also 
supported by a small sample (n=20) consisting of Mestizo (admixture of Spanish, 
Indian and Black genetic heritage) males.84 
 
Furthermore, in the only predominantly African-American schizophrenia sample 
reported on to date (using similar facial measurements and differentiating 
between genders), although the difference is much less pronounced, the same 
trend for a comparatively decreased AFH is demonstrated.76 Also, gender-
specific significant differences could be demonstrated in the Compton et al. 
sample between schizophrenia subjects and controls.76 (See table 3)  
 
TABLE 3: COMPARITIVE MEASUREMENTS (mm) BETWEEN OUR SAMPLE 
AND AN AFRICAN-AMERICAN (A-A) SCHIZOPHRENIA SAMPLE76   
 G – TR G – N G – SN G – GN T – SU 
XH MALE 56.84 21.25 57.68 128.88 132.85 
A-A MALE 61.6 18.6 71.2 136.1 134.5 
XH FEMALE 57.01 27.31 54.51 115.96 126.63 
A-A FEMALE 59.0 20.0 68.4 128.2 127.5 
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As discussed in previous chapters, the neurodevelopmental model of 
schizophrenia is increasingly being supported by new evidence. Amongst other 
data we find support for this model, which proposes that early brain insults 
eventually cause dysfunction and predisposition to schizophrenia, in the fact that 
some patients with schizophrenia exhibit subtle developmental abnormalities that 
presumably occur during embryogenesis.85 These gross somatic abnormalities 
(including minor physical anomalies such as facial dysmorphology) that tend to 
accompany the disease, have been proposed as one possible marker that could 
be used as an endophenotype in our search for schizophrenia susceptibility 
genes. 
 
Interestingly, when comparing the facial measurements of the five patients with 
documented chromosomal aberrations with the other males (n=37) who were 
karyotyped, a statistically significant difference could be observed for one 
measurement. Please see table 4 for comparison of all measurements. 
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The significant difference was observed for the measurement between the 
glabella and the subnasale. However, there was no significant difference for the 
measurement between the glabella and the nasion. Therefore it can be deduced 
that the significant difference actually occurs in the measurement stretching 
between the nasion and the subnasale, and that the five participants with 
chromosomal abnormalities had significantly longer noses in comparison to the 
rest of the group. 
 
TABLE 4: COMPARITIVE MEASUREMENTS (mm) BETWEEN ALL MALES 
OF KSG GROUP AND THOSE REPORTED WITH A CHROMOSOMAL 
ABERRATION   
MEASUREMENT 
OTHER MALES 
KSG GROUP (n=37) 
CHROMOSOMAL 
ABERRATIONS (n=5) 
p-VALUE 
Head circumference 581.05 576.00 0.670 
Trichion to Glabella  56.86 56.62 0.962 
Glabella to Nasion  21.01 23.06 0.684 
Glabella to Subnasale  57.13 61.76 0.036* 
Glabella to Stomion 83.77 87.54 0.171 
Glabella to Gnathion  129.19 126.62 0.602 
Tragion to Trichion 139.62 136.60 0.263 
Tragion to Subnasale 132.48 135.62 0.452 
Tragion to Gnathion 146.38 145.30 0.719 
* significance at p<0.05 
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3.2 SIGNIFICANCE OF FINDINGS 
 
It has previously been suggested that if minor physical anomalies were to be 
used to search for an endophenotype, facial measurements may be of particular 
interest given that the face and some of the regions of the brain develop in 
concert from the same ectodermal tissue.70;86;87 In fact, craniofacial 
morphogenesis proceeds intimately with cerebral morphogenesis, in accordance 
with a unitary embryological origin.  This is clearly illustrated in classical 
neurodevelopmental disorders (e.g. Down Syndrome, foetal alcohol syndrome, 
velocardiofacial syndrome) which are characterised by dysmorphic features 
involving different regions of the body but the craniofacies in particular. 
Furthermore, individuals with facial dysmorphogenesis such as cleft lip/palate 
have been reported to show abnormalities of brain structure in association with 
cognitive deficits.88;89 
 
There is a clear timeline to embryological events with the diverse but 
interdependent sequelae of craniofacial and cerebral morphogenesis evolving 
and attaining their basic structures at particular gestational intervals.90  In 
accordance with this, craniofacial dysmorphology has been shown to be 
associated in general terms with abnormalities found to evidence brain pathology 
in schizophrenia.91 For example, palatal morphology originates at 6-9 weeks and 
achieves its essential postnatal form by 16-17 weeks of gestation.92-94 The 
hippocampal formation is one of the first cortical areas to differentiate at 
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approximately 9-10 weeks, undergoing further tremendous differentiation, 
particularly up to weeks 15-19 of gestation, illustrating some temporal contiguity 
between the developmental trajectories of the aforementioned.95;96 Abnormalities 
of hippocampal structure have been demonstrated in schizophrenia whilst palatal 
anomalies are one of the most consistent minor physical anomalies reported in 
schizophrenia populations.87;97-100  
 
Therefore, when one tries to make sense of our finding of a significantly 
increased nasion to subnasale measurement it would be important to first have 
an understanding of foetal embryology. Development of the face and some facial 
proportioning occurs mainly between the sixth and the twelfth weeks of gestation 
with the frontonasal prominence forming the apex of the nose and the sides 
(alae) derived from the lateral nasal prominences.90 Morphogenesis of the 
frontonasal prominence, forebrain, and anterior midline cerebral regions are 
known to be intimately regulated via epithelial–mesenchymal signaling 
interactions.94;101-103  
 
Anterior facial dysmorphogenesis could thus be linked to several aspects of 
structural brain pathology as reported in adult schizophrenia, such as 
abnormalities of temporal lobe structures that over early foetal life emerge in the 
forebrain before rotating to their final location, together with thalamic and other 
anterior midline structures.94;95;104 Dysmorphogenesis along the anterior midline 
would be expected to disrupt neuroectodermal patterning and the critical 
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repulsive and attractive guidance cues which regulate neuronal connectivity.105 
This would be in line with models of neuronal network disconnectivity described 
in schizophrenia, particularly in a fronto–striato–pallido–thalamo–cortical-
temporal network.106;107 
 
One could argue that lengthening of the nose possibly represents a disruption in 
the development of the frontonasal prominence, a structure which enjoys the 
most intimate embryologic relationship with the development of the anterior 
brain.103;108 Importantly, the frontonasal prominence also contributes to 
development of the forehead, philtrum of upper lip, and primary palate, keeping 
in mind that the palate is a midline structure noted consistently to be dysmorphic 
in schizophrenia, as previously mentioned.87;98-100;103;108 Morphogenesis in other 
domains of facial development (such as the lateral nasal prominences forming 
the sides of the nose and the maxillary prominences contributing to the sides of 
the face and lips) also appear to be at least in part orchestrated by the 
frontonasal prominence.103;108 This suggests that understanding the genetic and 
epigenetic regulation of midline morphogenesis involving the frontonasal 
prominence may inform importantly on early developmental perturbation in 
schizophrenia. 
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4. CLINICAL  
 
4.1 GROUP DEMOGRAPHICS 
 
The total study group consisted of 112 participants, FISH analysis for 
chromosome 22 was conducted on samples from 110 participants and samples 
of 50 were karyotyped (KSG). The mean age at interview for the two groups 
(total 112 always reported first) was 36.2 and 35.82 years respectively and the 
majority of participants in each group were male (81.25%; 84%). Means for age 
of onset of illness (23.38; 23.04), number of hospitalisations (2.77; 2.65) and 
number of episodes (3; 2.86) were also calculated. Slightly more than a third of 
the sample reported a family history of psychiatric illness (40.2%; 36%). This 
would be in keeping with the fact that although schizophrenia has one of the 
highest heritabilities it does not equal 100% and in fact it is estimated that 85% of 
sufferers do not have a first-degree relative with schizophrenia.109 
 
 At the time of the interview only one participant was employed. This stands in 
stark contrast to the fact that more than a third of the sample (35.7%; 36%) 
reported having previously been gainfully employed. This downward shift in 
occupational status has previously been reported in the Xhosa schizophrenia 
population and our findings, once again, highlight the need for proactive 
engagement in work rehabilitation as part of the management of this illness.110  
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With no significant differences between the demographics of the two groups, the 
data supports the supposition that the KSG can be regarded as representative of 
the total sample. Furthermore, the composition of the group as a whole is similar 
to that of the largest Xhosa schizophrenia sample previously reported on 
clinically.111  
 
4.2 PRODROMAL PERIOD AND STRESSORS PRIOR TO ILLNESS 
ONSET 
 
For the majority of the sample information regarding the prodromal period was 
not available. Difficulties in retrospectively assessing the prodromal period have 
been highlighted by a number of authors.112;113 However, available research on 
the prodrome has shown some support that the treatment of such could delay 
onset of psychosis and that prodrome could possibly contribute to elucidating the 
pathophysiology of psychosis.114;115 Therefore, important consideration should be 
given to designing studies in the South African population that pay particular 
attention to overcoming barriers in illness mapping, such as selecting optimal 
sampling strategies and/or integrating procedures and data across prodromal 
and first episode research projects.112 
 
Approximately a quarter of participants related one or more stressors as possible 
precipitating events prior to onset of illness. Much literature has been devoted to 
the hypothesis that psychosis develops as a result of the interaction between 
genetic vulnerability and environmental stressors.116 Indeed, a previous study 
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focusing specifically on black South African women showed that stressful life 
events influenced the course of their mental health.117 
 
Of particular interest was the fact that five participants reported an association 
with their participation in an initiation ceremony. As previously stated, the 
traditional initiation ceremony (umkhwetha), represents a rite of passage for 
Xhosa boys entering manhood and has been reported as a stressor related to 
both initial onset and relapse precipitation in this population.118-121 Taking into 
account the cultural significance of this ceremony and the fact that those who do 
not participate are often regarded as being “less than men”, the importance of 
understanding and incorporating the cultural background of patients into the 
broader management of their illness is once again underlined.122 
 
4.3 POSITIVE SYMPTOMS 
 
A lifetime history of auditory hallucinations was by far the most common 
symptom reported. (97.3%; 98%) Perceptual disturbances in all other modalities 
were also reported although to a much lesser degree; visual (54.5%; 62%), 
olfactory (33%; 18%), tactile (32.1%; 22%), gustatory (24.1%; 12%). None of the 
differences between the two groups were significant. 
 
Although the prevalence of the different types of hallucinations tends to vary 
widely across different studies the rank order of frequency (auditory most 
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prominent, then visual and others less prevalent) remains the same.123 Our 
findings were therefore in keeping with previously reported studies in 
international,  South African and more specifically Xhosa samples.111;124-127 
 
Interestingly, all three of the usually less prevalent perceptual disturbances 
(tactile, olfactory and gustatory) were reported by a fair number of participants. 
Classically gustatory and olfactory hallucinations tend to be associated with 
organic illness. However in our sample, there was low rate of co-morbid 
neurological (and other medical illness) as well as developmental difficulties 
making any association unlikely. Some literature has also suggested that 
olfactory or gustatory hallucinations are in fact harbingers of severe delusions.128 
This opens up a myriad of possibilities because, if in fact we are able to link 
perceptual disturbances to a measurable characteristic this could ultimately lead 
to an endophenotype that could prove useful in the search for schizophrenia 
genes. 
 
With regard to lifetime delusions, the persecutory type was by far the most 
common. (89.3%; 88%) Other types of delusions commonly reported were: 
reference (57.1%; 56%), grandiose (41.1%; 42%), religious (36.6%; 42%) and 
mind-reading (42%; 30%). Once again the general pattern was in keeping with 
that of the broad spectrum of previously reported studies.111;124-127 
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A lifetime history of delusions has been used as a marker in both schizophrenia 
and bipolar disorder to search to possible genotype-phenotype associations. 
Working from the basis of the purported relationship between positive symptoms 
and hippocampal volume and the reported effects of DISC1 genotype on 
hippocampal volume, DeRosse et al. detected significant associations between a 
DISC1 haplotype containing Ser704Cys and lifetime severity of delusions in 
schizophrenia in a Caucasian population.129 The D-amino acid oxidase activator 
(DAOA/G30) locus found on chromosome 13q34, has been shown to be 
associated with both schizophrenia and bipolar affective disorder.130;131 Schulze 
et al. demonstrated in a Caucasian population that the association between 
bipolar affective disorder and DAOA/G30 was only seen when case definition 
was restricted to cases with persecutory delusions.132 Their data thus suggest 
that bipolar disorder with persecutory delusions constitutes a distinct subgroup of 
bipolar affective disorder that overlaps with schizophrenia. 
 
Behavioural disturbances as a core feature of the acute phase of illness was 
commonly reported with some form of verbal or physical aggression (75.9%; 
80%) by far the most prevalent. Although this may seem disproportionately high, 
it is important to note that the DIGS questionnaire only records qualitative 
statements regarding behaviour and therefore any incident (independent of 
severity) is noted.133 However, in schizophrenia, behavioural disturbances remain 
an important area of study as this illness seems to be overrepresented in 
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involvement with violent incidents during hospitalisation, having been shown to 
be the diagnosis in 30-45% of all such cases.134;135  
 
The contribution of genetic factors to the manifestation of aggressive behaviour 
associated with schizophrenia has been investigated in several studies, with data 
suggesting that a moderate to substantial influence can be attributed to genetic 
factors.136;137 However, to date the only such study done on a South African 
schizophrenia population investigated a role for functional variants in the 
catecholamine-O-methyl transferase gene (COMT) and the monoamine oxidase-
A gene (MOA-A), showing negative results, rather supporting non-genetic 
markers such as substance abuse and the presence of specific delusions as risk 
factors for violent behaviour.126 
 
The lifetime presence of catatonic symptoms was low (8.1%; 8%), which is in 
keeping with reports from previous studies.111;125;126 This area holds particular 
interest as previous data suggest that association with major disease loci can be 
demonstrated for periodic catatonia as a subtype of schizophrenia.138;139 
 
Lifetime presence of thought disorder was commonly reported (67.9%; 60%). 
Incoherence was most prevalent (36.6%; 34%) with loose associations least 
prevalent (9.8%; 12%). Although thought disorder is a common manifestation in 
schizophrenia, literature suggests that as such it plays no particular role in the 
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decreased quality of life experienced by schizophrenia patients in comparison to 
healthy subjects.140 
 
4.4 NEGATIVE SYMPTOMS 
 
Negative symptoms were commonly observed with especially affective flattening, 
anhedonia and avolition/apathy being very prevalent. However, those regarded 
to be markedly or severely affected never constituted more than 14% of the total 
sample of participants. The concept of remission in a psychiatric disorder (major 
depression) was first proposed 15 years ago. When we consider this concept for 
patients with schizophrenia, especially negative symptoms remain a challenge as 
we accept that remission needs to be thought of as being distinct from recovery. 
The proposal of the first set of standardised remission criteria for schizophrenia 
once again highlighted the importance of achieving resolution in all symptomatic 
domains of schizophrenia.141 Unfortunately, as a recent review underlines, in 
spite of numerous efforts no current treatment exists that effectively and 
consistently addresses this enduring and debilitating component of the 
psychopathology of schizophrenia.142  
 
4.5 TREATMENT 
 
Information was available for all except three participants, regarding the primary 
antipsychotic drug they were using at the time of the interview. As the sample 
consisted of in- and outpatients recruited either from the hospitals or psychiatric 
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community services, the high compliance rates could be due to selection bias. 
However, similar findings have been reported in other Xhosa schizophrenia 
samples.111;143 
 
Depot preparations were commonly prescribed, with a large portion of the 
participants using these (58.9%; 46%). These rates compared favourably to that 
previously reported in a Xhosa sample.111 Since the development of depot 
antipsychotic preparations in the 1960s, their advantages in relapse prevention 
due to (amongst others) stable plasma levels, a pattern of regular contact with 
the health care system and guaranteed drug delivery has repeatedly been 
demonstrated.111;144;145 However, as a recent survey of international psychiatrists’ 
prescribing habits showed, long-acting formulations, even after the arrival of a 
second generation preparation, are still usually reserved for patients with chronic 
schizophrenia who are at high-risk of non-compliance.146  
 
As our sample consisted primarily of multi-episode patients who had been 
diagnosed with the illness for an extended period of time, this could account for 
the high rate of depot prescriptions in comparison to international literature.147;148 
On the other hand, a number of previous studies have shown that African-
American patients are more likely to be prescribed depot antipsychotic 
preparations than Caucasian patients, possibly due to the perception that non-
compliance is more prevalent in this population.147;149 As no South African data 
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exist to either support or disprove this notion it would be interesting to do a 
comparative prescription analysis on an ethnically diverse sample. 
 
A trend that was observed in the sample was the high rate of antipsychotic 
polypharmacy in the form of two (32.1%; 24%) and in a few cases, even three 
(2.6%; 2%), antipsychotics being prescribed. This stands in sharp contrast to a 
previously reported Xhosa sample as well as international literature.111;150 This 
practice is specifically worrying if one takes into account the increased potential 
for adverse drug effects (notably extrapyramidal side-effects) and unwanted 
pharmacokinetic drug interactions.151 More than two thirds (42.3%; 40%) of the 
sample were using anticholinergic drugs. It has also been shown that exposure 
to high doses of antipsychotic medication could be a risk factor for the 
development of tardive dyskinesia.  
 
In contrast, the sample had quite a low rate of clozapine prescription (10.9%; 
10%) in comparison to that reported in international literature.152 The low 
frequency of clozapine use may merely reflect practical implications such as 
severity of side-effect profile, the requirement of regular leukocyte counts to 
monitor the risk of agranulocytosis and difficulties related to re-introduction of 
clozapine after discontinuation for longer than 48 hours. If so, this would be 
unfortunate as on interview a fair portion of the sample still had significant 
ongoing positive symptoms. Furthermore, at the time the data were collected, 
clozapine was the only atypical antipsychotic available in the state sector in the 
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Western Cape and, at the time of writing, still remains the only one that is readily 
available. 
 
The general impression created by the prescription data was that the medication 
requirements of the sample as a whole could stand reassessment. Unfortunately, 
many of the trends observed can probably be explained by the understaffed 
community psychiatric services where stable patients are evaluated by a 
psychiatric registrar only once in six months (if that often). Placing dedicated 
psychiatric medical officers at these clinics would no doubt lead to an 
improvement in prescription practices and consequently, patient care. Also, as it 
is true that many patients are discharged from hospital prior to being fully 
stabilised, it could be that ultimate medication goals, as planned, are never 
reached. Finally, as a fair portion of the sample were still inpatients at the time of 
interview, medication changes could still have been made prior to discharge. 
 
4.6 CO-MORBID CONDITIONS AND SYMPTOMS 
 
Internationally, high rates for the presence of co-morbid mood and anxiety 
disorders have been repeatedly reported for both first and multi-episode as well 
as childhood-onset schizophrenia.153-157 However, a more general overview 
shows there to be quite a bit of variation in different studies. For example in 
Braga et al.’s review, co-morbidity rates for the prevalence of the different anxiety 
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disorders ranged from 0-35% for obsessive compulsive disorder; 3.3-43% for 
panic disorder; 8.2-36.3% for social phobia; 1.3-51% for post traumatic stress 
disorder; 2.5-16.7% for generalised anxiety disorder; and 2.5-13.6% for specific 
phobia.158 Be that as it may, in comparison, the rates of suspected co-morbid 
mood (10.7%; 18%) and anxiety disorders (8%; 8%) reported for our study group 
still seem to cluster at the lower end of the spectrum. Although this could possibly 
be a function of the main assessment tool (DIGS) used (which relies heavily on 
self-report or the availability of collateral) or the fact that the DIGS needed to be 
translated orally into Xhosa; other factors could also very well be involved.  
 
Many of the previous studies (specifically with regards to multi-episode 
populations) focused on Caucasian samples. It could be that cultural factors 
influence the expression of mood and anxiety symptom profiles in patients with 
schizophrenia. In support of this notion, we find data from cross-national 
comparative studies that suggest a wide variation in rates of, for example major 
depression and social phobia, with especially Asian countries exhibiting much 
lower rates.159;160 Furthermore, not only do our rates compare well to that of a 
previous Xhosa sample, but they also compare favourably to rates found in a 
previous mixed-ethnicity South African sample.111;126 Interestingly, Emsley et al. 
also reported a generally low prevalence of anxiety and depressive symptoms in 
a South African schizophrenia sample.161 
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Therefore, if the data with regard to the low prevalence of mood and anxiety 
disorders could be replicated in a Xhosa or other South African sample by using 
more diagnostically specific (and if possible culturally sensitive) screening tools, it 
could support a possible protective role for cultural or genetic factors in the 
development of co-morbid disorders in schizophrenia. While it is recognised that 
specific biological mechanisms play an important role in the pathogenesis of 
mood and anxiety disorders, ethnic variations in these underlying factors could in 
fact be protective factors in certain groups. Further comparative studies would 
clearly be of value to investigate such a hypothesis. 
 
We relied on self-report and collateral information to collect data with regard to 
substance use disorders. However, within the confines of our setting we regard 
this as a reliable method as a previous study by our group in a Xhosa 
schizophrenia sample showed a low rate of inaccurate self-report.111 Regular 
tobacco smoking was reported by the majority of the participants (68.8%; 73%).  
This is in keeping with international data for both schizophrenia and mental 
illness in general that has shown people suffering from mental illness to be twice 
as likely to smoke than members of the general population.162 
 
A co-morbid substance use disorder could be documented for a significant 
portion of the sample (48.2%; 60%) with most participants using either alcohol 
(17.85%; 28%) or cannabis (40.1%; 50%) and only three reporting other 
substances. This compares with international literature that suggests that nearly 
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50% of schizophrenia patients have a co-morbid substance disorder (a rate of 
three times as high as that of the general population).163 Disturbingly, very high 
substance co-morbidity rates has also been documented for first episode 
schizophrenia (34.7%).164 It has been shown that these co-occurring substance 
use disorders contribute substantially to the financial and emotional burden of the 
illness – for patients, families and the mental health care system.165 Taking into 
account the already extremely constrained state sector in our setting, it would be 
in our best interest to develop a more integrated approach to the management of 
these disorders in our schizophrenia patients. 
 
A total of eleven participants admitted to having made one or more suicide 
attempts during their lifetime. This is quite low in comparison to previous data on 
a Xhosa sample (19.8%).166 International data also suggest that 20-40% of 
schizophrenia patients attempt suicide, with approximately 10% of patients with 
the diagnosis having suicide as cause of death.167 This has been supported by 
two recent national co-morbidity surveys, one in the UK and one in the US, both 
showing significantly excess co-morbidity for a diagnosis of schizophrenia.168;169 
Of note, however, was that nearly one third of the attempts in our sample were 
characterize by a more violent mode which was also reflected by the UK sample 
with over a quarter of the schizophrenia patients (27%) choosing a violent 
method in comparison to only 10% of the remaining sample. 
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Interestingly, a recent study aiming to investigate possible transcultural 
differences (comparing North America, Europe, Eastern Europe, South America 
and South Africa) between schizophrenia spectrum disorder patients who did or 
did not attempt suicide, showed that for all regions, except South Africa, the 
presence of comorbid substance abuse disorder and smoking could be 
significantly associated with suicide attempts.170 Our own previously reported 
sample revealed that earlier age of onset of illness as well as not being part of a 
sibship significantly increased the risk for suicide attempts.166 
 
Patients with co-morbid medical and mental illness are known to have higher 
mortality rates than those with medical illness alone. A recent literature review 
revealed that people with schizophrenia have higher prevalences of HIV infection 
and hepatitis, osteoporosis, altered pain sensitivity, sexual dysfunction, obstetric 
complications, cardiovascular diseases, being overweight, diabetes, dental 
problems, and polydipsia than the general population.171 In fact, in comparison to 
the general population patients with schizophrenia have been reported to have a 
40% increased risk of death from medical causes.172 Although, medical co-
morbidity could be documented for a fair percentage of our sample (28.5%; 
40%), pulmonary tuberculosis was the only diagnosis that was commonly 
reported. However, it is important to note that we relied on self-report and 
psychiatric folders alone and it is possible that all co-morbidity was not 
documented. Taking into account the significant role for co-morbid medical 
illness, we could once again argue that the presence of dedicated psychiatric 
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medical officers in the community setting would lead to improved care as earlier 
identification of such illness and initiation of appropriate treatment would be more 
likely. 
 
4.7 SIGNIFICANCE OF FINDINGS 
 
In general terms the demographic and clinical findings presented here correlate 
with those of the only other large Xhosa sample reported on in the literature. As 
noted in the results chapter, no significant differences could be demonstrated for 
any of the demographic or clinical variables for the group of five subjects with 
chromosomal aberrations, when compared to the rest of the KSG group.  
 
5. CONCLUSION 
 
Our findings, in contrast with those reported in e.g. the Turkish and Afrikaner 
populations, do not support a significant role for chromosomal aberrations in the 
susceptibility to develop schizophrenia in this population. However, ethno-
specific morphological characteristics could be demonstrated for our sample. 
Taken together, these results highlight the need for more non-Caucasian 
population-specific studies in schizophrenia, as clearly, morphological and 
genetic results cannot just be extrapolated across samples. 
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APPENDIX A: GLOSSARY 
 
Allele: One of the variant forms of a gene at a particular locus, or location, on a 
chromosome. Different alleles produce variation in inherited characteristics such 
as hair color or blood type. In an individual, one form of the allele (the dominant 
one) may be expressed more than another form (the recessive one).  
Autosome: Any chromosome other than the sex chromosomes. Man has 22 
pairs of autosomes. 
Contiguous gene syndrome: A characteristic complex phenotype produced by 
deletion of a short chromosome segment, resulting from haplo-insufficiency of 
several genes in the deleted segment. 
Cytogenetic: The study of the structure, function, and abnormalities of human 
chromosomes. 
Deletion: Absence of a segment of DNA; may be as small as a single base or 
large enough to encompass one or more entire genes. Large deletions involving 
a whole segment of a chromosome may be detected by routine examination of 
the chromosomes; intermediate deletions involving a few genes may be detected 
by using FISH; smaller deletions involving a portion of a gene may only be 
detected by analyzing the DNA.  
Epigenetic: Refers to heritable factors affecting the development or function of 
an organism that are not associated with its DNA sequence; relating to, being, or 
involving changes in gene function that do not involve changes in DNA sequence 
Fluorescent in situ hybridization: (FISH) A technique in which a 
deoxyribonucleic acid (DNA) probe is labeled with a fluorescent dye (that can be 
visualized under a fluorescent microscope) and then hybridized with target DNA, 
usually chromosome preparations on a microscopic slide. It is used to precisely 
map genes to a specific region of a chromosome in prepared karyotype, or can 
enumerate chromosomes, or can detect chromosomal deletions, translocations, 
or gene amplifications in cancer cells. Abbreviated FISH. 
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Gene: A hereditary unit consisting of a sequence of DNA that occupies a specific 
location on a chromosome and determines a particular characteristic in an 
organism.  
Genome: The total genetic content contained in a haploid set of chromosomes in 
eukaryotes, in a single chromosome in bacteria, or in the DNA or RNA of viruses; 
an organism's genetic material. 
Genomic imprinting: A genetic phenomenon by which certain genes are 
expressed in a parent of origin-specific manner. 
Genotype: The genetic makeup, as distinguished from the physical appearance, 
of an organism or a group of organisms. 
Haploinsufficiency: The situation in which an individual who is heterozygous for 
a certain gene mutation or hemizygous at a particular locus, often due to a 
deletion of the corresponding allele, is clinically affected because a single copy of 
the normal gene is incapable of providing sufficient protein production as to 
assure normal function. 
Heritability: The contribution of genetic as opposed to environmental factors to 
phenotypic variance; i.e. the proportion of phenotypic variance attributable to 
variance in genotypes. 
Heterochronia: The origin or development of tissues or organs at an unusual 
time or out of the regular sequence. 
Heterogeneity: Variance in characteristics within a defined illness. 
Heterozygous: Possessing two different forms of a particular gene, one 
inherited from each parent. 
Homozygous: Possessing two identical forms of a particular gene, one inherited 
from each parent. 
Inversion: A chromosomal rearrangement in which a segment of genetic 
material is broken away from the chromosome, inverted from end to end, and re-
inserted into the chromosome at the same breakage site. Balanced inversions 
(no net loss or gain of genetic material) are usually not associated with 
phenotypic abnormalities, although in some cases gene disruptions at the 
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breakpoints can cause adverse phenotypic effects, including some known 
genetic diseases; unbalanced inversions (loss or gain of chromosome material) 
nearly always yield an abnormal phenotype.  
Karyotype: A photographic representation of the chromosomes of a single cell, 
cut and arranged in pairs based on their banding pattern and size according to a 
standard classification 
Mendelian inheritance: Better known as Mendel’s laws or mendelian laws, 
which are the basic principles of genetics based on the experiments of Gregor 
Mendel in the nineteenth century. Two basic genetic principles were established: 
the law of segregation and the law of independent assortment. According to the 
law of segregation, the genetic characteristics of a species are represented in the 
somatic cells by a pair of units called genes that separate during meiosis so that 
each gamete receives only one gene for each trait. According to the law of 
independent assortment, the members of a gene pair on different chromosomes 
segregate independently from other pairs during meiosis, so that the gametes 
offer all possible combinations of factors. 
Metaphase: The stage of mitosis and meiosis, following prophase and preceding 
anaphase, during which the chromosomes are aligned along the metaphase 
plate. This is the stage at which chromosomes are most easily studied. 
Microdeletion: The loss of a tiny piece of a chromosome, a piece so small its 
absence is not apparent on ordinary examination (using a regular light 
microscope to look at chromosomes prepared in the usual fashion). The 
detection of microdeletions requires special techniques such as high-resolution 
chromosome banding, molecular chromosome analysis (with FISH), or DNA 
analysis. 
Mosaic: When an individual has two or more cell populations with a different 
chromosomal makeup, this situation is called chromosomal mosaicism. 
Orthologues: Sequences or genes in different organisms that are direct 
evolutionary counterparts; that is, they are related by descent from a common 
ancestor. Orthologous genes normally have the same cellular function. 
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Paracentric: An inversion in which the breakpoints are confined to one arm of a 
chromosome; the inverted segment does not span the centromere 
Pericentric: An inversion in which the breakpoints occur on both arms of a 
chromosome. The inverted segment spans the centromere. 
Phenotype: The observable physical or biochemical characteristics of an 
organism, as determined by both genetic makeup and environmental influences. 
Pseudoautosomal: Pertaining to segments of the X and Y chromosomes that 
undergo obligatory crossing-over so that they show on autosomal pattern of 
inheritance instead of the typical x- or y-linked pattern.  
Syndrome: A group of symptoms that collectively indicate or characterize a 
disease, psychological disorder, or other abnormal condition. 
Syntenic region: A genomic region found in two organisms with a co-linear 
order of genes (or nucleotides). 
Translocation: A chromosome alteration in which a whole chromosome or 
segment of a chromosome becomes attached to or interchanged with another 
whole chromosome or segment, the resulting hybrid segregating together at 
meiosis; balanced translocations (in which there is no net loss or gain of 
chromosome material) are usually not associated with phenotypic abnormalities, 
although gene disruptions at the breakpoints of the translocation can, in some 
cases, cause adverse effects, including some known genetic disorders; 
unbalanced translocations (in which there is loss or gain of chromosome 
material) nearly always yield an abnormal phenotype. 
